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Chapter 1. Abstract of thesis
Androgen insensitivity is an X-linked hereditary disorder characterised by failure of
virilisation during in utero and pubertal development. The genetic basis of the
disorder is now well defined with the finding that deletions or point mutations of the
androgen receptor (AR) gene are present in many affected patients. The AR is an
intracellular steroid receptor and acts by binding to DNA to cause transactivation of
target genes. The receptor protein possesses different structural domains which are
essential to effect hormone binding, DNA binding and transactivating functions. The
identification of mutations within the AR gene of affected individuals has allowed the
elucidation of certain key amino acids essential for receptor function. The mutations
which have been identified are located throughout the gene and cause a spectrum of
functional impairment from abolition of binding to subtle effects on conformational
stability of the receptor/1 igand complex. In the light of this it has been suggested that
androgen receptor gene mutations may be responsible for infertility in otherwise
normal men.
DNA was extracted from whole blood obtained from six patients with complete
androgen insensitivity and from nine patients with features of partial androgen
insensitivity and the individual exons of the AR gene were amplified by polymerase
chain reaction. Direct sequencing of the exons was performed to detect the presence
of point mutations. Of the fifteen patients, point mutations were detected in three with
complete androgen insensitivity and in four with partial insensitivity. Another of the
patients showed an amplification of the glutamine homopolymeric repeat region of the
receptor; this abnormality is known to be associated with spinal and bulbar muscular
atrophy (Kennedy's disease) and a review of the case history suggested that he had an
atypical presentation of this disease.
Blood was also obtained from a cohort of infertile men with endocrine
parameters suggestive of an impairment of androgen feedback and exons of the AR
gene amplified from these samples. To enable screening of the AR gene to be
performed the technique of denaturing gradient gel electrophoresis was established in
the laboratory using the previously identified mutations as positive controls. The
samples from the infertile men were screened using this method which was able to
detect 95% ofmutations present in a given sample. No mutations were detected in the
androgen receptor gene of any of the infertile men.
Chapter 1. Abstract of thesis 2
In conclusion, molecular methods have been employed to identify mutations in
the AR gene of patients with clinical symptoms of androgen insensitivity but an
examination of the AR gene of a selected population of infertile individuals failed to
identify defects in any of the men.
Chapter 2. Introduction and Literature Review
2.1. Preliminary remarks
In this chapter I will describe the current state of knowledge of the molecular basis of
androgen insensitivity syndromes and outline the objectives of the research which is
described in later chapters. I shall examine the mechanism of normal sexual
development from conception to birth and compare this with the abnormal
development seen in male pseudohermaphroditism. The central position occupied by
testosterone will be emphasised and the structure and function of the androgen
receptor discussed in health and disease.
2.2. The role of androgens in development and fertility
2.2.1. Gonadal control of sexual differentiation
The sex of an individual is determined by the sex chromosomes from the moment of
conception when the sperm fuses with the ovum. The presence of an X and a Y
chromosome within the zygote leads to differentiation as a male, while two X
chromosomes will produce a female. It has been shown that the Y chromosome is the
essential factor which directs male development, while female differentiation will
occur in the absence of the Y chromosome. The presence of a specific female factor
(i.e. the X chromosomes) is not required to initiate this process although they are
essential to attain full ovarian development and normal fertility (Moore, 1988). An
examination of the early embryonic development of the sexual organs reveals how the
Y chromosome functions.
The Y chromosome carries several genes which are thought to control the
differentiation of the primitive gonad during the seventh and eighth weeks of
embryonic life. The short arm (Yp) carries the gene for testis determining factor
(Vergnaud etal., 1986) which stimulates the development of the indifferent gonad into
an immature testis, with the formation of seminiferous cords, spermatogonia, Sertoli
cells and Leydig cells. A second gene (H-Y) lies on the long arm (Yq) of the
chromosome (Simpson et al., 1987) and is also thought to have some role in the
differentiation of the primitive gonad into a testis. It has recently been suggested that a
third gene on the Y chromosome is important for normal spermatogenesis to occur.
Infertile male patients have been reported with microdeletions of portions of the long
arm of the Y chromosome and the term azoospermia factor (AZF) applied to the
putative gene which is affected (Chandley et al., 1989). These deletions have been
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identified in a portion of the Yq region which is not contiguous with the H-Y antigen
gene in two patients with idiopathic infertility (Ma et al., 1992; Simpson et al. 1993)
but the actual gene has not yet been identified.
By eight weeks of life the Leydig cells begin to secrete testosterone (Laycock &
Wise, 1983) and the Sertoli cells of the primitive gonad produce Miillerian inhibitory
factor (MIF) (Lee & Donahoe, 1993). The early (seven week) embryo has two sets of
paired genital ducts: the Miillerian ducts and the Wolffian ducts. The Mlillerian ducts
are progenitors of the Fallopian tubes, uterus and upper two thirds of the vagina in a
female, and the Wolffian ducts are progenitors of the epididymides, vasa deferentia
and seminal vesicles in a male. In male embryos the presence of MIF causes
regression and degeneration of the Mullerian ducts (Lee & Donahoe, 1993) while
testosterone stimulates the growth and development of the Wolffian ducts. In the
absence of these hormones, the Mullerian ducts will develop spontaneously and the
Wolffian ducts will regress. The hormonal environment therefore determines
development of the reproductive tract so that by ten weeks of life the embryo has a
definable sex with either Wolffian duct structures and developing testes, or Mullerian
duct tissues and ovaries. The external genitalia develop from the genital swellings and
folds of the urogenital sinus. Development of these structures into penis and scrotum
is driven by an active metabolite of testosterone, dihydrotestosterone (DHT), and in
the absence of this stimulus, they develop into the labia majora and minora.
Thus the gonad has a central and fundamental role in the male differentiation of
the early embryo. Sexual development into a female can be considered to occur by
"default". The hormones secreted by the early, Y bearing, gonad drive male
differentiation by inhibiting this and stimulating the growth of the male duct system.
2.2.2. The central role of androgens in sexual differentiation
Androgens are steroid hormones synthesized and secreted almost entirely by the
Leydig cells in response to LH from the pituitary gland with about 5% of circulating
testosterone synthesized by the adrenal cortex (Laycock & Wise, 1983). Testosterone
circulates in the blood bound to albumin and sex hormone binding globulin. The
normal plasma levels are 12-35 nmol/1 in men and 0.5-2.5 nmol/1 in women. In many
target tissues (including seminiferous tubules, prostate and genital skin) testosterone is
converted to the more potent androgen dihydrotestosterone (DHT) by the cytoplasmic
enzyme 5 a-reductase. DHT is approximately 10-fold more active than testosterone
and acts via the same receptor as testosterone, to which it binds with 2-fold greater
affinity (Grino et al., 1990).
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In embryonic life testosterone is the major gonadal hormone responsible for the
development and growth of the genital ducts and accessory glands (Griffin & Wilson,
1980; Moore, 1988). DHT acts mainly upon the external genitalia, causing the growth
of the penis and scrotum from the genital folds and genital swellings of the embryo.
At puberty and in adulthood, androgens control the growth of the genitalia (via DHT)
and the development of secondary sexual characteristics: growth ofmuscle, facial and
body hair; deepening of the voice, and increased sebum secretion (Kiraly et al., 1987).
Androgens are also involved in normal spermatogenesis, acting on blood
vessels, peritubular cells and the cells within the seminiferous tubules. The main sites
of action appear to be the Sertoli cells and peritubular cells, since they are the only
cells which possess androgen receptors (Sar et al., 1990) (Fig. 2.1). Androgen action
upon spermatogenesis is effective during a small window of time in the spermatogenic
cycle; in the rat the available evidence indicates this to be at stage VII (Sharpe et al.,
1992). The precise mechanism whereby androgen stimulates and controls
spermatogenesis is poorly defined, partly because the entire cell population of the
tubules is engaged in complex cell-cell interactions which are extremely difficult to
examine (Sharpe, 1993).
It can be seen that testosterone and dihydrotestosterone are important hormones
for development and maintenance of male genital and secondary sexual development
and for the maintenance of spermatogenesis. Disorders of androgen action can be
predicted to have serious consequences in terms of both virilisation and fertility; such
predictions are readily borne out by examining the syndromes of male
pseudohermaphroditism where androgen action is impaired (see section 2.3).
2.3. Syndromes of androgen resistance
2.3.1. 5 a-reductase deficiency
5 a-reductase deficiency is an autosomal recessive hereditary condition characterised
by abnormalities of sexual differentiation (Madden et al., 1975; Wilson, 1992).
Patients are genetically male (46 XY karyotype) with testes and Wolffian duct
derivatives and androgen levels similar to normal men. The ducts terminate in a blind
ending vagina and the external genitalia are female in appearance. The cause for these
features is a deficiency of the 5 a-reductase enzyme which results in a failure of
synthesis of DHT. Tissues which are sensitive to DHT (external genitalia and
seminiferous tubules) fail to develop resulting in the mixture of male and female
structures seen in the adult. One family has been found to carry a deletion of the 5 a-
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reductase gene and the other cases are thought to be due to point mutations within it
(Wilson, 1992). In these cases the circulating testosterone acts normally via a normal
receptor on androgen-sensitive target tissues. The condition is therefore
fundamentally different from androgen insensitivity.
2.3.2. Androgen insensitivity syndromes
Androgen insensitivity (AIS) is a term which encompasses a range of clinical entities
all characterised by a tissue resistance to the effects of circulating testosterone. Levels
of testosterone are elevated above the normal male range and 5 a-reductase activity is
normal in these patients. The syndromes show a pattern of X-linked recessive familial
inheritance (Morris, 1953; Meyer et al., 1975). The incidence is estimated to be
between 1 in 20,000 and 1 in 64,000 live births (Griffin & Wilson, 1987).
2.3.2.i. Complete androgen insensitivity
In complete androgen insensitivity (complete AIS) total failure of virilisation of a male
foetus occurs resulting in an apparently female infant at birth. The condition usually
becomes apparent at the time of expected puberty when menarche and pubertal
development fail to occur. Occasionally, the condition comes to medical attention in
childhood when a patient presents with an inguinal hernia, which is found to contain a
testis. On examination, the patient exhibits a normal female phenotype with breast
development and female pattern fat deposition. The amount of pubic and axillary hair
is usually scanty. Genital examination reveals a normal vulva and labia, with a short,
blind-ending vagina. The gonads may be palpable within the inguinal canal but often
are intra-abdominal. Investigation of these patients reveals a 46 XY karyotype and
elevated blood levels of LH, FSH and testosterone.
The pathogenesis of the condition begins when the early embryo develops testes
which start to synthesize and release testosterone and Miillerian inhibitory factor. MIF
results in involution of the genital ducts which would give rise to the uterus and
Fallopian tubes. However, in the presence of tissue resistance to testosterone and
DHT, the Wolffian ducts do not develop into the accessory glands and virilisation of
peripheral tissues (including the external genitalia) and the brain cannot occur Thus,
the patient is phenotypically female in general body habitus and external genitalia but
possesses male gonads.
Clinically, there is no treatment which can be offered. The gonads are removed
because of the risk of malignant change, and oestrogens can be given to encourage
breast development. These patients usually require genetic and psychological
counselling to come to terms with their disease.
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2.3.2.ii. Partial androgen insensitivity
Partial androgen insensitivity (partial AIS) is a manifestation of the same underlying
disease process, but with a less severe form of expression (Madden et al., 1975).
About 10% of patients with AIS show this partial form (Griffin & Wilson, 1987).
Individuals are phenotypically female but show signs of virilisation with clitoromegaly
and partial posterior fusion of the labioscrotal folds. Some virilisation occurs at the
time of puberty. On examination, these patients are found to have testes (intra¬
abdominal or inguinal), a blind ending vagina, and elevated blood levels of
gonadotrophins and testosterone.
2-3.2-Iii. Reifenstein's syndrome
Reifenstein's syndrome is another clinical variant of partial androgen insensitivity.
Patients falling into this category are recognisably male, but have significant
impairment of virilisation (Reifenstein, 1947; Griffin & Wilson, 1980). Common
features include: severe perineoscrotal hypospadias; cryptorchidism; small testes and
penis; gynaecomastia; absence of secondary facial and body hair; female pattern pubic
hair; and the absence of Wolffian duct derivatives (e.g. vasa deferentia). Treatment
with high dose testosterone in an attempt to induce virilisation has been performed but
usually with little success (Rosenfield et al., 1971; Price et al., 1984).
2.3.3. Atypical forms of androgen resistance
In addition to the forms of androgen insensitivity detailed above there have been
reported cases of patients whose clinical and biochemical features fit none of the above
diagnostic categories. These cases are of interest because they reveal that the spectrum
of androgen resistance is very wide and in some cases the resistance is subtle and
mild. Larrea et al. (1978) described two brothers with gynaecomastia as the sole
feature. On investigation, the patients had small prostates, a small volume ejaculate,
with normal numbers of spermatozoa and elevated blood levels of gonadotrophins.
Androgen binding studies were performed upon samples of breast tissue from these
men, but no abnormality was detected. Two cousins (from the female line of
inheritance) had similar abnormalities of virilisation, indicating that the condition
appeared to follow an X-linked pattern of inheritance.
Migeon et al. (1984) described four male patients from three families who each
presented with pubertal gynaecomastia, short penis and a small prostate. One of the
men was oligospermic, while the others were azoospermia Investigation revealed
elevated blood levels of testosterone in all the men, elevated blood levels of LH in
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three of them, and some reduction in androgen binding capacity in genital skin
fibroblasts (GSF) from the two brothers.
Grino et al. (1988) reported a family in which the males were affected by
gynaecomastia, sparse pubic hair growth and small genitalia but were still normally
fertile. They had elevated serum levels of testosterone, but normal serum
gonadotrophin levels. Androgen binding studies on genital skin fibroblasts revealed a
reversible loss of binding affinity upon raising the incubation temperature and an
increased dissociation rate of ligand/receptor complexes.
The presence of different phenotypes in patients with similar abnormalities of
GSF receptor function suggest that there are other factors involved in virilisation of
particular tissues which are important. It may be that the local activity of modifying
enzymes (such as 5 a-reductase) is modulated in different tissues, leading to varying
responses to the same circulating levels of testosterone. Indeed, Jukier et al. (1984)
described a family of three brothers with Reifenstein's syndrome in which the
youngest was affected much less severely. The difference in clinical severity was due
to a combination of impaired androgen binding stability in the receptor which each
brother had inherited and an almost total absence of 5 a-reductase activity in the older
two brothers. There may be other local regulators of androgen action which are
modulated in this way.
2.3.4. Infertile men and androgen resistance
Atypical cases of androgen resistance indicate that the range of receptor abnormalities
extends beyond gross effects such as abolition of ligand binding to include less
apparent defects of function such as thermolability. It has been suggested that the
spectrum of abnormalities may extend to include some men whose only presenting
feature is infertility. Aiman et al. (1979) described three men who presented with
severe oligospermia; one of the men also had gynaecomastia. All three men had
elevated testosterone and abnormalities of androgen binding in genital skin fibroblasts.
Maximum binding was roughly 50% of normal in two and undetectable in the third.
On the basis of these investigations, they suggested that a mild androgen resistance
was responsible for their infertility. Aiman & Griffin (1982) determined the frequency
of androgen resistance in an unselected population of infertile men. Eighteen men
with idiopathic infertility were compared to ten with known abnormalities of
virilisation. Maximum androgen binding sites (Bmax) in the control group did not
differ from normal values, whereas in all the study group the value was significantly
lower, and comparable to that in patients with complete and partial AIS. They
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suggested a value of Bmax of 12 fmol/mg protein as defining androgen resistance, and
using this criterion applied to their subjects obtained a figure of 40% of infertile men
as having significant androgen resistance. A similar picture was described by Morrow
et al. (1987) in a sample of 21 men with sperm concentrations of less than 20
million/ml semen and infertility of more than twelve months duration. They found a
wide range of androgen receptor levels in the men and 19% of these were significantly
lower than in normal controls. In these men there was a mild elevation of serum LH
concentrations.
However, a different result was obtained by Eil et al. (1985) who investigated
fifteen men with 12 months of infertility, eight of whom had sperm counts of less than
20 million/ml semen. Whole cell uptake of radiolabelled androgen was used as a
quantitative measure of receptor levels, and nuclear uptake to measure the function of
the receptor. There was no difference in either whole cell or nuclear uptake of labelled
androgen between their subjects and normal fertile men, and no correlation with sperm
concentration. The apparent discrepancy between these three studies can be explained
partly by the small sample sizes in each group and it seems likely that androgen
insensitivity is responsible for infertility in some men, although the figure of 40% is
an overestimate. It should also be borne in mind that the methods of measurement
used were not sensitive enough to detect subtle abnormalities of binding affinity and
none directly measured the ability of the androgen receptor to transactivate target
genes.
2.4. The structure and function of the androgen receptor
2.4.1. The superfamily of steroid receptors
The androgen receptor (AR) is one of the family of steroid hormone receptors, the
protein sequences of which contain regions of striking homology (Evans, 1988). The
sequences of the genes for the thyroid hormone receptor, retinoic acid receptor and
vitamin D receptor (Carson-Jurica et al., 1990) also contain regions homologous with
those of the steroid receptors. All these receptors are now generally regarded as being
members of a large "superfamily" thought to have evolved from a common precursor
gene (Fig. 2.2) (Evans, 1988). Included in the superfamily are several proteins which
share homology with the other members but whose ligands have yet to be identified,
the so-called "orphan receptors" (O'Malley & Tsai, 1992).
Androgen, progesterone and oestrogen receptors are normally located within the
nucleus of the cell both in the presence and absence of ligand (Carson-Jurica et al.,
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1990; Pratt, 1990; Jenster etal., 1991), whilst the glucocorticoid receptor seems to be
partially cytoplasmic in the absence of ligand, and becomes entirely intranuclear upon
hormone binding. The receptors usually function as transactivating stimulators of
gene transcription (Rundlett et al., 1990) and exist in a complex with the heat shock
proteins (section 2.4.3). Binding of the appropriate steroid ligand causes a
conformational change in the receptor protein which renders it able to bind to specific
recognition sites, termed hormone response elements (HREs), on the target cell DNA.
Receptor/ligand complexes bound to the HRE interact with other transcription factors
including RNA polymerase to promote transcription (Carson-Jurica et al., 1990; Pratt,
1990). Thus, as a result of exposure to steroid hormones de novo synthesis of new
proteins occurs within the cell which may then alter the metabolism of the cell to bring
about the action of the hormone upon that tissue (Fig. 2.3).
The proteins of the steroid receptor family can each be divided into three basic
functional domains which are illustrated for the androgen receptor in Fig. 2.4. The
DNA binding domain has the most highly conserved sequence and possesses eight
cysteine residues which are conserved throughout the entire family (Carson-Jurica et
al., 1990). The carboxy- terminal (C-terminal) portion of the receptor is the region
responsible for binding to the specific ligand and also has several other functions
which will be discussed below. The amino- terminal (N-terminal) domain varies
greatly in size between the different receptors and has a number of functions which are
as yet poorly defined. The androgen receptor spans a length of 918 amino acids
(Chang et al., 1988), encoded on eight separate exons (see section 2.5.2).
2.4.2. Domains of the androgen receptor
2.4.2.i. The steroid binding domain
The steroid binding domain of the androgen receptor is encoded by exons 4 to 8 and
spans 250 amino acids (Jenster et al., 1991). Examination of the members of the
superfamily reveals two regions of high homology within the domain which are
hydrophobic in nature and thought to be involved directly in binding to the ligand
(Carson-Jurica et al., 1990). Jenster et al. (1991) investigated the ability of deletion
mutant androgen receptors to bind steroid. They discovered that ligand binding was
abolished by truncation of the C-terminal end of the domain (even if only 12 amino
acids were removed) or by deletion of small portions from the N-terminal end of the
steroid binding domain. Such deletions remove one of the hydrophobic regions
described by Carson-Jurica et al. (1990). Data from the study of patients with defects
of androgen and thyroid hormone action clearly indicate that the hormone binding
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function of the domain is highly sensitive to individual amino acid substitutions
(Sakurai et al., 1989; Brown et al., 1990; Wilson, 1992).
In the absence of hormone the C-terminal portion of the receptor serves to
suppress the DNA binding ability of the receptor (Danielsen et al., 1987). Deletion
mutants lacking the hormone binding domain show constitutive transactivating
function in in vitro systems (Jenster et al., 1991). This constitutive activity is less
than in a wild type receptor to which ligand is bound, consistent with the presence of a
second transcriptional activating domain within the steroid binding domain which is
active in the normal situation (Simental et al., 1991).
Nuclear targeting of the receptor is also determined by a region within the
hormone binding domain. The androgen receptor is almost totally nuclear in the
absence of hormone and translocation of the remaining receptor occurs upon the
addition of hormone, consistent with the presence of hormone-dependent and
independent targeting signals (Jenster et al., 1991). Deletion mutant studies reveal the
hormone independent signal to reside in the N-terminal part of the hormone binding
domain (encoded by exon 4), between amino acids 628 and 657 (Simental et al.,
1991). This region has homology to the nuclear localisation signal of the SV 40 large
T antigen, and is also present in other members of the steroid superfamily (Guichon-
Mantel et al., 1989). A mutant receptor lacking this signal will still translocate to the
nucleus upon binding to steroid, supporting the presence of a second, hormone
dependent, nuclear localisation signal (Jenster et al., 1991).
2.4.2.H. The DNA binding domain
The DNA binding domain of the receptor is the most highly conserved sequence
within the receptor and contains two "zinc fingers" encoded by exons 2 and 3. Most
of the research has been performed with glucocorticoid or oestrogen receptors, but the
information can be extrapolated to the other members of the superfamily. Each finger
contains a single zinc atom co-ordinating with four conserved cysteine residues in a
tetrahedral structure (Fig. 2.5) (Freedman et al., 1988). The critical role of all eight
cysteine residues has been confirmed by site-directed mutagenesis experiments which
systematically removed each of the cysteine residues (Hollenberg & Evans, 1988;
Schena et al., 1989) and abolished DNA binding and transcription.
In order to understand how the DNA binding domain of the receptor functions,
one must examine the structure of the hormone response elements (HREs) which can
be usefully divided into groups according to their structure (Fig. 2.6) (Berg, 1989).
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The glucocorticoid response element (GRE) is a 15 base pair partial palindrome with
the consensus sequence 5' GGTACA nnn TGTTCT 3' (Beato et al., 1989) and can
function as a gene promoter at great distances from the target gene. The spacing
between consensus half sites must be three base pairs. The GRE (and experimentally
designed perfect palindromes (Strahle et al., 1987)) will bind to progesterone,
androgen and mineralocorticoid receptors with similar affinity as to glucocorticoid
receptor (Freedman, 1992). It has been shown experimentally that certain nucleotides
are critical for the responsiveness of the GRE: changes to G+4, T+5, C+7, C-4 and
A-5 abolish binding to glucocorticoid receptor in vitro and prevent induction of
reporter genes in vivo (Nordeen etal., 1990; Freedman, 1992). These nucleotides are
the sites at which the DNA backbone makes specific contact with the receptor. The
thymidine at position T+5 would appear to be critical for receptor discrimination as a
functional oestrogen response element (ERE) differs from a GRE by only two
nucleotides in each half site, including this one (Fig. 2.6) (Freedman, 1992, and
references therein). The fact that HREs appear to be inverted palindromes is
consistent with binding of receptor occurring as a dimer, with each molecule in
opposite orientation (see section 2.4.2.iii).
The DNA binding domain is able to identify its specific response element in
isolation from the rest of the receptormolecule. This ability resides within three amino
acids at the C-terminal side of the base of the first zinc finger (Danielsen et al., 1989;
Mader et al., 1989; Umesono & Evans, 1989). The two amino acids between the
third and fourth cysteines, and the second amino acid after the fourth cysteine are all
necessary for a glucocorticoid receptor to recognise a GRE in preference to an ERE
(Fig. 2.5). Substitution of the amino acids in a glucocorticoid receptor for those in an
oestrogen receptor render the receptor able to bind to an ERE but not to a GRE. In
fact, steroid hormone receptors can be classed into two groups (depending on the
amino acids at these sites) which correlate with the type of HRE that they recognise
(Table 2.1) (Beato, 1989). The androgen receptor falls into the first group with the
sequence Cysteine-Glycine-Serine-Cysteine and Valine at these sites. Additionally,
the five amino acids lying between the first two cysteines of the second zinc finger are
important for recognising the half site spacing of the HRE (known as the "knuckle" of
this finger) (Beato, 1989; Martinez & Wahli, 1991) which contributes to the target
specificity of the receptor. Exchange of these amino acids within a glucocorticoid
receptor to the oestrogen receptor sequence produced a chimaeric receptor which was
able to recognise both HREs and transactivate genes through both (Danielsen et al.,
1989).
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The three dimensional structure of the DNA binding domain has recently been
elucidated by X-ray crystallography (Hard et al., 1990; Luisi et al., 1991). Data taken
from the glucocorticoid receptor revealed the three dimensional structure of the DNA
binding domain to contain two a-helices, lying C-terminal to each zinc finger, and a
distorted helix within the second finger (Hard et al., 1991; Freedman, 1992). The
overall shape of the domain was oblong with a compact hydrophobic core containing
several conserved hydrophobic amino acids, suggesting that it has an important
function to perform in maintaining the tertiary structure. A virtually identical pocket
has been described in the oestrogen receptor (Schwabe et al., 1990).
The way in which the glucocorticoid receptor interacts with DNA has also been
determined by crystallography (Luisi et al., 1991; Freedman, 1992). The receptor
binds to DNA as a head to head dimer. The first zinc finger of each receptor interacts
with the phosphate backbone of the DNA within the HRE, with the a helix which
follows it lying in the major groove and making all the specific base contacts involved
in HRE binding described above. The second finger makes further specific contacts
with the phosphate backbone of the DNA and also provides a dimerisation interface
for the other receptormolecule (see section 2.4.2.iii) (Luisi et al., 1991).
The DNA binding domain of the receptor also carries weak transcriptional
activity and a ligand dependent nuclear localisation signal (Jenster et al., 1991).
2.4.2.iii. The dimerisation domain
As mentioned above, the glucocorticoid receptor binds to its HRE as a dimer. Kumar
& Chambon (1988) showed that in vitro oestrogen receptor bound to its response
element only in the presence of hormone, and that the binding was dimeric. Tsai et al.
(1988) demonstrated that the two binding sites for receptor in a GRE lay on opposite
strands of the DNA and that dimeric binding occurred in a co-operative fashion.
There appears to be more than one area within the receptor involved in
dimerisation. The second zinc finger of the DNA binding domain interacts extensively
with its fellow (Luisi et al., 1991) but there is also a dimerisation signal resident
within the steroid binding domain of the receptor. Lees et al. (1990) identified a 22
amino acid peptide which restored dimerisation ability to mutant receptors lacking it.
Restoration of dimerisation also restored the DNA binding ability of the mutant
receptors, indicating that dimerisation is an essential process in the normal function of
the receptor. The 22 amino acid peptide sequence is highly conserved across the
steroid receptor superfamily and consists of a repeating motif of hydrophobic amino
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acids every seven residues (Fawell et al., 1990; Parker & Bakker, 1992). In the
androgen receptor this motif includes residues between 852 and 866 and overlaps one
of the essential regions for ligand binding. A heptad hydrophobic repeat is a motif
which has been identified in other nuclear proteins which interact with each other,
including the/0s and jun proteins which contain a "leucine zipper" motif (Konzarides
& Ziff, 1989). Schiile et al. (1990) showed that jun was able to inhibit the
transactivating ability of the glucocorticoid receptor in vitro in a dose dependent
manner, and that this inhibition resided in the leucine zipper of jun. It has been
proposed that steroid receptors have a dimerisation mechanism involving the binding
of an a helix in the heptad repeat region of each molecule (Forman & Samuels, 1990;
Lees et al., 1990) and that heterodimer formation between the receptor and other
nuclear proteins or steroid receptors may be a mechanism for autoregulation or
transcriptional control of receptor activation (Chaucereau et al., 1992; Parker &
Bakker, 1992)
2.4.2.iv. The N-terminal domain
The N-terminal domain of the androgen receptor is encoded by a single exon. It
appears to have several functions including transcriptional activation and regulation of
DNA binding specificity. Hollenberg & Evans (1988) identified a region within the
N-terminal domain of the glucocorticoid receptor which was essential for normal
hormone dependent activity. This region lay between residues 77 and 262 and its
function was independent of site within the whole receptor. The experimental
introduction of a second copy of this sequence into the receptor produced a more
active molecule (Hollenberg & Evans, 1988). These data correlate with the findings
of Simental et al. (1991) which indicated the presence of a transcriptional modulating
function in the first 338 amino acids of the androgen receptor. They found that co-
transfection of isolated N-terminal domains into cells bearing a reporter gene inhibited
transcription by androgen receptor in a dose dependent manner, indicating that the
domain interacted competitively with other transcription factors. Danielsen et al.
(1987) found that the N-terminal region reduced non-specific DNA binding by the
receptor and that this ability resided in an acidic portion (i.e. excess negative charge)
of the sequence. By contrast, the C-terminal part of the receptor is basic, and
Danielsen et al. (1987) showed that the degree of negative charge in truncated
receptors correlated with the specificity of DNA binding. The transcriptional activity
of the N-terminal domain appears to reside in a specific region of the domain, and it
depends upon both interaction with other factors in the cell and a charge effect.
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Jenster et al. (1991) found a similar localisation of transcriptional regulation to
two regions of the domain, one between residues 51 and 211 and the other between
244 and 360. The first of these regions contains a repeating region of glutamine
residues which in normal individuals can vary from 17 to 26 amino acids in length (La
Spada et al., 1991). There are two further repeats downstream in the exon, one of
eight proline residues and the other of 27 glycine residues (Chang et al., 1988). The
glutamine repeat region is thought to be one of the important areas within exon 1
responsible for regulation of transcription and DNA binding since its location
coincides with the functional localisations identified above. Courey & Tjian (1988)
identified the presence of two glutamine rich transactivating domains in the N-terminal
portion of transcription factor Spl, which supports the suggestion that glutamine
containing regions of the receptor can be involved in reguladon of function.
Recently, there have been some interesting observations which illustrate the
importance of the glutamine repeat, without throwing much light upon how it
functions. McPhaul et al. (1991a) described a patient with partial androgen
insensitivity in whom the genetic lesion comprised a point mutation and a truncation of
the glutamine repeat to 12 residues. Both changes were necessary to reproduce the
receptor abnormalities in vitro, which included thermolabile ligand binding (also see
section 2.5.2.vi). By far the most interesting and perplexing finding has been
reported by La Spada et al. (1991) who examined patients with a rare hereditary
wasting disease, X-linked spinal and bulbar muscular atrophy (SBMA), which
presents with a combination of muscular symptoms and features of androgen
resistance (gynaecomastia, erectile failure and oligospermia). The genetic locus for the
disease maps to the same region of the X chromosome as that of the AR gene (La
Spada et al., 1991). Sequencing of the AR gene in a series of thirty-five patients
revealed that they all had an approximate doubling of the size of the glutamine repeat
region. The absolute segregation of this size increase with the disease in these patients
(and in the expected family members drawn from the pedigrees of some of the
patients) indicated that this was the causative defect in the disease. These findings
have been confirmed by others (Belsham et al., 1992; Biancalana et al., 1992; Amato
et al., 1993). Precisely how this mutation of the receptor affects the function of the
androgen receptor within such a specific target tissue as motor neurones remains a
mystery, but suggests that there may be cell specific modification of the function of the
AR because of interaction with other transcription factors (see section 2.4.3).
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Bocquel et al. (1989) provided some evidence to support the presence of cell
specific modulation of function by their findings that the in vitro properties of different
members of the steroid family varied depending on which cell type was used as
expression host. Intact and deletion mutant receptors showed differences in hormone
binding and transcriptional activating ability in CV-1 cells and HeLa cells, suggesting
that other factors within each cell type modify the activity of the receptor.
2.4.3. Interaction with other transcription factors
The androgen receptor interacts with other intracellular proteins in both the bound and
unbound states. Unbound AR protein exists in the nucleus complexed with the most
abundant heat shock protein, HSP 90 (Pratt, 1990). The heat shock proteins are
abundant, mainly cytoplasmic proteins which are found in all species (Lindquist &
Craig, 1988) and are essential for normal eukaryotic cell function (Borkovich et al.,
1989), although their actual function is unknown. HSP 90 may be involved in
"chaperon" functions related to maintaining proteins (including steroid receptors) in a
particular conformation of folding; it may protect proteins against degradation within
the cell, and it may be a transport protein, involved in transmembrane carriage of
proteins across the nuclear envelope (Pratt, 1990).
In the case of the glucocorticoid receptor HSP 90 appears to bind to the receptor
as a dimer, in association with other HSPs (HSP 70 and HSP 59). All the steroid
receptors, including the androgen receptor, dissociate from the heat shock proteins in
response to ligand binding, inducing a conformational change of the receptor protein
(O'Malley & Tsai, 1992). This conformational change is rendered permanent by
covalent modification (see below) and then DNA binding and transcriptional activation
occurs.
2.4.4. Phosphorylation of the androgen receptor
Androgen receptor exists as a phosphoprotein in the absence of ligand. In cells from a
prostate tumour cell line (LNCaP) the receptor exists as two isoforms of about 110
kDa molecular weight with most of the receptor in the heavier form (van Larr et al.,
1990). Golsteyn et al. (1990) confirmed these findings and also showed that the
heavier form contained phosphotyrosine residues. The phosphorylated receptor
showed higher affinity binding to cell nuclei in culture than did the unphosphorylated
form and could be extracted from intact cell nuclei. Golsteyn et al. (1990) proposed
that phosphorylation was one of the steps required to transform the receptor into its
active DNA binding form, van Laar et al. (1991) investigated the time course of
phosphorylation of the receptor in response to ligand. They showed that the receptor
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has a basal level of phosphorylation which increases twofold upon exposure to ligand.
This increase in phosphorylation is simultaneous with the presence of increased
amounts of receptor recoverable from cell nuclei indicating that the phosphorylation is
required for nuclear translocation of the cytosolic receptor.
The majority of phosphorylation sites are serine and tyrosine residues and are
mainly located within the N-terminal domain of the receptor (Wilson et al., 1991).
Recently, Chaucereau et al. (1992) have demonstrated phosphorylation sites within the
N-terminal domain of the progesterone receptor between residues 166 and 520. Some
are sites of basal phosphorylation while other sites become phosphorylated upon
binding of ligand. The precise nature of the functional changes conferred by
phosphorylation of steroid receptors is not known but is the subject of intensive
research.
2.5. The genetic basis of androgen insensitivity
Androgen insensitivity has long been recognised as an X-linked recessive disorder
(Morris, 1953). In an elegant study in which GSF were cultured from two siblings
with complete AIS and their mother, Meyer et al. (1975) demonstrated that the
androgen receptor gene is located on the X chromosome. GSF from the affected
siblings showed absent binding of androgen and half of the mother's clones also
showed this abnormality. One of each X chromosome in every cell is inactivated to
form the Barr body, so that 50% of the mother's cells expressed the product of the
normal AR gene and the rest expressed the defective gene. The lack of androgen
binding in the affected cells suggested that the androgen receptor gene was a likely
candidate for the defective gene associated with androgen insensitivity.
2.5.1. Abnormalities of receptor function in androgen
insensitivity
At the time that the AR gene was implicated by Meyer et al. (1975) it was already
known that many patients with complete AIS had absent androgen binding to GSF
(androgen receptor negative, AR-) (Keenan et al., 1974) although not all patients with
the syndrome showed demonstrable abnormalities of ligand binding (Amrhein et al.,
1976). This latter group were dubbed androgen receptor positive (AR+). Kaufman
and colleagues showed that some patients in this AR+ group had receptors which did
not upregulate their levels in response to exposure to androgens (Kaufman et al.,
1981a), and which also dissociated with abnormal rapidity following ligand binding
(Kaufman et al., 1981b). In both studies, patients with partial AIS were also studied
and showed similar but less extreme abnormalities of regulation. Similarly, Brown et
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al. (1982) studied three patients with AR+ complete AIS; they found the receptors of
these patients to have an increased rate of dissociation from ligand, a high affinity for
progesterone in competition with testosterone and increased lability at elevated
temperature (42°C). A further example of qualitative abnormalities of the AR in AIS
were provided by Griffin & Durrant (1982). They examined the group of patients
who had grossly normal receptor binding levels and normal dissociation kinetics by
employing the novel technique of centrifuging receptor/ligand complexes through a
molybdenum gradient. They were able to further classify this group of patients into
those with receptors which were destabilised by the gradient and those whose
receptors behaved normally.
Thus, the premise was that patients with AR- insensitivity had receptors with
gross structural or functional abnormalities, while the AR+ patients had receptors with
subtle defects. The latter were further classified into subgroups: those with
thermolabile, low affinity receptors; those with molybdenate unstable receptors, and
those with apparently normal receptors. This spectrum of receptor classification was
not entirely interchangeable with the clinical classification of the patients since some
complete AIS patients had apparently normal receptors, but the severity of receptor
function abnormality seemed to correlate broadly with the phenotypic severity. Those
groups with normal or nearly normal receptors as assessed by these techniques
presumably possessed receptors which were defective in some intranuclear function,
such as dimerisation, DNA binding or transactivation. The technology to unravel
these functions only became available following the cloning of the androgen receptor
gene (see section 2.5.2).
2.5.2. Androgen receptor gene mutations
The androgen receptor gene lies on the long arm of the X chromosome in the Xq 11-
12 region (Brown et al., 1989) and its cDNA has been cloned by several groups
independently (Chang et al., 1988; Lubahn et al., 1988; Tilley et al., 1989). The gene
comprises eight exons, ranging in size from 1,607 base pairs for exon 1 to 117 for
exon 3 (Marcelli et al., 1990a). As already mentioned, the exons of the gene share
homology with the other members of the nuclear hormone receptor superfamily: exon
1 encodes the large N-terminal domain of the receptor and contains three
homopolymeric repeat regions. Exons 2 and 3 each encode one of the zinc fingers of
the DNA binding domain and exons 4 to 8 encode the hormone binding domain and
the hinge region of the receptor between the DNA and ligand binding domains (Fig.
2.4) (Chang et al., 1988). Exon 8 possesses a large 3' untranslated region following
the in-frame termination codon.
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Soon after the cloning of the AR gene, Brown et al. (1988) provided the first
evidence of a genetic lesion within the AR gene of patients with AIS. They made
Southern blots of genomic DNA from six patients with AR- complete AIS and probed
them with DNA probes specific for the N-terminal, DNA binding and hormone
binding domains. One of the patients had a deletion of a part of the steroid binding
domain, and this deletion could be traced through affected siblings and the female
carriers. The presence of apparently intact AR genes as assessed by Southern blotting
in the other patients indicated that they might contain smaller deletions or point
mutations. Shortly after this finding was published, Lubahn et al. (1989) identified a
point mutation within the steroid binding domain of the AR gene of a patient with
complete AIS. A single mutation from guanosine to adenosine in exon 7 produced a
substitution of valine 866 by methionine. Subsequent in vitro studies using
recombinant plasmids bearing mutated AR genes showed that this mutation produced a
receptor protein which had a 7-fold lower binding affinity and impaired ability to
activate an androgen responsive reporter plasmid at physiological concentrations of
androgen (Brown et al., 1990). These results supported the hypothesis that point
mutations of the AR gene can be the causative lesion in the pathogenesis of androgen
insensitivity. Since publication of the AR gene sequence, there has been a thorough
examination of the AR gene sequence of patients with AIS across the world, resulting
in the identification ofmany naturally occurring mutations within the gene (Fig. 2.7).
Some of these mutations are of particular interest and will be discussed in more detail.
2.5.2.i. Deletion mutations
Deletion mutations are known to be responsible for approximately 5% of all cases of
AR gene defects (Wilson, 1992). In addition to that described above, patients with
deletions of the entire gene, exon 2, exon 3, exon 5 or exons 6 & 7 (Trifiro et al.,
1991; Quigley et al., 1992a & b; Maclean et al., 1993) have been reported. These
mutations serve to highlight the importance of each zinc finger to the normal function
of the androgen receptor, and the importance of an intact ligand binding domain but
provide little information on the detailed functions within a region.
2.5.2.ii. Mutations of the hormone binding domain
Many mutations in the hormone binding domain have been described (see Fig. 2.7)
and they serve to illustrate some patterns in the aetiology of mutations in the entire
gene. 90% of mutations in the hormone binding domain are clustered in two regions:
residues 728 to 774, and 828 to 866 (McPhaul et al., 1992). The region 828 to 866 is
homologous to a region of the thyroid hormone receptor where mutations are clustered
in patients with hereditary thyroid hormone resistance (Refetoff et al., 1993). 50% of
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mutations are situated at CpG couplets within the DNA sequence (Quigley et al.,
1992c), which are recognised as "hot spots" for mutation by the mechanism of
methylation and deamination of cytosine producing a thymidine nucleotide
(Youssoufian et al., 1986). This is the commonest mode of mutation, and accounts
for the high frequency of premature termination codons substituting for arginine
codons, because of the C to T change which converts the arginine codon (CGA) to a
stop codon (TGA).
80% ofmutations in the hormone binding domain occur at the site of conserved
amino acids (Quigley et al., 1992c). These conserved amino acids occur in all regions
of the hormone binding domain, but there is a preponderance of them in exon 7,
around the region of the heptad hydrophobic repeat which is involved in ligand
binding and dimerisation. Mutations have been detected in several of these conserved
amino acids including 855 and 866 (Lubahn et al., 1989; De Bellis et al., 1992). The
high incidence of mutations of conserved amino acids is not really surprising in that
one would expect mutations in these critical amino acids to have a marked clinical
effect. More surprising is the fact that mutations of non-conserved amino acids also
can have profound effects on function of the receptor, suggesting that such amino
acids play an important role in maintaining the correct spatial configuration of the
receptor or in causing conformational changes along the length of the receptor protein
as part of the mechanics of receptor action.
It is worth noting that to date there is only one report of silent mutations detected
during screening of patients (Batch et al., 1992). One of these (a guanosine to
adenosine mutation at 995) abolishes a restriction site and was detected in the normal
population at a frequency of 8%.
2.5.2.iii. Premature termination codons
Mutation of existing codons to a premature termination signal has been found to be a
relatively common cause of complete AIS, partly due to the mechanism described
above. Mutations of this type have been found throughout the length of the gene in
exons 1, 3, 4, 6, 7 or 8 (Marcelli et al., 1990a & b; Sai et al., 1990; McPhaul et al.,
1991b; De Bellis et al., 1992; Trifiro et al., 1992a &b; Zoppi et al., 1993). These
mutations lead to the synthesis of a truncated receptor protein and it is striking how
even limited truncation can render the receptor unable to bind ligand. The exon 8
mutation described by Trifiro et al. (1992a) removes only the last 36 amino acids of
the protein but abolishes ligand binding completely. This is in agreement with the in
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vitro work of Jenster et al. (1991) in which a deletion of the last 12 amino acids of the
receptor was sufficient to abolish ligand binding.
2.5.2.iv. Mutations of the DNA binding domain
Mutations within the DNA binding domain have been detected relatively infrequently
when compared to those occurring within the hormone binding domain. Commonly,
one of the conserved cysteine residues is mutated (Chang et al., 1991; Zoppi et al.,
1992) and this results in disruption of the normal conformation of the finger which
abolishes or severely impairs DNA binding and gene transactivation. It is worthy of
note that receptors from these patients in which zinc finger mutations have been
reported retain normal hormone binding characteristics (i.e. they are all AR+ patients).
Mutations have also been identified in the a-helical region of the second zinc finger
which is part of the dimerisation interface (De Bellis et al., 1991). Marcelli et al.
(1991a) described a patient with complete AIS having a mutation of a residue in this
segment which results in loss of contact with a phosphate residue within the DNA
helix and subsequent loss of receptor function.
Few mutations have been reported in the DNA binding domain in patients with
partial AIS, indicating the importance of the structural integrity of this region.
Mutations have been reported in the knuckle of the second finger including the
substitution of alanine 596 by threonine (Klocker et al., 1992). This is an amino acid
conserved through all the steroid receptors except the oestrogen receptor and lies in the
region responsible for recognition of half site spacing in the HRE (Beato, 1989). In
co-transfection assays, this mutant androgen receptor had normal hormone binding
parameters but was only able to activate a reporter gene a third as efficiently as a wild
type receptor. In the glucocorticoid receptor Luisi et al. (1991) found that the
equivalent alanine residue was one of the amino acids involved in receptor
dimerisation, so a perturbation of dimerisation seems to be the likely mechanism of
action in this patient. A second mutation replaces serine 597 with glycine in
association with a change of arginine 617 for proline (Zoppi, et al., 1992). Residue
597 also lies within the knuckle of the finger responsible for recognition of the half-
site spacing of the HRE. Wooster et al. (1992) described a mutation of arginine 607
to glutamine in two brothers with partial AIS and breast cancer and suggested that the
mutation may have rendered the AR able to activate an ERE and thus stimulate the
development of the breast cancer. This residue is one of the amino acids involved in
receptor HRE contact via the phosphate backbone of the DNA (Luisi et al., 1991).
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In view of the critical nature of the function of the DNA binding domain, it is not
surprising that most of the identified mutations cause complete AIS. Examination of
those mutations which cause partial AIS provide more information on the nature of the
interactions of the subdomains of the zinc fingers.
2.5.2.V. Commonly occurring mutations
Mutations of certain amino acids have been reported independently by several groups
and many of these occur at conserved amino acid sites. The occurrence of the same
mutation at the same site in unrelated individuals suggests that the affected amino acid
is of particularly critical functional importance. Those amino acids falling into this
group are: numbers 576, 695, 774, 831, 855 and 866 (Lubahn et al., 1989; Brown et
al., 1990; Chang et al., 1991; Marcelli et al., 1991b; Ris-Stalpers etal., 1991, 1992;
De Bellis et al., 1992; Prior et al., 1992; Patterson et al., 1992; Zoppi et al., 1992;
Kazemi-Esfarjani et al., 1993). The mutations at 855 and 866 are particularly
interesting because different mutations at these sites have been detected in patients with
complete and partial AIS. At 855 a change from arginine to cysteine (large, positively
charged to a small polar amino acid) caused complete AIS while arginine to histidine
(both charged) caused partial AIS. Similarly, a change at 866 from valine to
methionine (small, uncharged to large, polar amino acid) led to complete AIS while
valine to leucine (both small and uncharged) produced partial AIS. Such mutations
suggest that the nature of the substitution, in terms of size and charge, can have an
effect upon the degree of functional impairment caused by mutations at a given site
(see also Chapter 4, section 4.5).
2.5.2.vi. Complex mutations
Some of the mutations which have been reported appear to cause their clinical effects
by more subtle and complex mechanisms. The occurrence of a size increase of the
glutamine repeat in patients with spinal and bulbar muscular atrophy and the evidence
highlighting the importance of the glutamine repeat provided by McPhaul et al.
(1991a) from a family with partial AIS has already been discussed (section 2.4.2.iv).
The AR gene from these patients was found to have a point mutation at 763 (from
tyrosine to cysteine) in association with a truncation of the glutamine repeat region to
12 residues. In vitro studies using genital skin fibroblast receptors showed the
receptor to be thermolabile in binding and to have an increased rate of dissociation
from ligand. Binding studies with mutated recombinant receptors in vitro revealed that
the point mutation was responsible for the increased dissociation but that the truncation
of the glutamine repeat was also necessary to reproduce all the functional abnormalities
displayed by the original mutant receptor.
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Marcelli et al. (1991b) described a mutation within exon 6 of the AR gene of a
patient with AR- complete AIS. In vitro studies using recombinant mutant AR genes
in expression vectors revealed that the point mutation caused a reduction of binding
affinity and an irreversible loss of binding ability on exposure to mild temperature
elevation. They also found very low levels of specific AR mRNA in genital skin
fibroblasts from the patient. It was proposed that the mutation produced the AR-
phenotype by a combination of the direct effect upon ligand binding and the effect
which the mutation seemed to have upon the stability of the mRNA, resulting in low
copy number of the receptor protein in vivo.
Another interesting mechanism for the generation of the AIS phenotype was
reported by Ris-Stalpers et al. (1990) from a patient with AR- complete AIS. Analysis
of the AR gene revealed a point mutation in the first nucleotide of the 5' splice site of
intron 4 from the normal GT site to a TT sequence. This resulted in an mRNA 123
bases shorter than normal, leading to a protein with a deletion of 41 amino acids
between 684 and 724. The mutation changed one of the two invariant nucleotides of
the donor site sequence of the splice site (Green, 1986; Padgett et al., 1986), which
caused activation of a cryptic donor splice site within exon 4, resulting in the missing
portion of exon 4 being spliced out during RNA processing. The mutant receptor
lacked all androgen binding and transactivating ability in in vitro assays. The deleted
region was part of the steroid binding domain and carries some transcriptional
activation function (Jenster et al., 1991).
2.6. Infertility as a disease
Infertility is a common problem amongst couples in Britain and around the world.
Estimates put the incidence at 14% to 25% of couples having some experience of
infertility (Diczfaluzy, 1986; Templeton et al., 1990). The inability to conceive a child
is expensive in terms of anxiety and stress for the partners, the amount of consultation
time which is required and in the cost of technological investigations and treatments.
Currently, infertility as a result of female factors (e.g. anovulation, tubal dysfunction)
can be treated with good results. The major obstacle in improving our ability to treat
couples lies in the realm of male factor infertility and unexplained infertility.
2.6.1. The incidence and causes of male factor infertility
Male factor infertility is the major factor in 24% of couples and is a contributory factor
in up to 75% of couples presenting for treatment of infertility (Hull et al., 1985;
Irvine, 1992) and men with sperm dysfunction have a poor rate of fertility in follow
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up of less than 27% (Hull et al., 1985). It is therefore the single most prevalent cause
of infertility. Male factor infertility encompasses the inability of spermatozoa to move
through cervical mucus, adhere to the zona pellucida of the egg and to effect
fertilisation. Most of these functions are difficult to examine and the standard semen
analysis is very crude, being little more than a descriptive comment on the sample.
However, there is a correlation between low sperm concentration and the inability to
achieve a pregnancy (Hargreave & Elton, 1986). Low sperm counts can be caused by
a variety of diseases including diabetes mellitus, bronchiectasis, epididymitis,
testicular injury, mumps orchitis and drugs including sulphasalazine, alcohol,
cimetidine and nitrofurantoin (Irvine, 1992). Exclusion of these known causes still
leaves a subset of men with low sperm counts of unknown cause, who comprise 20%
of infertile men attending infertility clinics (Hargreave, 1990).
Whilst men with oligo- and azoospermia and those with morphologically
abnormal spermatozoa will be identified, many men with an apparently normal semen
sample remain infertile. Hull et al. (1985) found 28% of men attending a large clinic
in Bristol fell into this category of unexplained infertility. More specialised tests are
available such as the post-coital test, sperm movement analysis and the zona-free
hamster oocyte penetration test (Irvine, 1992). These tests provide useful prognostic
information for each couple and can pinpoint the functional disturbance of the
spermatozoa but they do not provide any information on the underlying mechanism.
2.6.2. Unexplained infertility
There remains in any group of infertile couples roughly 28% for whom no obvious
cause can be found, and a group of men with oligospermia for which no explanation
can be provided. The pregnancy rate in such a group is not good and the only
effective intervention is in vitro fertilisation (IVF), with all the associated cost. IVF
requires a reasonable concentration of spermatozoa in semen and is therefore
contraindicated in those couples where the male has a low count. As we have seen, a
group of these men have no recognisable reason for their low sperm count and
therefore no treatment can be offered.
As discussed above (section 2.3.4), it has been suggested that a form of
androgen resistance may be responsible for infertility due to oligospermia (Aiman &
Griffin, 1982; Morrow et al., 1987). While the figures quoted seem rather high, the
rationale that mild abnormalities of androgen action can interfere with normal
spermatogenesis seems plausible. Given that our understanding of the intratesticular
action of testosterone is poorly understood (Sharpe, 1993), it may be that some men
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have such an androgen resistance which is amenable to high dose androgen therapy as
a means to improve their sperm count and fertility.
2.7. Aims and objectives
2.7.1. Characterisation of the genetic basis of androgen
insensitivity
The aim of this research was to investigate the structure/function relationships of the
androgen receptor gene in several ways. Firstly, I had access to patients with the
complete and partial forms of androgen insensitivity drawn from all over Scotland and
from northern England. Analysis of the sequence of the androgen receptor gene in
these patients was undertaken to identify the genetic basis of their syndrome in terms
of point mutations or deletions of the receptor.
2.7.2. Examination of the functional characteristics of mutant
androgen receptors
Having identified mutations within the AR gene in patients with AIS, it is important to
confirm that the mutation is responsible for the defects in the normal function of the
receptor. I intended to investigate this by constructing recombinant mutant androgen
receptor genes in plasmid DNA bearing eukaryotic promoter signals. Mutations
would be introduced into the AR in a plasmid by the technique of site-directed
mutagenesis (Deng and Nickoloff, 1992), and mutated plasmids transfected into
mammalian cells in culture. Measurement of androgen binding ability and
transactivating ability of the mutant androgen receptor would be measured in vitro and
the results correlated with the clinical phenotype of each patient.
2.7.3. Screening of infertile men for the presence of androgen
receptor mutations
I had access to an infertile male population numbering approximately 1,700 with all
relevant information retained on computer. I selected from them a cohort with
hormonal parameters suggestive of mild androgen resistance and obtained genomic
DNA samples. In order to accelerate the analysis of the AR gene in these men I
evaluated and established a screening method. Available methods included denaturing
gradient gel electrophoresis (DGGE) (Myers et al., 1987), temperature gradient gel
electrophoresis (TGGE) (Riesner et al., 1989) and single strand conformational
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Figure 2.2
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= DNA binding domain = homologous regions in hormone
binding domain
ER = oestrogen receptor; GR = glucocorticoid; MR = mineralocorticoid
PR = progesterone; RAR = retinoic acid; TR = thyroid; VDR = vitamin D
Protein sequences aligned at DNA binding domain with the amino
terminus on the left. Two regions in the hormone binding domain,
thought to be involved in hormone binding, are also shown. Figures
above each indicate % homology of the shaded portions to the sequence
of the progesterone receptor. Based on Carson-Jurica etal. (1990).
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Unliganded receptor exists in complex with heat shock protein 90.
Binding of ligand induces a conformational change releasing hsp 90
and rendering the receptor able to bind to the DNA of the response
element as a dimer. Binding to the response element is the first step in
initiating transcription of the target gene.
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Figure 2.4 Domains of the androgen receptor
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Androgen receptor coded on eight exons. The exon numbers are given
within the boxes and the number of nucleotides in each indicated above.
Note untranslated region at 3' end of exon 8. The receptor has three
main functional domains: the amino terminal domain (exon 1), the
DNA binding domain (exons 2 and 3) and the hormone binding domain
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Figure 2.6 Idealised HRE sequences according to type
GRE


























GRE: glucocorticoid response element ERE: oestrogen response element
TRE: thyroid hormone response element VDRE: vitamin D response element
HREs shown are idealised perfect palindromes for each type of repeat. The arrows
indicate the orientation of each half site. The numbering of the residues is given at the
top and the DNA orientation is 5' to 3' from left to right for the upper strand. Bold
type indicates the differences of sequence between the GRE and ERE. Note that the
ERE, TRE and VDRE share the same half-site sequence.
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Table 2.1 Steroid receptor grouping by HRE type












Chapter 3. General Methods
3.1. Extraction and isolation of genomic DNA
A modification of the method of Grimberg et al. (1989) was used for the rapid
extraction of genomic DNA. Briefly, 10-20 ml of peripheral blood were sampled
from each patient, mixed with 1 ml acid-citrate-dextrose buffer (ACD) (23 mM citric
acid, 45 mM sodium citrate, 0.8 M glucose) and stored at -20°C before being mixed
with a fourfold excess of cell lysis buffer (CLB) (0.32 M sucrose, 10 mM Tris.HCl
pH 7.6, 5 mM MgCl2, 1% Triton X-100). The lysate was centrifuged for 5 minutes
at 2,000 revolutions/minute (rpm) at 4°C, the supernatant discarded and the pellet
washed once in CLB and once in 0.5 ml of cold protein lysis buffer (PLB) (10 mM
Tris.HCl pH 8.0, 10 mM NaCl, 10 mM ethylenediamine tetra-acetate (EDTA)). The
pellet was centrifuged at 500 rpm for 2 minutes and resuspended in 3 ml of PLB.
Proteinase K (5 units) was added and the suspension incubated at 65°C for 2 hours,
with occasional agitation. Thereafter the digest was extracted twice with an equal
volume of phenol saturated with TE buffer (10 mM Tris.HCL pH 8.0, 1 mM EDTA
pH 8.0), and once with chloroform: isoamyl alcohol 49: 1, before 0.1 volume of 3 M
sodium acetate (pH 5.5) and 2.5 volumes of 95% ethanol were added to precipitate
high molecular weight DNA. Precipitated DNA was spooled out into a clean tube
and 0.5 ml 95% ethanol added. The tube was centrifuged at 13,500 rpm for 5
minutes, the supernatant discarded and the pellet air dried for 10 minutes. 100 jil of
sterile water were added and the sample left at 4°C overnight to dissolve.
3.2. Synthesis and selection of oligonucleotide primers
Oligonucleotide primers (20 to 29 base pairs) for use in polymerase chain reaction
(PCR) were synthesized on a "PCR-mate" DNA synthesizer, model 391 (Applied
Biosystems Ltd., Warrington, UK), recovered into 1 ml ammonia and incubated at
55°C overnight. The resulting stock solution was kept at -20°C and aliquots
removed for precipitation as required. 350 |il of stock solution were mixed with 50
jil unbuffered 2 M sodium acetate and 1 ml absolute ethanol and incubated at -20°C
for 30 minutes. Following centrifugation at 13,000 rpm for 15 minutes, the pellet
was washed twice in 70% ethanol, dried and redissolved in 200 |i.l of water. The
concentration of the primer was calculated from the optical density at 260 nm
(OD260) of a 1 in 200 dilution, measured in a Phillips PU 8800 UV/VIS
spectrophotometer.
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3.2.1. PCR primers
Oligonucleotide primer pairs synthesized were those published by Lubahn et al.
(1989), chosen by them to lie within the intronic regions flanking each of exons 2 to
8 of the androgen receptor gene. Primer pairs for exon 1 were chosen to amplify
overlapping portions of 200 to 500 base pairs in length to facilitate the analysis of
this region (Lubahn et al., 1989) (Table 3.1).
3.2.2. Primers for denaturing gradient gel electrophoresis
To undertake analysis by denaturing gradient gel electrophoresis (DGGE) of exons 2
to 8, primers were modified as follows: one of each primer pair was synthesized with
a 40 base pair sequence ("GC-clamp") rich in guanosine and cytosine at the 5' end.
The sequence of the clamp was: 5'- GCCGCCCG CCGCCGCC CGCCGCCG
CCGCCCGC CGCCCGCC-3' (Brown et al., 1990). The GC-clamp increases the
sensitivity of DGGE in detecting sequence changes to about 95% (Sheffield et al.,
1989) (see Chapter 5). Exons 3 and 4 were amplified using a 5' primer lying closer
to the beginning of the exon to ensure good resolution of bands in the gel by
eliminating one of the higher temperature domains of each fragment (De Bellis et al.,
1992).
For exon 1, an identical procedure was followed except that for the glycine
repeat coding region of exon 1 primers were used without the GC clamp, because the
GGC repeat region functions as a clamp in this PCR fragment (De Bellis et al,
1992).
3.2.3. Primers for temperature gradient gel electrophoresis
Temperature gradient gel electrophoresis (TGGE) was performed on samples
amplified with the same primers as were used for DGGE.
3.3. Polymerase chain reaction
Individual exons of the androgen receptor gene were amplified by the polymerase
chain reaction (PCR) (Saiki et al., 1988) using pairs of oligonucleotide primers
prepared as described above. The standard PCR reaction mixture was as follows: 50
mM KC1, 10 mM Tris.HCl pH 9.0, 1.5 mM MgCl2, 0.01% gelatin, 0.1% Triton
X100, 100 (iM dNTPs (Pharmacia Biosystems Ltd., Milton Keynes, UK), 0.5 (iM
each primer, 0.5 unit Thermus aquaticus DNA polymerase (Taq polymerase,
Promega Ltd., Southampton, UK), and 0.5-1.0 p.g genomic DNA in a final volume
of 100 jxl. Each tube was layered with mineral oil to prevent evaporation.
Amplification conditions typically consisted of an initial melt at 94°C for 2 minutes
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followed by 30 cycles of melting for 0.5 minute at 94°C, annealing for 1 minute at
55°C and extension for 0.5-1.0 minute at 72°C. Reactions were carried out in a
thermal reactor (Hybaid UK Ltd., Teddington, UK).
3.4. Purification and quantification of PCR products
Aliquots (10-20 (il) of each completed reaction were analysed by electrophoresis
with suitable molecular weight markers in Nuseive agarose gels (0.8-3.0%)
(Flowgen Instruments Ltd., Sittingbourne, UK) run in lx TBE buffer (90 mM Tris
pH 8.0, 90 mM boric acid, 2 mM EDTA) containing ethidium bromide. DNA bands
were visualised by examination of the gel under ultraviolet light. Samples
containing a single species of DNA of the expected size were purified using a PCR
purification spin kit (Qiagen GmbH, from Hybaid UK Ltd.) or Clontech Chromaspin
columns (Clontech Laboratories, from Cambridge Biosciences, Cambridge, UK) and
quantified by comparison with ethidium bromide/DNA standards (Sambrook et al.,
1989).
Where the reaction amplified more than one species of DNA, the remainder of
the sample was electrophoresed through a Nuseive agarose gel run in lx TAE buffer
(40 mM Tris pH 8.0, 40 mM sodium acetate, 1 mM EDTA). The desired band was
cut from the gel and the DNA recovered using a "Geneclean kit" (USB, from
Cambridge Biosciences).
3.5. Sequencing of PCR amplified DNA
3.5.1. Radioisotopic sequencing
Sequencing of purified fragments of DNA was performed using Sequenase enzyme
(Cambridge Biosciences) following a modification of the standard protocol.
Samples of DNA (0.5-1.0 |lg) were mixed with 1 (il of dimethylsulphoxide (DMSO),
300 ng of primer, 2 (il 5x Sequenase reaction buffer (200 mM Tris.HCl pH 7.5, 100
mM MgCl2, 250 mM NaCl) and made up to a final volume of 10 |il with sterile
distilled water. The double stranded DNA was thoroughly denatured by heating to
99°C for 2 minutes and then immediately placed on ice. To the mixture was added 1
fil 0.1M dithiothreitol (DTT), 2 (il labelling mix (1.5 (iM of each: dGTP, dCTP,
dTTP), 0.5 |il 35S-labelled dATP (10 |iCi/[il) (Amersham International pic,
Aylesbury, UK) and 13 units of Sequenase enzyme, diluted according to the
manufacturer's instructions. The reaction was incubated at room temperature for 5-
10 minutes, aliquoted to each of four tubes containing 2 |il of the appropriate
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termination mix (80 pM each of dATP, dCTP, dGTP, dTTP, 50 mM NaCl and 8 pM
of each di-deoxynucleotide) prewarmed to 37°C. Termination mixes were incubated
at 37°C for a further 10 minutes before stopping the reactions with 4 pi stop solution
(95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol
FF). Samples were stored at -20°C until analysis.
Sequencing gels were poured into a BioRad "Sequi-Gene" sequencing cell
(BioRad Laboratories Ltd., Hemel Hempsted, UK). Gels were of 12 M urea, lx
TBE and 10% acrylamide (acrylamide: bisacrylamide 19: 1). Solutions were mixed
immediately before use and filtered through 0.45 pm filters. Polymerisation was
initiated by the addition of TEMED (N, N, N', N'-tetramethylethylenediamine) and
10% ammonium persulphate (BioRad Laboratories Ltd.). Gels were run vertically
at 1,800 V and 50°C and then dried and exposed to X-ray film (Kodak X-OMAT
AR) for 24 -72 hours at room temperature.
3.5.2. Fluorescent sequencing
Fluorescent sequencing was performed using an Applied Biosystems 373-A
automatic DNA sequencer and fluorescent dye terminators according to the
manufacturer's protocol (Applied Biosystems Ltd.). Reactions were carried out in 20
pi TACS buffer (80 mM Tris.HCl pH 9.0, 2 mM MgCl2, 20 mM (NH4)2S04)
containing 0.5-1.0 pg DNA template, 4 units of AmpliTaq™ DNA polymerase
(Cetus Corporation, from Applied Biosystems Ltd.), 1 pi each Dyedeoxy™
terminator, 37.5 pM dITP, and 7.5 pM dGTP, dCTP and dTTP. Reactions were
overlaid with mineral oil and sequencing carried out in a Perkin Elmer thermal
cycler model 480. Typical conditions were 25 cycles of denaturing at 96°C for 30
seconds, annealing at 50°C for 15 seconds and extension at 60°C for 4 minutes. For
sequencing of the glutamine repeat region of exon 1, annealing and extension times
were increased by 50%.
Following completion of the programme, samples were stored at 4°C until
required. 80 pi of pure water were added to each sample and excess dye terminators
removed by two extractions with an equal volume of phenol: water: chloroform (68:
18: 14). After the second extraction the aqueous phase was removed to a clean tube
and the DNA precipitated by the addition of 15 pi 3 M sodium acetate, pH 4.5 and
300 pi absolute ethanol. Following incubation for 2 hours at 4°C, DNA was
recovered by centrifugation at 13,000 rpm for 30 minutes at 4°C. The pellets were
washed with 70% ethanol, left to air dry, dissolved in 4 pi of loading buffer
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(formamide: 50 mM EDTA, 5:1) and heated to 95°C for 5 minutes before loading to
the top of the gel.
Gels containing 6% acrylamide (acrylamide:bis-acrylamide 19:1), 8 M urea
and lx TBE in 100 ml were poured between optically clean glass plates and allowed
to polymerise for 1 hour before use. Reagents were deionised using Amberlite ion
exchange resin (Sigma Chemical Co. Ltd., Poole, UK) before the addition of buffer,
filtered through a 0.45 pm filter and polymerisation initiated by the addition of 45
pi TEMED and 0.5 ml 10% ammonium persulphate (BioRad Laboratories Ltd.).
Gels were run vertically in the Applied Biosystems 373-A sequencer at a
temperature of 40°C. The gel apparatus automatically read the fluorescent signal
generated and stored the data on a connected Macintosh Il-Ci computer, using
software supplied by Applied Biosystems.
The data generated from the automatic sequencer and the sequences manually
entered from the autoradiographs of sequencing gels were analysed and compared to
the androgen receptor gene sequence published by Lubahn et al. (1989) using the
GeneJockey software package (Biosoft, Cambridge, UK).
3.6. Culture and storage of bacterial cells
Good microbiological practice was employed in the handling of all bacterial
cultures. Stock cultures of Escherichia coli (E. coli) were stored at -70°C in 15%
glycerol. Cells were streaked from stocks and cultured on LB-agarose plates (1%
tryptone, 0.5% yeast extract, 1% w/v NaCl, 1.5% agar) at 37°C overnight. A single
colony from each plate was picked for analysis or further manipulations. Where
appropriate, ampicillin at 50 pg/ml was added to the medium. Liquid cultures of
cells were prepared by inoculation of a single picked colony into a starter culture of
L-broth (1% tryptone, 0.5% yeast extract, 1% w/v NaCl) and incubated at 37°C with
mixing at 200 rpm. A small volume of the starter culture (typically 3 ml) was added
to 1,000 ml of LB-broth and incubated at 37°C and 200 rpm until the optical density
of the solution at 600 nm (OD600) was 0.45-0.55. Cells were harvested by
centrifugation at 2,000 rpm for 10 minutes. Where indicated ampicillin at 50 pg/ml
was added to liquid cultures.
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3.7. Preparation of plasmid DNA
3.7.1. Large scale preparation
A liquid culture was started from a single colony of bacteria containing the desired
plasmid. When the OD600 of the culture was 0.45-0.55 cells were harvested by
centrifugation at 10,000 rpm and 4°C in a Beckman centrifuge. Plasmid was
recovered from the cells using a Promega Magic Maxiprep kit according to the
manufacturer's instructions (Promega Ltd.). Typical yields were 500-1,000 [ig of
plasmid DNA from 500 ml of cell culture. Purity of the DNA was calculated from
the ratio of OD260 to OD280 and was typically greater than 1.84. DNA was taken up
in sterile distilled water or TE buffer.
3.7.2. Small scale preparations
Small scale preparation of plasmid DNA was performed from a 3 ml culture of cells,
using a Promega Magic Miniprep kit (Promega Ltd.). Typical yields were of 2.5 fig
of high purity DNA.
3.8. Electroporation
3.8.1. Preparation of competent E. coli
A 100 ml liquid culture was prepared by inoculation with a single colony. When the
OD600 was between 0.45 and 0.50 the cell suspension was chilled on ice for 10
minutes and centrifuged at 4,000 rpm for 10 minutes at 4°C. Cells were resuspended
in 100 ml ice cold 10% glycerol, incubated on ice for 1 hour and harvested by
centrifugation as before. After resuspension in 10 ml cold 10% glycerol and a
further 1 hour incubation on ice, cells were harvested and suspended in 400 ftl cold
10% glycerol, and stored in aliquots of 40 jil at -70°C until required.
3.8.2. Transformation ofE. coli
Aliquots of electrocompetent E. coli were allowed to thaw on ice. Purified plasmid
DNA was added to each aliquot at a concentration of 1-5 ng/vial and the suspension
left on ice for 2 minutes. The cells were transferred to an ice cold 2 mm
electroporation cuvette (BioRad Laboratories Ltd.) and placed in the Gene Pulser
electroporation unit (BioRad Laboratories Ltd.). Electroporation was performed at
2.5 kV with a capacitance of 2.5 fiFarad and resistance of 200 Q. for 15 seconds.
Electroporated cells were then resuspended in 1 ml of SOC medium (2% tryptone,
0.5% yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 mM MgCl2, 10 mM MgSC>4, 20
mM glucose) or LB-broth and incubated at 37°C with gentle shaking for 45 minutes.
Transformed cells were harvested by centrifugation at 2,500 rpm for 5 minutes at
4°C, resuspended in 100 |il medium, spread onto LB plates with an appropriate
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antibiotic for selection (see above) and incubated at 37°C overnight. For some
experiments, selection was made directly in liquid culture. After the initial
incubation period 4 ml medium containing the selection antibiotic was added
directly to the culture bottle and incubation continued overnight
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0 5'-GCCTGCAGGTTAATGCTGAAGACC-3' 5'z 5'-CCTAAGTTATTTGATAGGGCCTTGCC-3' 3'
5'-GTTTGGTGCCATACTCTGTCCAC-3' * 5'
3 5'-TTATCAGGTCTATCAACTCTTGT-3' # 5'
5'-CTGATGGCCACGTTGCCTATGAA-3' 3'
5'-GGAGTTTAGAGTCTCTGACCAGG-3' * 5'







7 5'-CTTTCAGATCGGATCCAGCTATCC-3' 5'' 5'-CTCTATCAGGCTGTTCTCCCTGAT-3' 3'
8 5'-GAGGCCACCTCCTTGTCAACCCTG-3' 5'5 5'-GGAACATGTTCATGACAGACTGTACACTA-3' 3'
All primers were used as shown to amplify exons for sequencing and to amplify
exons for DGGE/TGGE analysis with the addition of the GC-clamp to the 5' primer
(see text).
Exon 1 was amplified in four fragments: A1A2= nucleotides 1-427; A3A4= 384-
799; A5A6= 721-1248; A7A10= 1148-1753.
For exons 3 and 4 the primers were used as follows: *= used for PCR amplification
of exon for sequencing; #= used for PCR amplification of exon for DGGE/TGGE
analysis.
Chapter 4. Androgen receptor gene mutations
in androgen insensitivity syndromes
4.1. Introduction
The occurrence of point mutations and deletions in the androgen receptor gene of
patients with the various forms of androgen insensitivity (AIS) is now well
documented (reviewed by Wilson, 1992). Correlation of the nature and site of such
lesions with their effect upon the function of the receptor in vitro and the in vivo
phenotype has provided information on the role of certain amino acids in the receptor.
The elucidation of the genetic lesions in more patients with AIS will clarify further the
structure/function relationships of the various regions of the receptor and also enhance
our understanding of the nature of inherited disease in general.
This chapter will deal with the analysis of DNA both from patients with clinical
features diagnostic of androgen insensitivity and from those patients with features
suggestive of androgen resistance who could not be firmly classified. The findings
will be discussed and considered in the context of the data from other researchers.
4.2. Patients
Blood samples were initially obtained from four patients with complete AIS and from
eight with partial AIS or clinical features suggestive of partial AIS. During the course
of the study samples became available from a further two patients with complete AIS
and one with features suggestive of partial AIS. DNA was extracted from these
samples and the AR gene analysed for the presence of mutations. Many of these
patients had been seen over several years by various clinicians and the information
was not complete in every case.
4.2.1. Complete androgen insensitivity
Patient 1 (S-AR) was referred to hospital at the age of 18 for investigation of
primary amenorrhoea. On examination she had a normal female appearance with
scanty pubic hair. Vaginal examination revealed a short vagina and the absence of
cervix and uterus. Karyotyping confirmed the diagnosis of testicular feminisation
with the finding of a normal male 46 XY pattern. She subsequently had gonadectomy
performed.
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Patient 2 (AC/c) was similarly referred because of primary amenorrhoea at the
age of 17 years. She presented a similar picture as patient 1 and karyotyping revealed
a 46 XY pattern. She underwent gonadectomy at the age of 19 and was commenced
on oestrogen replacement therapy.
Patient 3 (CG) presented at age 3 years with an inguinal hernia. The diagnosis
of testicular feminisation was made at the age of 6, following the birth of twin sisters
who were diagnosed with the same syndrome shortly after birth. She underwent
gonadectomy at age 23. She had a normal female habitus and her karyotype was 46
XY. She has a very strong family history of testicular feminisation which admirably
illustrates the X-linked inheritance pattern of the condition (Fig. 4.1).
Patient 4 (JR) presented at age 4 years with bilateral inguinal herniae. She was
admitted for surgical repair of these, at which time they were noted to contain testes.
There appeared to be no uterine or cervical tissue present. Gonadectomy was
performed and the histology reported as showing immature seminiferous tubules.
Karyotyping revealed a 46 XY pattern consistent with the diagnosis of complete AIS.
Plasma Cortisol, ACTH and urinary steroid were measured to exclude congenital
adrenal hyperplasia from the diagnosis. She is currently under annual follow up and
is due to have puberty induced at a suitable age.
Patient 5 (LI) presented at the time of a hospital admission for abdominal pain at
the age of 17 years. She was noted to have an absent cervix on rectal examination and
a later full gynaecological examination confirmed the absence of cervix, uterus and
Fallopian tubes. She was tall with long limbs, possessed a normal female habitus
with adequate breast development and scanty pubic hair. Karyotyping was performed
and reported as 46 XY. Laparotomy was performed at which the absence of internal
genitalia was confirmed; gonadectomy was carried out and the histology reported as
showing normal testicular tissue with seminiferous tubules and Leydig cell hyperplasia
but with no evidence of spermatogenesis.
Patient 6 (I) also presented to hospital with primary amenorrhoea, and was
found to have no internal genitalia on examination. Karyotyping confirmed the
diagnosis, being reported as normal 46 XY male pattern. The patient had been
referred from elsewhere and case notes were not traceable and therefore no further
information was available.
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4.2.2. Partial androgen insensitivity
A summary of serological, biochemical and in vitro androgen binding data available
from the case notes of patients 7 to 15 is presented in Table 4.1. Patient 7 (GHg) was
a 36 year old male with a 46 XY karyotype who was bom with ambiguous genitalia
but with palpable labial testes. He was reared as a boy and underwent numerous
penile reconstruction operations. At age 13 he developed bilateral gynaecomastia
requiring simple mastectomy. He had never needed to shave. His pubic hair had a
female distribution, the penis was 3 cm in length and the testes measured 6 ml and 8
ml. He was married and able to have intercourse, but had never produced an
ejaculate. Genital skin fibroblasts (GSF) failed to grow in culture and so 5 a-
reductase activity was not measured.
Patient 8 (AC/p) was 35 years old and the youngest of three brothers. The
whole family exhibited defects of virilisation and has been reported by Jukier et al.
(1984). Patient 8 had perineoscrotal hypospadias requiring a two stage repair,
gynaecomastia and a high pitched voice. Pubic hair distribution was normal but he
had scanty facial hair. The GSF cell line derived from patient 8 was lost before any
studies could be performed on it (Jukier et al., 1984) but 5 a-reductase activity was
measured and found to be normal. The two older brothers had severe abnormalities
including third degree penile hypospadias, bifid scrotums and gynaecomastia. They
both had sparse pubic hair and a female distribution of body fat. Specific
dihydrotestosterone binding activity of genital skin fibroblasts of the patient's brothers
showed a normal total number of binding sites (Bmax)> but the equilibrium
dissociation constant (Kd) was 1.16 nmol/1, compared to 0.22 nmol/1 in normal men.
Thus, the brothers appear to have a combination of 5 a-reductase deficiency and
impaired androgen receptor function giving rise to their undervirilisation while patient
8 would appear to have the qualitative abnormality of androgen receptor action in
isolation. It was not possible to obtain DNA samples from the brothers.
Patient 9 (JS) was born with ambiguous external genitalia showing a minute
phallus, non-fusion of labioscrotal folds and bilateral inguinal testes. Bilateral
mastectomy was performed because of marked gynaecomastia at age 18 years.
Because of repeated epididymitis the left testis was removed from the labioscrotal fold;
histology showed Sertoli cell-only seminiferous tubules and abundant Leydig cells.
The right testis was extremely small. In his family, abnormalities of male sexual
development have been evident in three generations consistent with transmission of an
X-linked recessive trait via carrier females (Fig. 4.2). Treatment with intramuscular
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Sustanon 250 mg/month (30 mg testosterone propionate, 60 mg testosterone
phenylpropionate, 60 mg testosterone isocaproate, 100 mg testosterone decanoate) had
no effect upon secondary sexual characteristics (hair growth, sebum secretion and
muscle anabolism) over two years.
Patient 10 (JM) presented at age 3 years for hypospadias repair. At 13 years he
underwent right orchidopexy for an undescended right testicle. He developed
gynaecomastia at 16 years and required bilateral mastectomy. Development of pubic
and axillary hair began only at age 15, and he had never shaved. The patient had
normal male habitus and musculature. Pubic hair was well developed but of a female
pattern with no escutcheon. The penis was 3 cm long and the urethral opening found
1 cm from the tip of the glans. The right testis was 15 ml and the left 20 ml in
volume, and both were of normal consistency. He had normal libido and was able to
maintain erection (erect penis length of 3 cm) and achieve orgasm but could produce
only a minute volume of azoospermic ejaculate. The prostate gland was small.
Biopsy of the testis showed arrest of spermatogenesis at the spermatogonia stage with
complete absence of spermatids. A diagnosis of Reifenstein's syndrome was made
and he was commenced on long term intramuscular Sustanon treatment at 500 mg
every two weeks for a period of two years. During that time there was no change in
his previously normal frequency of erection and sexual activity.
4.2.3. Atypical androgen resistance
Patient 11 (WF) was a 44 year old man who presented with erectile impotence and
failure of ejaculation. He was an apparently normal male with normal body habitus,
secondary sexual characteristics and two children aged 14 and 6 years. His genitalia
appeared normal with testes of 15 ml and 20 ml volume, and routine hormone
screening showed a grossly elevated serum testosterone in association with an elevated
steroid hormone binding globulin (SHBG) concentration and normal gonadotrophins.
On direct questioning he admitted to shaving at most twice a week and his facial hair
was sparse and fine. No cause for the elevation of SHBG was found and over the
course of six months his sexual function appeared to deteriorate. There was no
evidence of muscular or neurological deficit and no other signs of androgen
insufficiency.
Patient 12 (JL) was 44 years old and had been born with perineoscrotal
hypospadias and a bifid scrotum which required a three stage surgical repair. On
examination he had a normally pitched voice, scanty facial hair and pubic hair of
female pattern. The left testis was palpable in the scrotum, soft and 1 ml in volume.
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Karyotyping revealed an apparently normal 46 XY pattern and a semen analysis
showed azoospermia. He was commenced on oral fluoxymesterone 5 mg three times
daily in an attempt to improve facial hair growth. Some improvement was obtained
but he also developed bilateral gynaecomastia which required surgical removal.
Hormone analysis revealed him to have a low serum testosterone (Table 4.1) and
elevated FSH and LH. An hCG stimulation test suggested some response and he was
commenced on intramuscular Sustanon at 250 mg per month. This treatment
provoked some response with an increase in facial and body hair, increased libido and
an increase in the girth of his penis. It was felt that the response was slightly less than
optimal and on the basis of this and the nature of his previous complaints it was
suggested that his androgen receptor gene should be screened to exclude any
abnormality.
Patient 13 (KW) was 16 years old and had been born with bilateral
cryptorchidism and perineoscrotal hypospadias. The hypospadias required several
operations and at the age of 5 he was treated with topical testosterone to increase the
size of his penis before a definitive repair of the defect. Some increase in size of the
penis was achieved in response to this; at this time the testes were palpable at the
internal inguinal ring on each side, being of very small volume. He underwent right
orchidopexy at age 5, but the left side was deferred in the hope of spontaneous
descent. However, this did not occur and his penis remained very small and at age 11
he had a course of intramuscular testosterone to improve the size of his genitalia before
a left sided orchidopexy was performed. Good penile growth was seen in response to
the injections and following the second orchidopexy he entered puberty spontaneously
and seemed to develop normally, but slowly. He was discharged from follow up at
age 16 with testicular volumes of 7 and 10 ml.
Patient 14 (GHd) was born in 1979 and presented at birth with severe
perineoscrotal hypospadias, cryptorchidism of the left side and a firm mass of tissue in
the right scrotum. He underwent examination under anaesthesia at the age of 1 week,
at which time the right sided mass was excised, having the appearance of a tumour.
Histology reported it to be an androblastoma, a rare tumour of gonadal stroma.
Karyotyping revealed a normal 46 XY pattern. At the age of 4 years he underwent
repair of the hypospadias when the left testicle was noted to be at the inguinal ring and
of very small size. There was no change in the size of this over the next five years.
At this time he was investigated by an endocrinologist and found to have no remaining
functional testicular tissue (Table 4.1). Blood was taken at this point to exclude any
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AR gene defect. At the age of 11, he was commenced on exogenous androgens to
induce puberty and initial results appeared normal. However, after 4 years of
androgens, although pubic and facial hair development was fairly normal, it was not
fully developed and there had been only a slight increase in size of his penis and
scrotum.
Patient 15 (RG) was 31 years old and presented with his wife for investigation
of primary infertility. He had been born with bilateral inguinal herniae and a right
hydrocoele requiring surgery. There was no history of abnormal pubertal
development or gynaecomastia. On examination he appeared normally virilised with
normal external genitalia. His testes were 15 ml on the left and 20 ml on the right.
The right testis was very soft and could be easily pushed into the inguinal canal. A
semen analysis revealed a sample of 8 ml volume with abnormal liquefaction and a
sperm concentration of less than 1 million/ml semen. Serum hormone profile (Table
4.1) revealed elevated blood levels of gonadotrophins suggestive of a defect of
spermatogenesis and some borderline unresponsiveness to androgens.
4.3. Methods
4.3.1. Analysis of DNA samples
DNA was extracted from the blood samples as described in Chapter 3 (section 3.1).
PCR amplified exons of the AR gene from each patient were analysed by direct
sequencing of the DNA (Chapter 3, section 3.5). The samples from patients obtained
later in the study were analysed by the technique of denaturing gradient gel
electrophoresis (DGGE) since the method had become established by that time (see
Chapter 5).
4.3.2. Culture of genital skin fibroblasts
Genital skin fibroblasts (GSF) were cultured by Dr Malcolm Hodgins (Department of
Dermatology, Robertson Building, University of Glasgow, Glasgow) and all the
androgen binding, nuclear translocation and up-regulation assays were performed by
him according to recognised protocols (Hodgins, 1982; Hodgins et al., 1984; Ring &
Hodgins, 1984).
4.3.3. Analysis of RNA samples
4.3.3.i. Extraction of RNA
RNA was extracted from genital skin fibroblasts according to the method of
Chomczynski & Sacchi (1987). GSF were grown in 75 ml culture flasks after
reseeding for 48 hours before harvesting. The medium was removed and the cells
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washed with 4 ml ice cold phosphate buffered saline (Flow Laboratories, Irvine, UK)
before the addition of 1 ml of solution D (4 M guanidinium thiocyanate, 25 mM
sodium citrate, 0.5% sarcosyl, 0.1 M (3-mercaptoethanol) to lyse the cells. After
washing the flask with a further 1 ml of solution D, the pooled lysate was decanted
into a sterile tube and mixed sequentially with 0.1 volume of 2 M sodium acetate pH
4.0, 1 volume of water saturated phenol and 0.2 volume of chloroform: isoamyl
alcohol (49: 1). The tubes were shaken for 15 seconds and incubated on ice for 15
minutes before centrifugation at 10,000 rpm for 20 minutes at 4°C. The upper
aqueous phase was removed to a fresh tube and the RNA precipitated by the addition
of 1 volume of cold isopropanol. After incubation at -20°C for 1 hour the RNA was
recovered by centrifugation at 10,000 rpm for 20 minutes at 4°C, redissolved in 0.3 ml
solution D and re-precipitated by the addition of isopropanol as before. The RNA
pellet was then washed in 75% ethanol, vacuum dried for 2 minutes, dissolved in 50
p.1 pure, RNAase-free water and the concentration and purity calculated by measuring
the OD260 and OD280 as described in Chapter 3 (section 3.7.1). A typical value for
the OD260: OD280 was 1.8 or greater.
4.3.3.ii. Reverse transcriptase PCR
To determine whether splicing was impaired at the exon 5/6 splice site reverse
transcriptase PCR (rtPCR) was performed on total RNA extracted from GSF of
patient 10 using exonic primers to amplify across the whole of exons 5 and 6. These
were: exon 5 (sense) : 5'- GCTTCCGCAACTTACAC -3'; exon 6 (antisense): 5'-
TAATGCTGAAGAGTAGCAG -3'. Total RNA (250 ng) was added to the reaction
mix which contained 0.75 pM 3' primer, 200 [iM dNTPs, 10 mM MnCl2, 10 mM
Tris.HCl pH 8.3, 90 mM KC1 and 5 units rTth DNA polymerase (Cetus Corporation,
from Applied Biosystems) in a final volume of 20 (il sterile water overlaid with
mineral oil. rTth is a DNA polymerase with reverse transcriptase activity in the
presence of manganese chloride. Reverse transcription was performed by denaturing
the RNA at 95°C for 5 minutes, annealing the primer at 50°C for 10 minutes followed
by incubation for 15 minutes at 72°C. An additional 80 |il of PCR reaction buffer was
added to each reaction to give a final 100 fil volume containing 5% glycerol, 10 mM
Tris.HCl pH 8.3, 100 mM KC1, 750 pM EDTA, 0.05% Tween 20, 1.5 mM MgCl2,
and 0.15 (iM 5' primer. Reactions were completed by 35 cycles of denaturing at 95°C
for 2 minutes, annealing at 50°C for 1 minute and extension at 72°C for 2 minutes.
Electrophoresis through a 2% Nuseive agarose lx TBE gel was performed on 20 |il of
sample to examine the reaction products as described in Chapter 3 (section 3.4).
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4.4. Results
The results of sequencing and screening of the AR gene in the patients with androgen
insensitivity are summarised in Tables 4.2 & 4.3. Point mutations were detected in
three of the six patients with complete AIS and in four of the nine patients with partial
AIS. Five of these were detected by direct sequencing (Fig. 4.3) and two by DGGE
(Chapter 5, Fig. 5.4). All detected mutations were confirmed by reamplifying the
affected exon from the original DNA and repeating the sequencing twice, in order to
eliminate the possibility of PCR artefacts.
The AR gene sequences of patients 1, 2, 4, 6, 7-9, and 12-13 were partly
obtained by Dr. T. Padaychi; exons 2, 3, 7 and 8 were sequenced by him and the
mutations in these exons in patients 1, 7, 8, and 9 were identified by him (exon 7 in
patient 2 was sequenced by myself). The full sequence in these patients and the exon
1 sequences in all of them were entirely my own work (see also Tables 4.2 and 4.3)
In patient 1, a single nucleotide mutation of cytosine to thymidine which
changed the codon for the conserved amino acid arginine 855 to cysteine was detected.
The glutamine repeat region contained 20 residues (Fig. 4.4). Patients 2 and 3 each
had a single nucleotide mutation which introduced a premature termination codon into
the coding sequence of the receptor: cytosine to thymidine in the codon for arginine
831 in patient 2, and the same mutation in the codon for arginine 752 in patient 3
(Figs. 4.5 & 4.6).
Patients 7 and 8 shared the same mutation of guanosine to thymidine, changing
the codon for valine 866 to leucine, although they were unrelated (Figs. 4.7 & 4.8).
The length of the glutamine repeat in each patient clearly indicates this. Patient 9
possessed a point mutation within the DNA binding domain of the receptor of
guanosine to adenosine which changed arginine 608 to lysine (Fig. 4.9). Patient 10
had a mutation of adenosine to guanosine, changing glutamic acid 772 to glycine (Fig.
4.10 and Fig. 5.4, Chapter 5). This mutation also altered the sequence of the 5' splice
site of intron 5 but reverse transcriptase PCR of RNA isolated from GSF of this
patient amplified a single band of comparable size to that generated by PCR from a
plasmid bearing the AR cDNA (Fig. 4.11), consistent with the presence of a full
length mRNA transcript.
In patient 11 no point mutations were detected. However, following the
amplification of the glutamine repeat coding region of exon 1 a PCR product of
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increased size was generated (Fig. 4.12). Sequencing of the amplified DNA revealed
an approximate doubling in size of the repeat to 46 residues (Fig. 4.13).
Analysis of the entire gene in some patients was hampered by difficulties
encountered in PCR amplification of exon 1 of the gene. The glutamine repeat coding
region proved difficult to amplify in five of the patients and the glycine repeat coding
region was only successfully amplified from two samples. These two regions have
also proved refractory to PCR in the hands of other groups (Lubahn et al., 1989;
Marcelli et al., 1990a). In a few cases, sequencing was unable to entirely resolve the
identity of some bases and re-amplification of the exon was not possible. These are
indicated by 'N?' in Tables 4.2 & 4.3.
Two patients (9 and 10) had had genital skin biopsies performed and androgen
binding parameters had been measured on genital skin fibroblasts by Dr Malcolm
Hodgins (Glasgow). The results are included in Tables 4.4 and 4.5.
4.5. Discussion
The androgen receptor gene sequence has been examined by a combination of
direct sequencing and screening in fifteen patients with symptoms, signs and
endocrine data compatible with androgen resistance. Six of these patients had
complete androgen insensitivity by the criteria of female habitus, 46 XY karyotype,
elevated testosterone and male gonads and mutations have been detected in the AR
gene of three of them. The mutation in patient 1 changes the codon for arginine 855
into a cysteine codon. This same mutation has been detected by De Bellis et al. (1992)
in a different patient with complete AIS and found to completely abolish androgen
binding of the receptor when expressed in vitro. Arginine 855 has also been found to
be mutated to a histidine residue in two patients with partial AIS (Chang et al., 1991;
Batch et al., 1992) and a comparison of the change in amino acid structure in each case
is revealing (Fig. 4.14). The normal amino acid is a positively charged amino acid
with a bulky side chain, and in our patient with complete AIS the substituted amino
acid is polar with a very small side chain group. The amino acid substituted in the
patient with partial AIS is another charged amino acid with a large side chain. These
features suggest that the substituted amino acid affects the function of the receptor
because the charge and size of the normal residue are important. Loss of charge and
size severely disrupts the function while a change to a different charged amino acid
(with a larger side chain) causes a less severe effect. This residue is within the region
of the heptad hydrophobic repeat thought to be involved in steroid binding and
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dimerisation (Fawell et al., 1990; Parker & Bakker, 1992) and the need for a charged
amino acid of particular size at this position implies that arginine 855 has a role in
maintaining a particular spatial configuration within the steroid binding domain which
is necessary for normal function.
In patients 2 and 3, single point mutations have resulted in the introduction of
premature termination codons into the reading frame of the gene. In patient 2 the
codon for arginine 831 is changed by a cytosine to thymidine transition and in patient
3 the codon for arginine 752 is changed by the same nucleotide substitution (Fig. 4.5
& 4.6). The occurrence of two mutations introducing termination codons in the six
patients in this study supports the theory that this is a frequent mechanism by which
the complete AIS phenotype is produced (Chapter 2, section 2.5.2.iii). Both these
substitutions are of the type described by Youssoufian et al. (1986) which occur by
methylation and deamination of cytosine to thymidine at CpG couplets (see Chapter 2,
section 2.5.2.ii) and which Quigley et al. (1992c) calculated were responsible for 50%
of the mutations that have been detected in the hormone binding domain. The
introduction of a termination codon will cause the synthesis of a truncated receptor
protein lacking a large part of the hormone binding domain which is therefore unable
to bind androgen. The introduction of a termination codon at 752 had not been
described elsewhere at the time it was identified in this patient, but Pinsky et al. (1992)
have recently reported another patient with this defect. The arginine 831 substitution
has been independently identified by De Bellis et al. (1992) and by Ris-Stalpers et al.
(1992) in unrelated patients. Brown et al. (1990) described a patient with complete
AIS with a mutation of arginine 831 to glutamine as a result of substitution of the
second base of the codon from guanosine to adenosine, and Pinsky et al. (1992)
reported a substitution of leucine at the same site in another complete AIS patient.
In the three patients in this study with complete AIS, all of them had mutations at
positions which have been found to be mutated in patients with complete and partial
AIS by other researchers (Chang et al., 1991; Batch et al., 1992; De Bellis et al.,
1992; Evans, 1992; McPhaul et al., 1992; Pinsky et al., 1992; Ris-Stalpers et al.,
1992). That multiple defects occur at the same site and that the same defects occur in
unrelated individuals suggests that the codons for these amino acids 752, 831 and 855
are particularly susceptible to mutation.
The three patients with complete AIS in whom no mutations were found present
a perplexing problem. On clinical grounds there was no difference between these
three and the patients described above. It may be that there are mutations lying within
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the regions of exon 1 which were resistant to PCR and therefore undetected by this
study. Some mutations have been described in this exon including termination codon
insertions (McPhaul et al., 1991; Zoppi et al., 1993) and the insertion and deletion of
nucleotides (Batch et al., 1992). In patient 5 the entire gene was screened by DGGE
and although the sensitivity of detection is around 95% (Myers et al., 1985b) it is
possible that this patient harbours a mutation which cannot be detected by the method.
The other possibility is that these patients in fact do not have mutations within the
coding sequence of the AR gene. Direct PCR of individual exons of the gene from
genomic DNA will not have identified rearrangements of the gene which leave the
exons intact which might be detected by Southern analysis (Brown et al., 1988).
However, whilst the presence of large deletions can be excluded on the basis of
successful PCR reactions in each case, it is possible that a chromosomal translocation
or inversion of some kind has occurred in one or more of these patients which
interrupts the transcription and translation of the whole gene sequence. There may
also be mutations or other abnormalities of function of the promoter and enhancer
regions that modulate transcription of the AR gene which might lead to aberrant,
reduced or absent synthesis of the AR protein.
Among the nine patients with partial androgen insensitivity and those with signs
of impaired virilisation, defects were detected in four. Patients 7 and 8 possessed the
same mutation despite being unrelated (Fig. 4.7 & 4.8). The mutation of valine 866 to
leucine alters one of the key hydrophobic amino acids in the dimerisation domain of
the AR. Lubahn et al. (1989) identified a mutation causing a substitution of
methionine for the same amino acid in a patient with complete AIS and our finding of
an identical mutation in two patients at the same site supports the theory put forward
by them that amino acid 866 is a "hot-spot" for mutation in the same way as the amino
acids discussed above. As with the mutations at position 855, an examination of the
structure of the amino acids provides some clues to the mechanism by which the
mutations cause their effects (Fig. 4.15). Valine and leucine are both hydrophobic
with compact side chains, while methionine has a longer side chain. The change to a
larger amino acid in the hydrophobic repeat of exon 7 appears to cause a severe
disruption to steroid binding and dimerisation, giving rise to the complete AIS
phenotype while the change in patients 7 and 8 appears to affect the normal function of
the receptor less severely, judging by the less severe abnormalities in these patients.
Patient 9 was the only patient in whom a mutation was detected in the DNA
binding domain of the receptor. The mutation in exon 3 of arginine 608 to lysine
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changes an amino acid which lies towards the tip of the second zinc finger and is
conserved throughout the entire steroid receptor superfamily (Figs. 4.9 & 4.16). The
second finger is involved in orientation of the receptor for DNA binding, stabilising
DNA/protein interactions between other members of the transcription complex, and
providing the interface for dimerisation (Freedman, 1992). Crystallographic analysis
of the second zinc finger has identified the amino acids which are in direct contact with
the DNA of the hormone response element during binding of the domain to the HRE
(Luisi et al., 1991). Arginine 608 (and its equivalent in the other steroid receptors)
makes specific contact with the phosphate backbone of the DNA within the HRE, and
is thus a key residue in correctly orienting the dimerisation surface of the zinc finger.
Substitution of the equivalent arginine (498) in the glucocorticoid receptor (GR) by
lysine has been shown to inhibit binding to a glucocorticoid response element (GRE)
in vitro (Schena et al., 1989). This mutant GR was able to activate transcription from
an MMTV-CAT (mouse mammary tumour promoter-chloramphenicol acetyl
transferase) reporter gene as efficiently as a wild type GR when transfected into CV-1
cells, but showed markedly reduced activity when expressed in yeast. It is clear from
the phenotype of patient 9 that arginine 608 to lysine has markedly impaired function
in several target tissues, including external genitalia, testes and androgen sensitive hair
follicles. Studies of nuclear uptake of receptor in GSF (Table 4.4) indicate that this
mutation has some effect upon nuclear binding without abolishing it completely. This
may be due to an alteration of binding affinity by the mutation directly or to failure of
stabilisation of the receptor dimer. The marked tissue effects of the androgen
insensitivity despite residual nuclear binding in this patient may be explained by an
interaction of the AR with other steroid receptors or transcription factors. Both AR
and GR can bind to the same response element (HRE) and they may compete with
each other for binding to other nuclear factors such as jun and/os, and thereby
regulate each other's actions (Chaucereau et al., 1992; Parker & Bakker, 1992). The
mutation at 608 may alter the affinity of the AR for heterodimer formation and thereby
alter the normal interaction between these different molecules. Evidence for the
presence of factors which modulate the action of the steroid receptors in specific cell
types was provided by Bocquel et al. (1989) who found that the transactivating ability
of the members of the steroid family varied depending on which cell type the receptors
were expressed in. More recently McPhaul et al. (1992) described a number of
patients, some of whom shared the same molecular defect of the androgen receptor but
who showed markedly different severities of clinical features (e.g. complete AIS as
opposed to Reifenstein's syndrome). These data indicate that other factors in addition
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to the molecular lesion contribute to the physiological effect both in individual tissues
and between individual patients.
Patient 10 possessed a mutation within exon 5, detected by DGGE (Fig. 5.3,
Chapter 5), which altered the last nucleotide of the exon and results in a change from
glutamic acid 772 to glycine. The GSF androgen receptor from this patient showed
normal androgen binding capacity with a variably increased dissociation constant and a
biphasic dissociation pattern indicative of loss of stability of the receptor/ligand
complex. Exon 5 lies within the hormone binding domain of the androgen receptor
but outside the regions involved in dimerisation and nuclear localisation (Fawell et al.,
1990; Jenster et al., 1991). Marcelli et al. (1992) noted in three patients with complete
AIS that the effect of mutations on receptor function in exon 5 depended on the
location within the exon. Towards the N-terminal end, substitution of tyrosine 739 by
arginine abolished ligand binding completely while mutations nearer the C-terminal
end (phenylalanine 764 to leucine, and proline 766 to serine) altered ligand binding
qualitatively yet preserved a degree of transcriptional activation in cotransfection
assays. In view of the fact that patient 10 presented with defects of virilisation in
conjunction with an unambiguously male phenotype and relatively normal sexual
function (contrasting with the complete AIS phenotype in these other patients with
exon 5 mutations (Marcelli et al., 1992)) it would appear that the receptor with the
mutation at amino acid 772 retains significantly more transactivating ability than those
with mutations elsewhere in this exon.
The mutation of the last nucleotide of exon 5 introduces a mutation into the 5'
donor splice site sequence of intron 5 at the -1 position. Although a splice site
mutation has been reported in a patient with complete AIS resulting in a partial deletion
of exon 4 due to activation of a cryptic site (Ris-Stalpers et al., 1990), that mutation
was in the invariant GT couplet at +1/+2 (Green, 1986; Padgett et al., 1986) (Fig.
4.17). The sequence of the 5' site of intron 5 differs from the consensus sequence at
several positions including the -1 position and so generalisations about the effect of
mutations here cannot be readily made. Studies on the [3-globin gene have shown that
the effect of mutations in the splice site are unpredictable in any given instance
(Wieringa et al., 1983). Mutations in the intronic part of the sequence lead to partial
inactivation of the site and result in the presence of more than one size of mRNA
transcript. Activation of cryptic donor sites occurs when the mutation in the normal
site alters its binding affinity for the small nuclear ribonucleoprotein particles (involved
in splicing) to approach the affinity of any nearby cryptic sites (Nelson & Green,
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1990). An examination of the mutations found in splice sites of several genes where
cryptic site activation or exon skipping had occurred revealed that most of the
mutations in the original site were at the +1 or +2 positions (where the invariant GT
dinucleotide lies) while there was a relative lack of mutations at the -1 or -2 sites
(Krawczak et al., 1992).
On the basis of these findings one can propose that aberrant splicing of the pre-
mRNA in patient 10 is unlikely to occur, but an attempt was made to verify this by
amplifying exons 5 and 6 across the splice site by reverse transcriptase PCR from total
RNA in order to confirm the normal size of this mRNA fragment. Samples of total
RNA from patient 10 produced a single species of DNA when amplified by reverse
transcriptase with exonic primers from the 5' end of exon 5 (beginning at the first base
of the exon) to the 3' end of exon 6 (ending with the last base of exon). This band was
the same size as those from RNA from normal male skin fibroblasts and from a
plasmid bearing the human AR gene cDNA. Thus splicing at the 5' site of intron 5
appears not to be affected. However, the primers used to screen for cryptic splice site
activation do not include the fourth intron (between exon 4 and 5) and it could be
argued that a cryptic splice site upstream of exon 5 may have been activated. This
possibility should have been explored by repeating the experiment using a 5' primer
lying within or at the end of exon 4 as well.
It may be argued that the gel should have been Southern blotted and probed to
exclude the presence of another species of DNA in the reaction mix which would
represent a low copy number of aberrantly spliced RNA and which was not present in
high enough concentration to appear on ethidium bromide staining. However, since
reverse transcriptase PCR was used, even RNA species in low amounts should have
been amplified many-fold in the reaction and one would expect them to be visible on
the gel. The apparent weakness of the signal on the gel is compared to the PCR
reaction from a highly purified DNA plasmid (lane 5, Fig. 4.11), and both lanes from
RNA template have a similar intensity of staining. Therefore, I feel that a Southern
blot would not have provided any extra information, but it may have been worth
repeating the reverse transcriptase PCR in an attempt to improve on the amplification
of the samples.
Pinsky et al. (1992) have described a patient with partial AIS with a mutation at
amino acid 772 from glutamate to alanine. Both this change and the change in patient
10 are from an amino acid with a bulky, charged amino acid to one with a small
uncharged side chain (Fig. 4.18). This situation is in contrast to that for amino acids
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855 and 866 where even small changes in the size and charge of the side chain
produced an effect upon the activity of the receptor (Fig. 4.15 & 4.16) and suggests
that the C-terminal region of exon 5 is not subject to such severe conformational
constraints as the region of exon 7 from 850 to 866.
The nature of the abnormality detected in patient 11 is particularly interesting.
The size increase of the glutamine repeat region to approximately double the normal
range is exactly similar to that seen in patients with spinal and bulbar muscular atrophy
(SBMA) (La Spada et al., 1991) where this increase in the repeat of the AR gene is
thought to be the causative lesion of the disease. SBMA is an X-linked condition
which presents with bulbar palsy and lower motor neurone paralysis with onset in the
third decade of life (Kennedy et al., 1968). Some of the reported cases show features
of androgen resistance including gynaecomastia, testicular atrophy, oligospermia and
failure of erection (Arbizu et al., 1983). The clinical history and signs in this patient
are suggestive of only a very mild abnormality of androgen action with poor facial hair
growth in the presence of an elevated testosterone, associated with problems
maintaining an erection. No other stigmata of undervirilisation were apparent. He
showed no sign of neurological disease and was past the usual age of onset of SBMA,
although a few patients have been reported where symptoms appeared beyond age 40
(Stefanis et al., 1975; Barkhaus et al., 1982). His testicles were of normal volume.
La Spada et al. (1991) found that the increase in glutamine repeat was absolutely
associated with the disease state, being present in 35 patients and in none of 75 control
samples. It seems most likely that this man represents a late-onset variant of SBMA
but there is, at present, no evidence of neurological disease. The other possibility is
that the genetic lesion identified is an isolated phenomenon and not linked to any
disease but in view of the size of the study of La Spada et al. (1991) this is very
unlikely to be the case. Assuming that patient 11 goes on to develop SBMA this will
be the first incidence of analysis of the AR gene providing the diagnosis, and the first
description of a patient with SBMA presenting with androgen resistance rather than
neurological features.
The remaining patients in whom no mutations were found are a heterogeneous
group. Of these, patient 12 presented with the most undervirilised phenotype with
severe genital abnormalities in association with a female type body habitus.
Nevertheless he showed a considerable response to exogenous androgen both in terms
of hair growth and in genital development. It is possible that a mutation exists within
the glutamine or glycine repeat regions of exon 1 which would produce this pattern of
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apparent androgen unresponsiveness during fetal life followed by responsiveness in
later life since mutations have been reported by other workers which produce
apparently isolated defects of virilisation (Larrea et al., 1978; Grino et al., 1988;
McPhaul et al., 1991a). However, since hypospadias and cryptorchidism are
relatively common congenital abnormalities (Gearhart et al., 1988; Evans et al., 1991)
and can occur in otherwise healthy infants in the presence of normal androgen action
(Roberts & Lloyd, 1973), the undervirilisation and the absence of significantly
elevated testosterone levels in patient 12 may be due to testicular damage as a result of
his cryptorchidism.
Patient 13 appears to present exactly this picture of hypoandrogenism secondary
to testicular maldescent. The aetiology of the maldescent and hypospadias is unlikely
to be due to an abnormality of androgen action because there appeared to be a normal
response to androgen during his treatment and following puberty. Patient 14 seems to
have a primary failure of testicular development, since there was no functional tissue
in the left-sided testicular remnant. The question remains whether there was any
functional tissue in the right testis, because this was removed shortly after birth.
Whether the genital abnormalities were due to androgen resistance is impossible to
say, although the response to exogenous androgen in this patient appeared to be
suboptimal (section 4.2). However, no mutation in the AR gene has been detected in
this patient. Patient 15, in retrospect, is likely to be azoospermic secondary to
testicular damage as a result of his cryptorchidism as a child, particularly in view of
the normality of genital and general body development. The absence of defects in the
AR gene is therefore not surprising.
However, the investigation of patients with atypical features of androgen
resistance is still a worthwhile exercise, particularly following the report by Batch et
al. (1993) which described the identification of a point mutation within the AR gene of
two brothers with isolated perineal hypospadias. The mutation was situated in exon 8
and resulted in the replacement of isoleucine 869 by methionine. The GSF AR from
these patients showed an abnormally elevated rate of dissociation, and this is the first
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Portion of autoradiograph of sequencing of exon 7 from patient 7. Sense runs from
the bottom of the photograph and the coded amino acids are indicated at the sides. The
mutation is indicated by an asterisk (*) at the point in the photograph and in the
schematic figure to the side.
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Figure 4.4 Mutation detected in patient 1
N-terminal DNA binding Hormone binding
20
855
Schematic representation of the mutation detected in patient 1. The substituted
nucleotide and the presumed coding change are indicated in bold type.
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Figure 4.5 Mutation detected in patient 2
STOP
N-terminal DNA binding Hormone binding
Schematic representation of the mutation detected in patient 2. The substituted
nucleotide and the presumed coding change are indicated in bold type.
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Figure 4.6 Mutation detected in patient 3





Schematic representation of the mutation detected in patient 3. The substituted
nucleotide and the presumed coding change are indicated in bold type.
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Figure 4.7 Mutation detected in patient 7
N-terminal DNA binding Hormone binding
26
866
Schematic representation of the mutation detected in patient 7. The substituted
nucleotide and the presumed coding change are indicated in bold type.
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Figure 4.8 Mutation detected in patient 8
N-terminal DNA binding Hormone binding
22
866
Schematic representation of the mutation detected in patient 8. The substituted
nucleotide and the presumed coding change are indicated in bold type.
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Figure 4.9 Mutation detected in patient 9






Schematic representation of the mutation detected in patient 9. The substituted
nucleotide and the presumed coding change are indicated in bold type.
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Figure 4.10 Mutation detected in patient 10
N-terminal DNA binding Hormone binding
772
Schematic representation of the mutation detected in patient 10. The substituted
nucleotide and the presumed coding change are indicated in bold type.
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Figure 4.11 Agarose gel of rtPCR of exon 5/6
68
Agarose gel of reaction products from rtPCR across exons 5 & 6. The expected size
of PCR product was 276 bp. Lanes 1 & 6: <()X134/Hae III DNA markers: (|)X134
digested to completion with Hae III. Sizes of the visible bands are: 1,353, 1078, 872,
603, 310, 281, 271, 234, 194. lane 2: no DNA control; lanes 3: whole RNA from
patient 10; lane 4: whole RNA from normal male GSF; lane 5: pSV.ARo. lOjil of
completed reaction added to each lane.
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Figure 4.12 Gel of PCR fragment A1A2 of exon 1
1 2 3 4 5 6 7 8
Agarose gel of exon 1 PCR product containing the glutamine repeat coding region.
Lane 1: 22 repeats; lane 2: 22 repeats (patient 5); lane 3: 46 repeats (patient 11); lane 4:
20 repeats; lane 5: 25 repeats; lane 6: 18 repeats; lane 7: 20 repeats; lane 8: pGEM
DNA markers: pGEM digested separately with Sin I, Hinf I & Rsa I. Sizes of the
visible bands are: 2645, 1605, 1198, 676, 517, 460, 396, 350 bp. The no DNA
control contained no bands (not shown in photograph). 10 |il completed reaction mix
added to each lane.
Figure4.13aExpansionofglutaminerepe texo1
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Figure 4.17 Consensus splice site sequence compared to
the 5' splice site of intron 5 of the AR gene
Exon Intron
Consensus A G/G U A A G U
Intron 5, 5' site G A*/G U A A G U
Figure comparing the consensus splice site sequence with the sequence of the 5' splice
site of intron 5. The GU dinucleotide in bold type is the invariant donor site; the base
marked with an asterisk (*) is the mutated base in patient 10 (A to G).
Figure4.18
Comparisonofam nocidsubstitutionphe otypeo772
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Table 4.2 Analysis of samples from patients with complete
AIS
Patient Exon 1 Exon
A1A2 A3A4 A5A6 A7A10 2 3 4 5 6 7 8
1 (S-AR) 20 N n n N N N d n
2 (AC) N n n N N N d n
3 (CG) 25 N N N N N D N N N
4 (JR) N N n n N N? N n n
5 (LI) 23 N N N N N N N N N
6 (I) N n n? N? N N n n
N=normal sequence; N?=one or more uncertain base calls in exon.; D or d=defect
detected (Table 4.6). Exon 1 segments defined by primers used (Chapter 3, Table
3.1). Column A1A2 gives the number of CAG (glutamine) repeats in the
homopolymeric region of that segment.
The mutation in patient 1 was identified by Dr T. Padaychi, although the sequence
work was completed by myself.
Exons recorded in lower case letters were sequenced manually; the other exons were
sequenced fluorescently. All the regions of exon 1 apart from A1A2 were confirmed
as having normal sequence by DGGE analysis (see Chapter 5).
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Table 4.3 Analysis of samples from patients with partial
AIS and features of androgen resistance
Patient Exon 1 Exon
A1A2 A3A4 A5A6 A7A10 2 3 4 5 6 7 8
7 (GH) 26 n n N N N d n
8 (AC) 22 n n N N N d n
9 (JS) 24 N n d N N N n n
10 (JM) 26 N N N N N N D N N N
11 (WF) 46 N N N N N N N N N
12 (JL) N N n n N N N n n
13 (KW) n n N? N N n n
14 (SH) 24 N N N? N N N N
15 (RG) 21 N N N N N N N N N
N=normal sequence; N?=one or more uncertain base calls in exon.; D or rf=defect
detected (Table 4.6). Exon 1 segments defined by primers used (Chapter 3, Table
3.1). Column A1A2 gives the number of CAG (glutamine) repeats in the
homopolymeric region of that segment.
Patients 7 to 10 were diagnosed as partial AIS or Reifenstein's syndrome. The
remainder had some features of androgen resistance (see section 4.2).
The mutations in patients 7, 8 and 9 were identified by Dr T. Padaychi, but the
complete sequence was obtained by myself.
Exons recorded in lower case letters were sequenced manually; the other exons were
sequenced fluorescently. All the regions of exon 1 apart from A1A2 were confirmed
as having normal sequence by DGGE analysis (see Chapter 5).
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Table 4.4 Nuclear translocation assay from patient 9
Specific binding of radioactivity (%)
Patient 2 Control P
Nuclei 27.13 (1.75) 36.48 (4.05) <0.001
Cytosol 47.40 (4.25) 35.78 (6.67) <0.05
Numbers are the mean (SD) of four experiments, p values, calculated using Student's
t test, are of the significance of difference between patient and control in each line of
the table.
Note: non-specific binding did not exceed 10% of total binding in whole cells and
was negligible in isolated nuclei. Recovery of nuclei was 40-50%.
Data from M.B. Hodgins, University of Glasgow.
Table 4.5 Half-life determination for GSF of patient 10
Half-life (min)






Note biphasic response in patient. 70% of complexes dissociated at 60 min.
Data from M.B. Hodgins, University of Glasgow.
Chapter 5. Screening for androgen receptor
gene mutations
5.1. Introduction
5.1.1. Aims of screening
The spectrum of androgen insensitivity has been reported to include patients with
isolated abnormalities of virilisation and genital development in addition to those with
testicular feminisation (complete AIS) and partial insensitivity syndrome (partial AIS).
Larrea et al. (1978) identified a family with gynaecomastia in isolation which appeared
to follow an X-linked pattern of inheritance and more recently a family with
gynaecomastia, small genitalia yet with normal fertility were described (Grino et al.,
1988). When the androgen receptor (AR) expressed in genital skin fibroblasts (GSF)
from these patients was analysed, subtle abnormalities of androgen binding were
detected. It has been suggested on the basis of several similar GSF receptor studies
that a mild form of androgen resistance may be responsible for idiopathic infertility
(Aiman et al., 1979) and that the incidence in the infertile population could be as high
as 40% (Aiman & Griffin, 1982) although other groups have doubted the magnitude
of this figure (Eil et al., 1985; Morrow et al., 1987). The data from individual patients
in these studies are convincing even if the conclusions regarding incidence are less so,
and it therefore seems possible that mild abnormalities of androgen action could be
responsible for infertility in a subset of patients.
In the light of these data, the findings of Akin et al., (1991) were unexpected.
They analysed the AR gene in seven men with azoospermia who all had serum levels
of testosterone and gonadotropins within the normal range and found that it was not
possible to amplify exon 4 of the AR gene of one of them by PCR using the primers
described by Lubahn et al. (1989). The presence of a deletion of exon 4 was
confirmed by Southern analysis of digested DNA using AR specific probes (Akin et
al., 1991). It is surprising that a deletion of this exon apparently has no effect upon
the action of androgen in all other tissues of this patient since he had normal endocrine
parameters of androgen feedback. The finding of one in seven azoospermic men
carrying a deletion of the AR gene is almost certainly not a true estimate of the
frequency of such lesions.
It was decided to investigate the frequency of AR gene mutations in the infertile
population by obtaining blood samples from a selected group ofmen from the patients
attending a busy infertility clinic. The frequency of mutations of the AR gene in this
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group was expected to be low and in order to facilitate and accelerate the search for
mutations in a number of patient samples I established a screening method.
5.1.2. Available techniques for screening
The sequencing of the AR gene from a large number of patients is time consuming and
laborious. Since in male patients there is only one copy of the gene, screening
techniques for gene mutations should be readily applicable to search for changes in the
AR gene. There are three methods of screening currently in use: single stranded
conformational polymorphism analysis, denaturing gradient gel electrophoresis and
temperature gradient gel electrophoresis.
5.1.2.i Single stranded conformational polymorphism
Single strand conformational polymorphism analysis (SSCP) exploits the presence of
a unique sequence in a fragment of single stranded DNA (Orita et al., 1989). Briefly,
PCR reactions are performed in the presence of 32P-dATP to radiolabel the amplified
DNA, samples are denatured by heating and immediately loaded onto a non-denaturing
polyacrylamide gel and subjected to electrophoresis. The position of the bands is
visualised by autoradiography. The sensitivity of this method depends upon the
formation of bonds between nucleotides within the single strand of DNA, which
produces a characteristic conformation of that strand and thus a specific mobility
through the gel. A change in sequence will alter the configuration of the double
stranded regions of each strand and hence alter the mobility of it through the gel. The
presence of a mutation is indicated by radiolabeled bands appearing on the
autoradiograph at positions different to that of control samples. The ability of the
method to detect mutations in any given sequence is quoted as being 80-90%
(Hayashi, 1992), and to achieve this two gel runs have to be performed in different
conditions. SCCP can be performed equally well with unlabelled DNA samples,
when silver or ethidium bromide staining is used to visualise the sample bands.
5.1.2. i i Denaturing gradient gel electrophoresis
Denaturing gradient gel electrophoresis (DGGE) is a method of screening which
requires no radio-isotopes and has a sensitivity of 95% or greater (Myers et al., 1987).
Double stranded DNA undergoes denaturation in the presence of an elevated
temperature or a high concentration of denaturant (usually urea and formamide). With
increasing concentration of denaturant, strand separation initially occurs in a reversible
fashion producing a partially single stranded molecule, termed a "Y-form". The
concentration of denaturant at which the Y-form is generated (Dm) differs for each
DNA molecule or fragment and is a function of its sequence. As denaturant
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concentration is raised beyond the Dm of a molecule irreversible strand separation will
occur.
DGGE exploits this characteristic of DNA. DNA samples are run through a
polyacrylamide gel which contains a linearly increasing gradient of denaturants (urea
and formamide) aligned parallel to the direction of electrophoresis. As each sample
reaches the point in the gel where denaturant concentration is equal to its Dm it
separates into the Y-form. The Y-form has an extremely low mobility through the gel
and the sample is retarded at the position corresponding to the Dm. Thus, samples
with different sequences (and therefore a different Dm) will reach different positions in
the gel. Samples showing differential mobility from controls can be sequenced to
determine the exact mutation.
The appearance of the Y-form depends upon the presence of subdomains within
the DNA which separate (or "melt") at different concentrations. The retention of some
double stranded DNA is essential to produce the Y-form with its low mobility. If
there are any mutations within the region which remains double stranded they will not
be detected. In order to improve the detection of such mutations, the addition of a
GC-clamp has been recommended (Myers et al., 1985a & b; Sheffield et al., 1989).
The GC-clamp is a 40 base pair sequence of guanosine and cytosine nucleotides which
can be added to the 5' end of one oligonucleotide used to amplify the samples by
PCR. The clamp remains double stranded throughout the range of denaturant
concentration used in the gels and so the whole length of the sample of interest
becomes single stranded, revealing any sequence changes within it. By the use of the
GC-clamp over 95% of possible mutations present in a length of DNA can be detected
(Sheffield et al., 1989).
5.1.2.iii Temperature gradient gel electrophoresis
Temperature gradient gel electrophoresis (TGGE) is a method essentially similar to
DGGE (Riesner et al., 1989) which also exploits the characteristic melting properties
of DNA. The denaturing environment is provided by means of exposing the gel (of a
fixed concentration of urea and formamide) to a linearly increasing temperature
gradient. The effect of temperature and denaturant gradients are entirely equivalent
(Myers et al., 1987) and the two techniques provide exactly similar information. The
temperature at which strand separation occurs is termed Tm. TGGE should be
methodologically easier to perform since there is no requirement for pouring gradient
gels and the gel run time can be reduced.
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In both TGGE and DGGE samples can be mixed with an equal amount of
control DNA in order to enhance the visibility of the altered mobility of the mutant
samples (De Bellis et al., 1992). After denaturing and reannealing, if a sample
contained a mutation there would be two homodimers with matched sequences (the
normal control and the mutated strand) and two heterodimers with a mismatched base
due to annealing of non-complementary strands (Fig. 5.1). Such a mixture produces
four bands on the gel because each has a different melting temperature and the
heterodimers denature much sooner than the homodimers.
On consideration of the three methods available it was decided to establish a
TGGE system for screening of AR gene samples because it did not involve the use of
radio-isotopes or the pouring of gradient gels. However, due to various technical
problems (see below) the alternative DGGE system was also attempted and became the
method of choice.
5.2. Patients
Patients were selected from a busy infertility/andrology clinic. The records from each
couple have been stored on computer since 1978 (Hargreave & Elton, 1986) and data
were available from 1,700 couples. Follow up information was available on all
couples. Criteria for selection, in an effort to identify those men with features
suggestive of mild androgen resistance, comprised testosterone > 30 nmol/1, FSH > 6
IU/1, LH > 6 IU/1 and a sperm concentration < 20 million/ml semen. When applied to
the clinic population, these criteria selected a group of 50 men, 11 of whom wished no
further follow up and 32 of whom failed to respond to three standard letters inviting
them to attend. A final group of 7 men was successfully recruited and blood was
sampled from them. Thus, less than 1% of the total clinic population were studied.
Relevant details of the patients involved in the study are shown in Table 5.1. Patient 7
was particularly interesting because he had a brother who was infertile with
azoospermia, and this suggested some inherited problem which may have been
responsible for their infertility.
5.3. Methods
5.3.1. Temperature gradient gel electrophoresis
The equipment for TGGE was obtained from Diagen GmbH, Hamburg, Germany (via
Hybaid UK Ltd., Teddington, Middlesex, UK) and comprised an aluminium plate
with circulation tubes at each end to which waterbaths set to the limit temperatures
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were connected. The plate could be arranged such that the temperature gradient was
either parallel or perpendicular to the direction of electrophoresis. The gel was laid
horizontally on the plate and temperature equilibration allowed to occur over 30
minutes. The plate, the buffer tanks and the gel were supported within a perspex
cabinet.
Gels were of 8% acrylamide (acrylamide: bis-acrylamide 37.5:1), 20mM MOPS
(4-morpholinopropanesulphonic acid), 8 M urea, 1 mM EDTA and 2% glycerol.
Polymerisation was initiated by the addition of TEMED and 10% ammonium
persulphate and the gels allowed to set for 1 hour. GC clamped exons from patients
were mixed 1:1 with clamped exons from DNA of normal fertile men and added to 1
volume of denaturing buffer (400 mM MOPS, 8 M urea, 10 mM EDTA), denatured
by boiling for 5 minutes and allowed to re-anneal at 50°C for 15 minutes before
loading to the gel. After electrophoresis gels were stained by silver staining as
follows: gels were washed twice in 10% ethanol/0.5% acetic acid (v/v) for 3 minutes,
stained in 0.1% AgNOs, (w/v in distilled water) for 10 minutes and then rinsed twice
in distilled water. The stain was developed by washing in 1.5% NaOH, 0.01%
NaBH3 (w/v), 0.15% formaldehyde (v/v) for 20 minutes and then fixed in 0.75%
NaCC>3 (w/v) for 10 minutes. All manipulations were carried out in a large glass dish
on a rocker plate.
For each exon of the AR gene PCR amplification was carried out with the
addition of the 40 base pair GC clamp to the 5' primer, and amplified DNA purified as
described in Chapter 3 (sections 3.2 to 3.4). A preliminary gel was run with the
temperature gradient (typically 20°C - 60°C) applied perpendicularly to the direction of
electrophoresis, with the DNA added in a long slot across the top of the gel, and
electrophoresed for 2.5 hours at 300 V. The melting properties of each sample were
shown as a curve ofmelting behaviour against temperature after staining (Fig. 5.2). A
temperature bracket embracing the melting range of the fragment (the steep part of the
curve) was calculated from this curve and used as the limits of the temperature gradient
for subsequent gels. These gels were ran with the temperature gradient and electric
field in the same orientation. In this parallel orientation, samples containing a
mismatch or mutation compared to the control DNA migrated as three or four distinct
bands on staining (Fig. 5.3). Exons from these patients were then re-amplified by
PCR without the GC clamp and sequenced (Chapter 3, sections 3.3 & 3.5).
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5.3.2. Denaturing gradient gel electrophoresis
Denaturing gradient gels were run on the same apparatus used for TGGE but at a
constant temperature of 60°C at 75 V for 16 to 20 hours, and stained as above. 100%
denaturant was 7 M urea with 40% formamide and gradient limits for the different
exons were as described by De Bellis et at. (1992). Typical limits were 35% and
60%. Gels were poured using a 40 ml capacity gradient maker by the addition of the
lower concentration mix to the higher with constant stirring after the addition of 20 pi
TEMED and 50 pi 10% ammonium persulphate to each mixture. Samples were run
on the gels without mixing and annealing with control samples.
5.4. Results
Initial attempts to establish the TGGE system were performed using samples known to
contain mutations from those patients described in Chapter 4. Perpendicular gels to
establish the temperature gradient conditions for each exon were performed without
difficulty (Fig. 5.2). Parallel gels were run with exon 7 samples to confirm that the
method was sensitive and reproducible (Fig. 5.3). Samples from the patients with
mutations in exon 7 showed the expected pattern of four bands produced by mixing
control and mutant samples before loading to the gel.
However, repeat mns of the same samples and gels of other exons proved very
troublesome with a smear of DNA rather than defined bands being visualised.
Modification of the electrophoresis voltage or duration of annealing time made no
significant difference to the reproducibility of the gel runs. A switch to DGGE was
therefore made with an immediate improvement in resolution and reproducibility of the
gel data (Fig. 5.4). In view of the greater reliability ofDGGE, all of the data from the
infertile patients in this chapter were obtained using this method rather than TGGE.
The results of screening of AR gene exons from the infertile patients by DGGE
are shown in Table 5.2. All exons of the gene from 2 to 8 were amplified in all
patients and found to be normal. Exon 1 proved difficult to amplify in many of the
patients, especially across the glutamine and glycine repeat coding regions. The
glycine repeat region of exon 1 did not amplify from the DNA of any patient, and the
glutamine repeat region failed to amplify in patient 2. Of the exons of the gene
examined by DGGE no samples with altered mobility were detected. The glutamine
repeat region of exon 1 (bases 250-312) showed variation in size between patients
from 20 to 25 CAG codons which is within the normal range for this region (La Spada
etal., 1991).
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5.5. Discussion
In this chapter I have described the establishment of a screening technique for the
androgen receptor gene. Initially TGGE was used because it appeared to be the most
straightforward to set up, and there was no need to pour gradient gels. The technique
was claimed to be rapid and sensitive. However, after early success with control
samples known to contain mutations, the method became unreliable and inconsistent to
use. The difficulties stemmed from two sources: the annealing procedure and also
from the method of controlling the temperature.
The annealing procedure for samples was intended to enhance the ease of
detection of mutations by creating four hybrid molecules in each sample. However,
this step proved troublesome, producing partially annealed or single stranded samples
resulting in smears of DNA on the gel, obscuring any defined bands and rendering
interpretation of the data impossible; single stranded DNA provides no information on
TGGE. Adjustments to the length and temperature of the annealing step were made in
an effort to encourage complete reannealing but with no improvement in the results of
the gels.
The maintenance of the stable linear temperature gradient is of critical importance
to the success of TGGE. Even minor fluctuations in the temperature at either end of
the gel plate will disturb the gradient and thereby cause the position of Tm of any
sample to move slightly in the gel. If this occurs it will result in a broad, smeared
band in the region of the Tm rather than a sharp one. The relative positions of the
bands cannot then be interpreted with any confidence. The temperature control of the
cold end of the apparatus was troublesome in particular since it tended to rise with
increased run times. With the water baths available this situation could not be
overcome and the decision was taken to switch to denaturing gradient gels.
The use of denaturing gradient gels and DGGE was very successful. Because
the methods are equivalent the same primers and samples could be used for DGGE as
were used for TGGE. De Bellis et al. (1992) have used this system successfully for
examining the AR gene of patients with androgen insensitivity. We adopted the same
gradient parameters as these investigators but did not routinely anneal samples with
control DNA in the light of previous difficulties with this step. With the use of
samples with a GC clamp, DGGE is sensitive enough to detect at least 95% of
mutations present in a given strand without the need to undertake annealing (Sheffield
et al., 1989) and this was considered sufficient for the study. The use of gradient gels
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completely eliminated the problems associated with fluctuations in gradient limits seen
with the TGGE and the technique was easily and reproducibly performed.
The results from the analysis of the 7 patients with infertility are shown in Table
5.2. No mutations were detected in any of these patients and the glutamine repeat
region was of normal size in each. This cohort of men is small, but has been selected
on the basis of there being an identifiable disturbance of androgen feedback. The
criteria of elevated testosterone and LH with low sperm density are comparable to the
biochemical findings of patients with recognised androgen in sensitivity associated
with impaired receptor function. The LH-testosterone product (LH-T) is used as an
index of androgen resistance (Morrow et al., 1987) and in all of our patients was
elevated well above the normal range (26-97) (Table 5.1). This is similar to the results
of Morrow et al. (1987) who found the LH-T elevated in all their cohort of infertile
men.
Using these criteria we have selected the 3% of 1,700 men attending an
infertility clinic most at risk of an abnormality of androgen receptor function on the
basis of their endocrine profile. From the seven responders in this cohort, none
possessed a mutation and that they all presumably carry a normal, functional androgen
receptor. This finding appears to contradict the results of Aiman & Griffin (1982) and
Morrow et al. (1987) who found in independent studies that between 20% and 40% of
a sample of infertile men had levels of androgen receptors in GSF lower than normal
controls. However, the presence of a normal androgen receptor gene does not
necessarily lead to the expression of normal levels of receptor. Aiman & Griffin
(1982) found that the Bmax of the infertile men with severe oligospermia (less than 1
million/ml semen) was significantly lower than in controls while in less severe
oligospermia there was no difference, but they only reported the mean result for each
group. Morrow et al. (1987) found low levels of receptor in only 5 men from a
sample of 21 with idiopathic infertility, but reported the results on each patient which
indicated that the range of Bmax was somewhat wider in the infertile group, although
the mean values were not significantly different. It is difficult to interpret the results of
Aiman & Griffin in the absence of the individual results from each patient, particularly
in the light of the findings of Eil et al. (1985) who examined the GSF androgen
binding sites and nuclear uptake of androgen in a group of 15 infertile and
oligospermic men. They found no difference in the mean values or the range between
patients and controls, although the infertile group had more men with results at the low
end of the range. Thus, one can say that infertile, oligospermic men fall into a group
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who tend to express lower levels of normal androgen receptor than other men, but it is
not possible to say whether this is the cause of their low sperm count and fertility.
Oligospermic men may represent merely the bottom end of the normal range of fertility
for which there is no definable, correctable cause.
However, the findings ofAkin et al. (1991) appear to contradict the assumption
that AR mutations in infertile men will have any endocrine markers at all. Of seven
azoospermic men with normal endocrine profiles, they found a deletion of exon 4 in
one of them. It is highly surprising that such a gross deletion appears to have no
effect upon the endocrine feedback of the hypothalamic pituitary axis (particularly
when exon 4 carries the hormone independent nuclear localisation signal (Simental et
al., 1991)) and implies that the selection of patients with endocrine features of such
perturbation may be somewhat misguided. None of the patients in this study were
azoospermic and perhaps a screening programme aimed at a large number of
azoospermic men would be more fruitful.
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Annealing of separated strands from two samples with a single base substitution
produces two homodimers and two heterodimers. Pairing bases are shown in the
same shading.
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Figure 5.3 Parallel TGGE of exon 7
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Photograph of parallel gel of exon 7. C: control, normal DNA from a fertile man; lane
1: patient 1 (C to T mutation); lane 2: patient 7 (G to T mutation); lane 3: patient 8 (G
to T mutation); lane 4: patient 4 (no mutation). Electrophoresis was performed for 4.5
hours at 300 V.
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Figure 5.4 Parallel DGGE of exon 5
93
1 2 3 4 5 6
Photograph of DGGE gel of exon 5. Lanes 1 and 6: control DNA; lanes 2 & 3: patient
10 (A to G mutation); lane 4: control DNA; lane 5: patient 3 (C to T mutation).
Electrophoresis was performed for 16 hours at 75 V. The C to T mutation results in a
lower Dm and a sooner retardation in the gel than control, while the A to G mutation
results in a higher Dm and a later retardation.
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4 31.10 9.10 10.80 283.01 0.15
5 41.70 8.40 N/A 350.28 8.02
6 36.30 11.00 N/A 399.30 4.00
7 43.20 6.90 17.50 298.08 0.00 Azoospermicbrother
Mean 38.19 10.04 16.12 326.19 6.83
LHxT = LH testosterone product; N/A = not available.
*Morrow et al., 1987
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Table 5.2 Screening of AR gene from infertile men
Patient Exon 1 Exon
A1A2 A3A4 A5A6 A7A10 2 3 4 5 6 7 8
1 25 N N N N N N N N N
2 N N N N N N N N N
3 27 N N N N N N N N N
4 24 N N N N N N N N N
5 26 N N N N N N N N N
6 24 N N N N N N N N N
7 25 N N N N N N N N N
N=normal sequence. Exon 1 segments defined by primers used (Chapter 3, Table
3.1). Column A1A2 gives the number of CAG repeats (coding for glutamine) in the
homopolymeric region of that segment
Chapter 6. Site-directed mutagenesis
6.1. Introduction
Since the initial discovery of mutations within the androgen receptor (AR) gene of
patients with clinical features of androgen resistance (Lubahn et al., 1989; Wilson,
1992), confirmation that these changes alone are responsible for the in vivo features of
the syndrome has been sought by a variety of in vitro investigations. A number of
workers have reproduced point mutations within cloned AR cDNAs by site-directed
mutagenesis and have examined the ability of the proteins synthesized from the
modified cDNA to bind androgen (Marcelli et al., 1990a, Ris-Stalpers et al., 1991)
and to activate gene transcription (Brown et al., 1990) after introducing the cDNA into
a suitable cell line host.
Recombinant plasmids bearing the androgen receptor gene in a highly expressed
form have been used in in vitro transfection assays of normal receptor function within
CV-1 cells (Quarmby et al., 1990) and COS cells (Jenster et al., 1991). The plasmid
AR can be mutated by a variety of means and the androgen binding parameters
compared to controls after transfection into these cell lines (Marcelli et al., 1990b; Ris-
Stalpers et al., 1990). However, measurement of normal hormone binding does not
indicate a normally functioning receptor, since mutations of the DNA binding domain
would not be expected to show abnormal hormone binding. Co-transfection of an
androgen responsive reporter plasmid, such as one carrying the chloramphenicol
acetyl transferase gene (CAT), under the control of the mouse mammary tumour virus
(MMTV) promoter region to act as an androgen responsive HRE, allows the
transactivating ability of mutant receptors to be measured directly (Brown et al.,
1990).
In order to examine the effect of the mutations which were identified in the
patients with androgen insensitivity (Chapter 4), and to confirm that they altered
receptor function, an attempt was made to mutate the AR cDNA supplied in a
eukaryotic expression vector. The technique described by Deng & Nickoloff (1992)
was employed as this allows the mutation of cDNA to be performed within any
plasmid which possesses a unique restriction endonuclease site. Two oligonucleotides
are required in the mutagenesis step: one to introduce the desired mutation and the
second to eliminate a unique restriction site in the vector (Fig. 6.1). The plasmid is
denatured and the two oligonucleotides are simultaneously allowed to anneal to one
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strand. The annealed primers are used for elongation to synthesize a pool of "mutant"
plasmid using the original as template which is then transformed into E. coli defective
in mismatch repair. Transformed bacteria are pooled, cultured and the plasmid DNA
extracted and digested with the restriction enzyme whose site should have been
eliminated from the plasmid by the specific oligonucleotide. The digested plasmid
DNA is retransformed into bacteria and should result in a high selection of the mutant
plasmid since the original unmutated plasmid is linearised and will therefore be
transformed with approximately 100-fold less efficiency than the circular (mutated)
plasmid DNA.
6.2. Methods
6.2.1. Selection of plasmid and oligonucleotide primers
The AR cDNA containing plasmid, pSV.ARo, was a gift from Dr Albert Brinkmann
(Erasmus University, Rotterdam, The Netherlands) and contained a full length cDNA
of the human androgen receptor gene subcloned into a eukaryotic expression vector
where its transcription was under the control of the SV 40 early promoter region and
origin of replication, and terminated by the polyadenylation signal of the rabbit (5-
globin gene. Selection in prokaryotes was achieved using the ^-lactamase gene for
ampicillin resistance (Fig. 6.2). The sequence of the plasmid was not available but a
unique Sfi I site was identified within the SV40 origin of replication. The sequences
of this selection primer and of three mutagenic primers (designed to mutate specific
single bases within the AR cDNA, as identified from the patients in Chapter 4) are
given in Table 6.1. Primers were synthesized on an Applied Biosystems "PCR-mate"
DNA synthesizer, model 391 (Applied Biosystems Ltd., Warrington, UK) as
described in Chapter 3 (section 3.2).
6.2.2. Phosphorylation of primers
Before use, the primers were phosphorylated at their 5' ends so as to be suitable
templates for the action of DNA ligase. Primer DNA (1 pg) was mixed with 2 pi lOx
kinase buffer (500 mM Tris.HCl pH 7.5, 100 mM MgCl2, 50 mM dithiothreitol
(DTT), 10 mM ATP), 10 units of T4 polynucleotide kinase (Promega Ltd.,
Southampton, UK) and made up to 20 p.1 with sterile distilled water. The mixture was
incubated at 37°C for 1 hour before terminating the reaction by heating to 65°C for 10
minutes to inactivate the enzyme. Phosphorylated primers were stored at -20°C until
required.
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6.2.3. Mutagenesis of plasmid
The protocol provided with the Transformer™ site-directed mutagenesis kit
(Clontech Laboratories Inc., from Cambridge Bioscience) was followed. Briefly, 0.1
pg purified plasmid DNA was mixed with 0.1 |ig phosphorylated selection primer,
0.1 pg phosphorylated mutagenic primer, 2 pi lOx annealing buffer (200 mM
Tris.HCl pH 7.5, 100 mM MgCl2, 500 mM NaCl) and made up to 20 pi with sterile
distilled water. The DNA was denatured at 100°C for 5 minutes and then plunged
onto ice and incubated for 5 minutes at 0°C to allow the primers to anneal. To each
tube was added 2 units of T4 DNA polymerase (an enzyme lacking strand
displacement activity (Masumune & Richardson, 1971; Nossal, 1974)), 2 units of T4
DNA ligase, 3 pi lOx synthesis buffer ("optimised concentrations" of nucleotides in
200 mM Tris.HCl pH 7.5; Clontech Laboratories Inc.) and sterile distilled water to a
final volume of 30 pi and the mixture incubated at 37°C for 4 hours. Following
incubation, the samples were heated to 65°C for 5 minutes to inactivate the enzymes.
6.2.4. Transformation of bacteria
A specialised strain of E. coli, BMH 71-18 mut S, was used for transformation. This
strain is defective in mismatch repair (Wallace et al., 1981) and is used to prevent
repair of the mutant strand. For electroporation, the entire purified DNA mixture from
each mutagenesis reaction was diluted fivefold and 1 111 (1 ng) used per 40 |il aliquot
of cells. Transformation and selection of transformed cells was performed in liquid
culture (Chapter 3, sections 3.6 to 3.8).
6.2.5. Digestion of plasmid DNA
The overnight culture of transformed bacteria was harvested and the plasmid DNA
recovered using a Promega Magic Miniprep kit (Promega Ltd., Southampton)
(Chapter 3, section 3.7.2). Purified plasmid DNA (500 ng) was mixed with 10 units
of Sfi I and 2 pi of lOx restriction buffer (60 mM Tris.HCl pH 7.5, 60 mM MgCl2,
500 mM NaCl, 10 mM DTT) (Promega Ltd.) in a final volume of 30 pi and incubated
at 50°C for 3 hours, before the addition of another 10 units of enzyme and additional
incubation for 3 hours. The enzyme was inactivated by heating for 5 minutes to 70°C,
before removing the enzyme and reaction buffer by filtration through a Chromaspin
TE-100 column (Clontech Laboratories Inc., via Cambridge Bioscience, Cambridge).
This purified, digested DNA (3 ng) was used in the second transformation step;
following electroporation and recovery (Chapter 3, section 3.8), the cells were
centrifuged at 3,000 rpm for 5 minutes, resuspended in 100 pi of LB-broth and spread
over an LB-agarose plate containing ampicillin for selection. The plate was incubated
at 37°C overnight.
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6.2.6. Selection and screening of transformants
The plasmid containing the AR cDNA possessed no colour selection system and
therefore, in each experiment, transformation of a control plasmid, pUC19M DNA
(provided in kit), was performed in parallel. This plasmid, derived from the wild type
pUC19, contains a mutation within the coding sequence of the lac Z gene which
introduces a termination codon. Mutagenesis of this plasmid using the provided
primers restores the functional lac Z gene to allow positive colonies of bacteria to be
identified by their blue colour when grown on plates containing 5-bromo-4-chloro-3-
indolyl-(3-D-galactoside (X-gal) and isopropyl-fJ-thiogalactopyranoside (IPTG).
Following mutagenesis and digestion of the control plasmid, bacteria transformed with
pUC19M were mixed with 40 |il of X-gal (20 mg/ml) and 10 |il of IPTG (20 mM)
(Promega Ltd.) immediately before plating out. The ratio of blue colonies to the total
number of colonies on each plate was used to calculate the efficiency of the
mutagenesis procedure.
Colonies of bacteria from the mutated pSV.ARo plates were inoculated into
liquid cultures and plasmid DNA recovered the following day by Promega Magic
Minipreps (Chapter 3, section 3.7.2). Following agarose gel electrophoresis of the
DNA to confirm the presence of intact circular plasmid DNA, PCR amplification of the
mutated region of the plasmid was performed for each sample and the PCR product
purified and sequenced (Chapter 3, section 3.5). The primers used to amplify the
relevant portions of the AR cDNA are given in Table 6.2.
6.3. Results
Initially mutagenesis was attempted at three sites in the AR cDNA: guanosine to
adenosine at nucleotide 1843 (arginine 608 to lysine); cytosine to thymidine at
nucleotide 2265 (arginine 752 to STOP), and cytosine to thymidine at nucleotide 2574
(arginine 855 to cysteine). The protocol provided with the Transformer™ kit was
followed for the first two experiments and mutagenesis was performed with the
control experiment in parallel in every case. In each experiment the control rate of
mutagenesis appeared satisfactory but in every case the selected colonies from the
mutated pSV.ARo plates yielded wild type plasmid after sequencing (Table 6.3, Exp.
1 &2).
In an effort to improve the success rate of the mutagenesis, modifications of the
basic method were introduced. Initially, the restriction digestion incubation was
increased to 8 hours to ensure complete digestion of the unmutated parent strand and
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thus avoid a high rate of transformation with wild type plasmid. There was no
improvement in the yield ofmutant DNA following this step (Table 6.3, Exp. 3).
An additional Chromaspin column purification step was introduced following
synthesis of the mutant strand and before the initial transformation to minimise the
transfer of partially synthesized DNA, enzymes and possible contaminants which may
have interfered with the transformation efficiency. Once again, there was no
improvement in the outcome (Table 6.3, Exp. 4)
Finally, the mutagenesis was attempted with the modification that the DNA
polymerase and DNA ligase were added sequentially rather than simultaneously with
incubation at 37 °C between each addition. This was done because of the large size of
the plasmid used (7.2 kilobases) in an effort to encourage strand synthesis to be
completed before ligation occurred and prevent the possible synthesis of truncated
plasmids which were confounding the results of transformation. Following the
addition of 2 units of T4 DNA polymerase and incubation at 37°C for 2 hours, a
further 2 units of T4 DNA polymerase were added together with 2 units of T4 DNA
ligase and incubation continued for a further 2 hours. Finally, 2 units of T4 DNA
ligase were added and a final 2 hour incubation at 37°C carried out before heating to
65°C for 5 minutes to inactivate the enzymes. Unfortunately, this modified protocol
was no more successful than the others (Table 6.3, Exp.5).
A summary of the results of the mutagenesis experiments is presented in Table
6.3.
6.4. Discussion
Methods for site-directed mutagenesis of plasmid DNA which have been developed
during the past 15 years utilise a variety of techniques to achieve the desired goal of
the insertion ofmutant bases into the DNA. All of the available methods make use of
single stranded plasmid DNA as a template, either for synthesis of a mutant strand
from a specifically designed oligonucleotide primer annealed to the strand (Zoller &
Smith, 1983), or as a template for nick-translation in the presence of modified
nucleotides (Miiller et al., 1978). These methods are hampered by the continued
presence of the unmutated strand in the final DNA sample and the presence of in vivo
repair mechanisms which result in low yields of the desired mutant DNA (Kramer et
al., 1984; Dohet et al., 1985). Subsequently, modifications have been introduced in
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an effort to improve the yield of mutant DNA from these procedures and thereby
reduce the need to screen large numbers of samples to find mutated plasmid.
Kunkel (1985) published a method in which he claimed that the yield of mutated
DNA was increased to the order of 60-80%. Single stranded DNA was prepared
using a bacteriophage grown in an E. coli dut~ ung~ strain. This strain lacks the gene
for the enzyme dUTPase (dut) and therefore contains an increased intracellular pool of
dUTP (uracil triphosphate) which is incorporated into newly synthesized DNA in
competition with dTTP (thymidine triphosphate). This DNA is biologically active in
this strain which also lacks the gene for the enzyme uracil glycolase (ung). In cells
containing this enzyme, the uracil residues are hydrolysed leaving abasic sites which
are lethal in single stranded DNA. The uracil containing plasmid is used as a template
in combination with an oligonucleotide mutagenic primer and the newly synthesized
DNA transfected into an ung+ host bacteria. The template strand is hydrolysed
resulting in selection of mutant DNA which is then amplified. The ability of this
method to select the mutant strand and lyse the template allows the selection ofmutant
DNA without having to resort to phenotypic selection since the percentage ofmutant
DNA in the surviving bacteria is high (Kunkel, 1985).
An alternative method where phosphorothioate analogues (i.e. containing a
sulphur species) of nucleotides were incorporated during synthesis of the mutant
strand was described by Taylor et al. (1985a & b). The phosphorothioate bonds
between nucleotides are resistant to digestion by many restriction enzymes (Taylor et
al., 1985a) which therefore can be used to produce a "nicked" form of the double
stranded plasmid with the digested bonds all present in the template strand. Digestion
with exonuclease III removes the nicked native strand, allowing resynthesis of the
complementary mutant strand (Taylor et al., 1985b). A third approach involves
synthesizing the mutant strand from the template in the presence of 5-methyl-dCTP
(Vandeyar et al., 1988). The presence of methylated cytosine within the restriction
sites of certain restriction enzymes results in the site being nicked in the non-
methylated strand rather than being completely cleaved. Subsequent exonuclease III
digestion removes the native strand in a manner similar to the technique of Taylor et
al., (1985b).
All of the methods described above rely upon the synthesis of single stranded
DNA for use as a template before the start of the procedure and are therefore time
consuming to perform. The method chosen for use during the current study was that
of Deng & Nickoloff (1992) which had the advantage of being flexible and rapid to
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perform, requiring only two overnight bacterial cultures and could be performed on
any double stranded plasmid, with no need for helper phage rescue of single stranded
DNA. It was therefore disappointing that we failed to detect any mutants in five
experiments in spite of modifications to the method to take account of the large size of
of the pSV.ARo plasmid and to ensure completion of each step of the procedure.
The fact that good numbers of colonies contained mutant plasmid in the positive
control group indicates that there was no problem with the fundamentals of the method
and good numbers of transformed colonies were obtained from the cells transformed
with pSV.ARo. The problem appeared to be one of failure to incorporate the
mutations into the vector. The possible reasons for the failure of the method include:
incomplete linearisation of the parental plasmid before transformation, leading to high
numbers of wild type transformants; synthesis of truncated plasmid DNA lacking a
portion of the sequence, and some problem with the mutagenic primers themselves.
In all experiments recovered plasmids were subjected to electrophoresis in agarose
gels to confirm the presence of circular DNA of the appropriate size, and full length
copies were present in all samples (data not shown). The adjustments made to the
incubation time with the enzyme Sfi I were designed to overcome any problems with
incomplete digestion of the parental DNA, as was the incorporation of an additional
purification step. No improvement in the yield ofmutants was observed with either of
these steps.
The nature of the oligonucleotides chosen remains a likely cause for the failure
of the method. The elimination oligonucleotide changes the Sfi I site from
GGCCnnnnnGGCC to GACCnnnnnGGTC which is not recognised and both it and
all the mutagenic primers were designed according to the guidelines suggested by
Deng & Nickoloff (1992). The oligonucleotides were subjected to electrophoresis
through a non-denaturant polyacrylamide gel which confirmed the presence of a
species of the expected length in each case (data not shown). It may be possible that
the phosphorylation step to prepare the oligonucleotides was not efficient, rendering
them unable to provide substrate sites for the action ofDNA polymerase once annealed
to the template, but the experiments were performed with freshly phosphorylated
primers once the potential problem had been recognised. It would be advisable to
repeat the mutagenesis experiments using freshly made oligonucleotides containing
different sequences and modifications of the duration of the reaction steps in order to
optimise the procedure but unfortunately the constraints of time rendered this option
impossible.
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The plasmid pSV.ARo was a gift from Dr Albert Brinkmann and has been used
in in vitro investigation of mutations of the AR gene (Ris-Stalpers et al., 1991, 1992).
In these studies, mutagenesis was performed by ligating restriction endonuclease
digestion fragments into the wild type cDNA. The fragments were obtained by
digesting cDNA synthesized by reverse transcriptase PCR using RNA from genital
skin fibroblasts from affected patients. This method is another time consuming
approach, but it has generated useful data using the pSV.ARo as a template and
vector.
In retrospect, the design of the mutagenesis strategy was probably seriously
flawed. The only unique site which could be identified was the Sfi I site within the
SV40 origin of replication. The mutagenesis changed two nucleotides within this
region, and it is impossible to predict whether these mutations would affect the normal
function of the region. An untested mutation within the region could have abolished
two critical functions: the control of replication of the plasmid and the promoter
function of the region on the expression of the AR gene in the host cell.
The aim of the experiments was to produce a plasmid capable of expressing
mutant AR in a cell line in vitro (COS cells were to be used). If the mutant plasmid
was defective in replication to high copy number in the host cell, or incapable of
controlling expression of the mutant gene, the results of any transfection studies and
measurements ofmutant AR function would have been meaningless.
To overcome this problem, ideally another restriction site should have been
chosen; this would have been facilitated if the sequence map of the whole plasmid had
been available. An alternative would have been to have performed mutagenesis on the
AR plasmid with the Sfi I mutation primer and a dummy primer within the AR gene
sequence. Then the effect of mutation within the origin of replication could have been
measured directly in vitro ; the control experiment would also have excluded any other
effect of the mutagenesis procedure upon the remainder of the plasmid sequence.
The mutagenesis method chosen has been declared to be accurate and specific
(Deng & Nickoloff, 1992). However, exposing a vector of such large size to these
enzymes may introduce extraneous mutations elsewhere in the coding region of the
AR gene. Had the necessary time been available, it would have been better to
subclone the region of the AR to be mutated into another smaller vector for the actual
mutagenesis. This would have allowed confirmation of the mutation by sequencing
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more easily, and would probably have made the mutagenesis more successful because
a smaller plasmid vector would have been used.
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Mutant DNA in high Low transformation
yield efficiency
EnzR oligo eliminates restriction site for the enzyme Enz. Gene is any target gene.
Mutant sites are indicated by bullets.
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Figure 6.2 Androgen receptor gene plasmid pSV.ARo
Hind III
Diagram of pSV.ARo showing orientation of cDNA to the origin of replication and the
polyadenylation signal. Some of the restriction sites are shown. Courtesy ofDr A.O.
Brinkmann.
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Table 6.1 Mutagenic and selection primers
Primer sequence Mutation
S'-GAGGCCGAGACCGCCTCGGrCTCTGAGCTA-S' Eh™nfatl"n ofSfil site
5'-GATAAATTCCGAA4GAAAAATTGTCCATC-3' Arg608 -» Lys
5'-GTTTGCCATGGGCTGGrGATCCTTCACCAATGTC-3' Arg752 -» STOP
5'-CATCCTGCTCAAGArGCTTCTACCAGCTC-3' Arg855 -> Cys
The first oligonucleotide is the selection oligo. All others mutate bases within the
coding sequence of the receptor. Bases mutated from wild type sequence shown in
bold italic type.






5'- GGAAACAGAAGTACCTGTG -3' 5'
5'- CTCCCAGAGTCATCCCTG -3' 3'
5'- GCTTCCGCAACTTACAC -3' 5'
5'- TCATTGAAAACCAGATC -3' 3'
5'- TCTTTGATGAACTTCGAATGA -3' 5'
5'- TCACTGGGTGTGGAAATA -3' 3'
All primers are exonic. *The 5' primer for exons 7 & 8 lies within the first third of
exon 7. All other primers lie at the ends of the relevant exon.
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Arg608/Lys 8 of 8 0
Increase
3 Arg752/STOP digest time 19 21 90 9 of 9 0

























Figures in the "colonies selected" column indicate the number of transformed colonies
selected from the total number appearing on the agarose plate after final antibiotic
selection.
Chapter 7. General Discussion
7.1. Introductory remarks
In this thesis I have described the analysis of the androgen receptor (AR) gene
sequence of patients with androgen insensitivity syndromes and from a cohort of
infertile men. Two methods of screening the AR gene for mutations have been
established and used successfully in the detection of point mutations and an effort has
been made to examine the functional parameters ofmutant androgen receptors. I shall
discuss the relevance of these findings in the light of the data from other researchers
and also indicate the future direction which the work might take.
7.2. Mutations in patients with AIS
The analysis of the AR gene has been carried out for six patients with complete
AIS, four with partial AIS and five with features suggestive of androgen resistance.
Following PCR amplification, mutations were detected in eight of the patients tested
(Table 7.1). Point mutations were detected in three patients with complete AIS, all
four with partial AIS who were tested and in one patient who appears to have
Kennedy's disease. Since the cloning of the AR gene (Chang et al., 1988),
examination of the gene for the presence of mutations in patients with AIS has been
undertaken by several groups of investigators and has resulted in a rapid increase in
the available information about the effects of defects in this gene. Indeed, whilst the
current study has been under way, many publications have appeared describing AR
gene mutations. Some of the mutations detected in this study have also been described
in patients investigated by other groups: arginine 752 to a termination signal; arginine
831 to a termination signal; arginine 855 to cysteine, and valine 866 to leucine (De
Bellis et al., 1992; McPhaul et al., 1992; Pinsky et al., 1992; Ris-Stalpers et al.,
1992).
The location of the hormone binding domain mutations identified in the patients
in this study reinforces the observation of McPhaul et al. (1992) that 90% ofmutations
in this domain are clustered in two regions (residues 728 to 774 and 828 to 866
(Chapter 2, section 2.5.2.ii)), one of which is homologous to a region of the thyroid
hormone receptor where most of the identified mutations lie (Refetoff et al., 1993).
This similarity indicates that these regions are probably critically important in the
function of the receptor. Within these regions, the occurrence of the same mutations at
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the same amino acid position in unrelated patients may indicate that the nucleotides of
these codons are particularly susceptible to mutation. Three of the four mutations
listed above are due to a cytosine to thymidine transition, believed to result from
methylation and deamination of the pyrimidine as described by Youssoufian et al.
(1986). Other mutations have been identified in more than one patient at positions
throughout the gene: namely amino acids 695, 732, 749, 752, 762, 764, 774, 780,
831, 840, 855, 864 and 866 (Lubahn et al., 1989; Brown et al., 1990, 1992; Mebarki
et al., 1990; Chang et al., 1991; De Bellis et al., 1991, 1992; Marcelli et al., 1991b,
1992; Batch et al., 1992; Evans, 1992; Jakubiczka et al., 1992; McPhaul et al., 1992;
Pinsky et al., 1992; Prior etal., 1992; Ris-Stalpers et al., 1991; Trifiro et al., 1992b).
Patients sharing the same mutation generally appear to express the same phenotype
and GSF from them show the same functional abnormalities (but see below). All of
the duplicate sites lie within the steroid binding domain of the receptor and this
tendency for multiple mutations in the domain to manifest with clinical symptoms
further supports the notion that this portion of the receptor is critical in normal
androgen action. However, whilst mutations associated with symptoms of AIS have
been found in other regions of the receptor (notably within the DNA binding domain,
exons 2 and 3) there have been no reports to date of duplicate mutations in this region,
a fact which is difficult to explain.
In addition to the presence of duplicate mutations, some amino acids have been
found to be changed to different residues in different patients. Clinical information
regarding the severity of AIS in these individuals and, where possible, examination of
the function of the AR protein has added considerably to our understanding of the
spatial and charge restraints and requirements of each critical amino acid (Chapter 4,
section 4.5). For example, substitution of the normal arginine at position 855 for
cysteine replaces a residue with a positively charged side chain by one with a small
polar side chain (patient 1, Chapter 4; De Bellis et al., 1992) and has been found to
result in the expression of a complete AIS phenotype because the receptor appears
unable to bind androgen (De Bellis et al., 1992; McPhaul et al., 1992). Alternatively,
substitution of histidine at this site (with a charged side chain) results in a partial AIS
phenotype (Chang et al., 1991; Batch et al., 1992) and a receptor with disturbed
binding properties (Batch et al., 1992; McPhaul et al., 1992). Taken together, these
findings would be consistent with a charge dependent configuration or interaction at
this site which is critical for normal receptor function. Correlation of these data with
the crystallographic analysis of the steroid receptors (Luisi et al., 1991), together with
the information on the structure/function relationships of the various subdomains of
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the receptor, and their interaction with ligand and hormone response elements will add
to our understanding of normal receptor function and provide a mechanism by which
the mutations cause disease.
However, it would appear that the nature of the amino acid substitution is not the
only factor which affects the function of the AR. For example, a mutation of arginine
855 to histidine was identified in a patient with partial AIS by several groups (Chang
et al., 1991; Batch et al., 1992) but McPhaul et al. (1992) identified two patients with
this mutation, one of whom had partial AIS and the other of whom had complete AIS.
The GSF AR binding characteristics in each patient were the same. Similarly,
McPhaul et al. (1992) found the mutation of valine 866 to methionine in a patient with
partial AIS, while the same mutation in patients with complete AIS has been identified
by Lubahn et al. (1989) and Pinsky et al. (1992). The conclusion from these findings
must be that other factors act to modulate the action of the receptor.
Evidence for such factors has been provided by Bocquel et al. (1989) who
found that in vitro assays of receptor function produced different results depending
upon the type of host cell used. Some clinical studies have also provided clues to the
presence of other cellular factors; Jukier et al. (1984) described a family of brothers
with variable severity of undervirilisation where the most severely affected had 5 a-
reductase deficiency in association with an abnormality of the androgen receptor,
while the less severely affected brother had normal 5 a-reductase activity, but the same
abnormal AR (patient 8, Chapter 4). The activity of the enzyme appeared to synergise
with the receptor defect in this family. The presence of an AR gene mutation in spinal
and bulbar muscular atrophy (Kennedy's disease) which appears to cause a specific
effect upon the viability of spinal motor neurones provides circumstantial evidence for
the presence of a cell specific interaction between the AR and some other intracellular
factor (Chapter 2, section 2.4.2.iv). Whilst there is, therefore, evidence for
interaction between the AR and other intracellular factors having an effect upon the
action of the receptor in different target tissues which can modify the clinically
apparent changes in this patient, elucidation of the precise nature of these interactions
will require further study.
The three patients in the study with complete AIS where no mutations were
detected are a perplexing group. Whilst the failure to detect mutations may be due in
part to methodological difficulties, the possibility remains of alternative mechanisms
for the causation of the complete AIS phenotype. As discussed (Chapter 4, section
4.5), rearrangements of the gene or mutations within the promoter regions, or
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message translation abnormalities are all possibilities and deserve to be considered and
examined experimentally. Such work was outside the scope of this study but would
require an examination of the mechanics of the initiation of transcription and
translation of the gene. The transcription initiation sites of the AR gene have only
recently been identified (Faber et al., 1991) in the region upstream of the gene. The
promoter region lacks TATA/CCAAT boxes and has two separate sites for initiation
(AR-TIS I and AR-TTS II). Preliminary data indicate that utilisation of the two sites is
regulated differently: AR-TTS I is dependent upon sequences close to itself for activity,
while AR-TIS II depends upon the presence of an upstream GC-box which contains
an Spl binding site (Faber et al., 1993). Mutations introduced into the site abolish
transcription in vitro. These early findings indicate that mutations and other structural
defects of the transcription sites and their regulators can affect AR gene transcription,
and thus activity.
7.3. Infertile patients
The screening of a small cohort of infertile men for mutations of the AR gene was also
undertaken during the course of this study. The study was hampered by difficulties in
recruiting patients and in some degree by methodological difficulties. Patients were
selected on the assumption that there would be endocrine markers of receptor
dysfunction in terms of gonadotrophin profile and serum testosterone.
The seven men in this study were a subset of the 3% with oligospermia or
azoospermia who showed elevated testosterone and gonadotrophins selected from a
population of 1,700 men attending a local clinic. In this highly selected group no
mutations were detected in exons 2 to 8 of the AR gene. Problems in amplification of
GC-rich domains meant that the glycine repeat coding region of exon 1 was not
completely sequenced but no evidence of the presence of defects was found in the
remainder of exon 1. The current data would be consistent with the argument that
mutations of the androgen receptor gene are not common causes of infertility.
However, additional data from a population of azoospermic men with no endocrine
abnormality would be useful in order to expand the study of Akin et al. (1991) who
have published a paper in which they describe the detection of a deletion of exon 4 of
the AR gene in one of seven azoospermic men with normal endocrine parameters.
Their finding of a mutation in 1 of 7 men is almost certain to be partly due to fortunate
sampling, otherwise a comparable size of sample in this study would have been
expected to produce a positive result. This defect in association with normal hormonal
parameters is in agreement with Aiman & Griffin (1982) who proposed that infertility
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could be due to androgen resistance without endocrine markers. It is difficult to see
how androgen resistance can be present with no perturbation of the pituitary-testicular
axis unless the androgen receptor is defective in some testis specific function.
In considering the pathogenesis of infertility, the recent results of Ma et al.
(1992) should also be borne in mind. They detected microdeletions in the Y
chromosome of two azoospermic men, in the region of the azoospermia factor (AZF)
(Simpson et al., 1993). There are likely to be multiple aetiologies of non-obstructive
azoospermia, and it may be that interaction between the androgen receptor, testis-
specific factors and possibly the product of the AZF are all important for normal
spermatogenesis.
7.4. Trinucleotide repeats
The finding of an amplification of the glutamine repeat region of exon 1 of the AR in
patient 11 who was referred following routine endocrine screening is exciting. This
patient appears to have a late onset form of X-linked spinal and bulbar muscular
atrophy (SBMA) (Kennedy et al., 1968; Arbizu et al., 1983). The amplification of the
CAG trinucleotide repeat has been shown to be associated with this disease in a large
study (La Spada et al., 1991). It has recently been shown that this repeat is variable
and unstable in transmission during meiosis, and that the larger repeats tended to be
associated with more severe disease of earlier onset (Biancalana et al., 1992; La Spada
et al., 1992). Trinucleotide repeat amplifications appear to be responsible for a
number of inherited diseases and provide a mechanism to explain some previously
perplexing observations on the transmission of genetic disease, examples of which are
given below.
Fragile X syndrome is an X-linked dominant disorder with reduced penetrance
characterised by mental retardation (Fryns, 1989). Either sex may exhibit mental
retardation when carrying the affected chromosome. It has recently been shown that a
trinucleotide CGG repeat of thirty codons lies in the region of the fragile site of the X
chromosome (Verkerk et al., 1991). This repeat shows a variable increase in size in
DNA from affected patients relative to control samples and appears to be within the
coding region of a gene (FMR-1) which lies in this vicinity also.
Myotonic dystrophy is an autosomal dominant condition characterised by muscle
wasting and myotonia in association with cardiac problems, cataracts, testicular
atrophy and diabetes (Harper, 1989). The disease occurs in three forms of increasing
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severity; often the age of onset falls and the severity of symptoms increases in
successive generations of affected families (termed "anticipation") (Howeler et al.,
1989). A CTG trinucleotide repeat which is expanded in affected patients has been
identified at the genetic locus for myotonic dystrophy (Brook et al., 1992). In
addition, the repeat sequence also increases in size through successive generations
(Harley et al., 1992) and the size of the repeat sequence correlates with disease
severity and young age of onset (Redman et al., 1992; Tsilfidis, et al., 1992), giving a
molecular basis for the phenomenon of anticipation.
The third disease recently attributed to trinucleotide repeat expansion is
Huntington's disease (Huntington's Disease Collaborative Research Group, 1993). A
gene has been identified which carries a CAG trinucleotide repeat which was expanded
in all of 75 disease families studied. The size of the repeat was variable in normal
patients. Thus far, the identity of the encoded protein is unknown, and the repeat lies
within the coding region.
All these different diseases share the same underlying mechanism of an
amplification of a trinucleotide repeat region but the mechanism of how they exert their
effects is still unknown. In SBMA, the repeat lies within the coding region of the
gene while in myotonic dystrophy, the repeat is not translated (Brook et al., 1992).
The repeat in fragile X syndrome lies within the 5' untranslated region of the gene
FMR-1 (Verkerk et al., 1991), but the site in the Huntington's disease gene may be in
either situation (Huntington's Disease Collaborative Research Group, 1993). There is
little evidence to indicate how the mutation is effective. It may be a spatial effect
which causes disruption of the conformation of the three dimensional structure of the
DNA, interfering with the activity of the gene or an adjacent gene, but the presence of
a truncation of the repeat in the AR gene of a patient with partial AIS (McPhaul et al.,
1991) suggests that in this case the mechanism may be more subtle and involve some
perturbation of function of the protein. The finding of an elargement of the CAG
repeat in SMBA also suggests the possibility of some dominant negative action of the
mutant protein, inhibiting a normal protein-protein interaction.
7.5. Future direction
This study has examined the AR gene of patients with androgen insensitivity and of a
cohort of infertile men. The mutations identified in the patients with AIS have added
to the database of mutations responsible for the syndrome and have contributed to the
understanding of the mechanism of action of the steroid receptor. The examination of
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the entire coding region of the gene has been slightly hampered by difficulties with
PCR amplification of certain regions and it would be worth a concerted effort to
modify the protocol in order to improve the efficiency of the PCR and allow
completion of the analysis of the patients (in particular the infertile cohort). The
inclusion of 7-deaza-guanosine as a nucleotide in the PCR reaction (Innis, 1990) was
adopted briefly in an attempt to improve the specific amplification of the GC-rich
glycine repeat coding region of exon 1, but there was no immediate improvement.
Additional effort attempting to optimise the use of this nucleotide in PCR amplification
of exon 1 would probably be of benefit since this approach has resulted in successful
amplification of GC-rich domains of other genes, notably the CGG repeat in the FMR-
1 gene in fragile X syndrome (Kremer et al., 1991).
The continued analysis of the AR gene of patients with AIS as they come to
clinical attention will be useful to complement the available data on the location of AR
gene mutations and how they affect the function of the receptor protein. The number
of patients is likely to be low in view of the low incidence of the disease and the small
size of the Scottish population. Additional information about regions upstream of the
start site of transcription of the AR gene is now required and this would be worthy of
an entirely new study initially focussing upon patients with no demonstrable defect
within the coding region of the AR gene but symptoms and signs of AIS, such as
patients 4 to 6 in this study.
Modification and optimisation of the method for site-directed mutagenesis
should be undertaken in order to reproduce the sequence of the AR detected in the AIS
patients in this study, and to utilise in vitro assays to determine whether the function of
the resultant AR protein is affected. This will be particularly useful in the patients
where data from genital skin fibroblasts are not available and there is no information
about receptor status and binding capacity of GSF. The mutations introducing
premature termination codons are more predictable in their effect, but it is nevertheless
worth confirming the translation of a truncated protein.
The analysis of infertile men for the presence of AR gene mutations should be
continued to complete the analysis of exon 1, as discussed above, and to provide a
larger sample size. In view of the findings of Akin et al. (1991) a sample of
azoospermic men should be studied. The likelihood of a low rate of mutation
detection will make such a study labour intensive even using the DGGE technique
established in this study, but even negative findings such as were obtained in this
study are of interest in resolving the debate about the prevalence of AR gene mutations
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in infertility.
In conclusion, this study has identified mutations in the AR gene of patients with
androgen resistance which have contributed to a greater understanding of the
mechanism of action of these mutations in the pathogenesis of the disease. They have
also, in context with the data of other workers, provided insights into the mechanics of
the steroid receptor function in the normal situation. A preliminary study of a cohort
of infertile men has been undertaken without finding any evidence of AR gene
mutations.
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Table 7.1. Summary of all detected AR gene mutations
Patient Nucleotide Change Amino acid Change
1 (complete AIS) 2574 CGC -> TGC 855 Arg —> Cys
2 (complete AIS) 2502 CGA -> TGA 831 Arg -» STOP
3 (complete AIS) 2265 CGA -> TGA 752 Arg —> STOP
7 (partial AIS) 2607 GTG -> TTG 866 Val —> Leu
8 (partial AIS) 2607 GTG -> TTG 866 Val —> Leu
9 (partial AIS) 1834 AGG -> AAG 608 Arg —> Lys
10 (Reifenstein's) 2326 GAG -» GGG 772 Glu —> Gly
11 (?Kennedy's) Exon 1 Glutamine No. of residues Increased to
repeat 46 Gin
Note: numbering of amino acids in this table and throughout the thesis is taken to be
that of the androgen receptor gene sequence published by Lubahn et al., 1989.
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Appendix 1. Abbreviations
ACD: Acid citrate dextrose buffer
AR+: Androgen receptor positive (androgen insensitivity)
AR-: Androgen receptor negative (androgen insensitivity)
ATP: Adenosine triphosphate
AZF: Azoospermia factor
Bmax; Maximum binding sites
Complete AIS: Complete androgen insensitivity syndrome
CAT: Chloramphenicol acetyl transferase
cDNA: Complementary DNA
CLB: Cell lysis buffer
C-terminal: Carboxy-terminal end of peptide chain
CTP: Cytosine triphosphate
DGGE: Denaturing gradient gel electrophoresis
DHT: D ihyd rotestosterone






ERE: Oestrogen response element
Exp.: Experiment
FSH: Follicle stimulating hormone
GRE: Glucocorticoid response element
GSF: Genital skin fibroblast
GTP: Guanosine triphosphate
hCG: human chorionic gonadotropin
HRE: Hormone response element





LH-T: LH x testosterone product
MIF: Miillerian inhibitory factor
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MMTV: Mouse mammary tumour virus
MOPS: 4-morpholinopropanesulphonic acid
mRNA: Messenger ribonucleic acid
N-terminal: Amino-terminal end of peptide chain
Partial AIS: Partial androgen insensitivity syndrome
PCR: Polymerase chain reaction
PLB: Protein lysis buffer
rpm: Revolutions per minute
rtPCR: Reverse transcriptase PCR
SBMA: Spinal and bulbar muscular atrophy
SHBG: Steroid hormone binding globulin
SOC: 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KC1, 10
mM MgCh, 10 mM MgS04, 20 mM glucose
SSCP: Single strand conformational polymorphism
Sustanon: 30 mg testosterone propionate, 60 mg testosterone phenylpropionate,
60 mg testosterone isocaproate, 100 mg testosterone decanoate
TAE: Tris/acetate/EDTA buffer: 40 mM Tris pH 8.0, 40 mM sodium
acetate, 1 mM EDTA
TBE: Tris/Borate/EDTA buffer: 90 mM Tris pH 8.0, 90 mM boric acid, 2
mM EDTA
TE: Tris/EDTA buffer: 10 mM Tris.HCL pH 8.0, 1 mM EDTA
TEMED: N, N, N', N'-tetramethylethylenediamine
TGGE: Temperature gradient gel electrophoresis




Yp: Short arm of Y chromosome
Yq: Long arm ofY chromosome
Appendix 2. IUPAC codes for amino acids




Aspartic acid D Asp
Cysteine C Cys















Appendix 3. Addresses of suppliers
Applied Biosystems Ltd. Amersham International pic
Kelvin Close Lincoln Place
Birchwood Science Park Green End
Warrington Aylesbury
Cheshire WA3 7PB Buckinghamshire HP20 2TP
BioRad Laboratories Ltd. Biosoft
BioRad House 22 Hills Road
Maylands Avenue Cambridge
Hemel Hempsted Cambridgeshire
Hertfordshire HP2 7TD CB2 1JP
Cambridge Bioscience Flow Laboratories




Flowgen Instruments Ltd. Hybaid UK Ltd.
Broad Oak Enterprise Village 111-113 Waldegrave Road
Broad Oak Road Teddington
Sittingbourne Middlesex TW11 8LL
Kent ME9 8AQ
Pharmacia Biosystems Ltd. Promega Ltd.
Biotechnology Division Delta House
Davy Avenue Enterprise Road
Knowlhill Chilworth Research Centre
Milton Keynes MK5 8PH Southampton SOI 7NS
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British Andrology Society: Anglo-Scandinavian Conference on
Andrology, London, 6th - 7th December 1991
Point mutations in the androgen receptor gene of patients suffering from
androgen insensitivity syndrome.
D.G. Tincello, P.T.K. Saunders*, F.C.W. Wu* and T.B. Hargreave.
Department of Surgery, Western General Hospital, Crewe Road, Edinburgh and *
MRC Reproductive Biology Unit, 37 Chalmers Street, Edinburgh.
Androgens are responsible for development of the male phenotype. Syndromes of
androgen insensitivity ranging in severity from slight undervirilisation to complete
testicular feminisation have been described in patients with an XY karyotype (Grino
et al., 1988). These latter patients are phenotypically female but have a blind-ending
vagina and lack a uterus and Fallopian tubes. They also have testes either intra-
abdominally or within the inguinal canal. Typically they present with primary
amenorrhoea or an inguinal hernia.
The first step in androgen action is binding to a specific cellular receptor (Carson-
Jurica et al., 1990). The cloning and sequencing of the androgen receptor (AR)
cDNA and the mapping of a single gene to the X-chromosome has facilitated
examination of its structure in patients with androgen insensitivity (Chang et al.,
1988; Lubahn et al., 1988). We have examined the sequence of the androgen receptor
gene in patients who are insensitive to androgen (testicular feminisation).
Whole blood was mixed with acid-citrate buffer and DNA extracted from the nuclei
of leucocytes. Portions of DNA encoding the exons of the human androgen receptor
gene were amplified by polymerase chain reaction using specific pairs of
oligonucleotide primers (Lubahn et al., 1989). The amplified DNA was purified and
the sequence determined. To date we have detected single point mutations in two of
four patients under investigation. In patient 1, a single base pair change (C to T)
within an area of the receptor gene known to encode the steroid binding portion of the
receptor, results in an arginine residue being replaced by cysteine. In patient 2 the
codon for amino acid 831 (CGA= arginine) has been changed to a 'stop' codon(TGA).
This patient would therefore appear to be unable to translate a full length receptor
protein from her mRNA.
In conclusion, techniques of DNA amplification and sequencing have enabled us to
pin point the genetic defects responsible for the abnormal phenotype of two patients
suffering from complete androgen insensitivity syndrome.
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11th Joint meeting of British Endocrine Societies, Harrogate, 23rd -
26th March 1992
Mutations in the androgen receptor gene of patients with androgen
insensitivity
(Tincello et al., 1992a)
D.G. Tincello*, T.B. Hargreave*, F.C. Wu,T. Padayachi, and P T. Saunders. MRC
Reproductive Biology Unit, Centre for Reproductive Biology, 37 Chalmers Street,
Edinburgh EH3 9EW, &*University Department of Surgery, Western General
Hospital, Crewe Road, Edinburgh EH4 2XU, UK
Androgens are responsible for development of the male phenotype. Syndromes of
androgen insensitivity range in severity from complete failure of virilisation
(complete AIS) to partial androgen insensitivity (partial AIS) with hypospadias,
gynaecomastia and small testes. The first step in androgen action is binding to a
specific cellular receptor. The cloning and sequencing of the androgen receptor (AR)
cDNA has facilitated examination of its structure. We have examined the sequence of
the AR gene in patients with both complete AIS and partial AIS in order to determine
the genetic basis of their androgen resistance.
Genomic DNA was extracted from whole blood. DNA encoding the exons of the AR
gene was amplified by polymerase chain reaction (Lubahn et al, 1989), purified and
sequenced. To date we have detected single point mutations in five of sixteen
patients under investigation. In patient 1, (complete AIS), the codon for amino acid
831 (CGA= arginine) has been changed to a 'STOP' codon (TGA). This would
produce a truncated receptor protein lacking a portion of the steroid binding domain.
In patient 2, also with complete AIS, a single base pair change (C to T) within an area
of the receptor gene coding for the steroid binding portion of the receptor, results in
an arginine residue (855) being replaced by cysteine. Two unrelated patients with
partial AIS have the same mutation substituting valine for leucine at position 866,
again in the steroid binding region of the receptor. Patient 5, with partial AIS, has a
mutation within the DNA binding domain of the receptor, changing a lysine to
arginine at residue 607 of the second "zinc finger " of the domain, closely involved in
DNA binding. This amino acid is conserved through the entire steroid receptor
family. We plan to examine the androgen receptor gene in the remaining patients by
the technique of temperature gradient gel electrophoresis. This method allows the
analysis of DNA fragments on the basis of sequence composition (Myers et al.,
1985a).
In conclusion, techniques of DNA amplification and sequencing have enabled us to
pin-point the genetic defects responsible for the abnormal phenotype of five patients
suffering from varieties of androgen insensitivity. We find that both the nature of the
amino acid substitution caused and its location can have a profound effect upon the
function of the AR and the consequent phenotype of the individual.
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5th Simpson Symposium, 8th - 11th September, Edinburgh 1992
Detection of point mutations in the androgen receptor gene of patients
with androgen insensitivity by the use of temperature gradient gel
electrophoresis
D.G. Tincellot. F.C.W. Wu#, T.B. Hargreavef & P.T.K. Saunders*
*MRC Centre for Reproductive Biology, 37 Chalmers St., Edinburgh,
UK;fUniversity Department of Surgery, Western General Hospital, Edinburgh,
UK;#Department of Medicine, University of Manchester Medical School, Salford,
Greater Manchester, UK
Androgen insensitivity (AIS) is a rare X-linked inherited disorder characterised
by a failure of androgen action. Patients either show an unambiguously female
phenotype (complete AIS) in association with a total failure of androgen action; or a
phenotype within a spectrum from ambiguous genitalia with labioscrotal fusion
through hypospadias to isolated gynaecomastia, in conjunction with a partial defect
in androgen action (partial AIS) (Wilson, 1992). Defects in the androgen receptor
(AR) gene have been found in these patients ranging from deletions of whole or part
of the gene (Brown et al., 1988) to single mutations scattered throughout the eight
exons of the gene, causing single amino acid substitutions, premature termination
codons (Marcelli et al., 1990a) and aberrant splicing of messenger RNA (Ris-
Stalpers et al., 1990).
The AR gene is coded for on eight exons and is over 3000 base pairs long.
Screening of a large number of patients is very laborious. We have used the
technique of temperature gradient gel electrophoresis (TGGE) to screen individual
exons of the AR gene for mutations. TGGE involves the electrophoresis of DNA
fragments in a polyacrylamide gel over a linearly increasing temperature gradient.
At a certain temperature (Tm, governed by the sequence composition of the
fragment) the DNA strands begin to separate and the fragment is retarded in the gel
by these single stranded regions. A single base mutation is sufficient to alter the
temperature (Tm) at which this separation occurs and fragments with different Tms
will migrate different distances in the gel (Riesner et al., 1989). Thus, samples
which are mutated relative to control DNA can be easily identified by their final
position in the gel. Only these identified samples need to be sequenced to determine
the nature of the mutation.
We have established a TGGE system in our laboratory using samples from
patients previously identified as having mutations as positive controls (Saunders et
al., 1992). In addition, using TGGE we have identified two novel point mutations in
two more patients: a C to T mutation creating a premature termination codon in exon
5, in a patient with complete AIS; an A to G mutation causing the substitution of
glycine for the normal glutamine at amino acid 772, in a patient with partial AIS.
Thus TGGE is an efficient method for the detection of point mutations in the AR
gene.
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Society for Endocrinology 183rd Meeting, London, 25th - 27th
November 1992
Temperature gradient gel electrophoresis can detect point mutations in
the androgen receptor gene in patients with androgen insensitivity
(Tincello et al., 1992b)
D.G. Tincello, F.C.W. Wu#, T.B. Hargreave & P.T.K. Saunders* University
Department of Surgery, Western General Hospital, Edinburgh, UK; MRC Centre for
Reproductive Biology, 37 Chalmers St., Edinburgh, UK; #Department of Medicine,
University of Manchester Medical School, Salford, Greater Manchester, UK
TGGE is a fairly new technique for the analysis of DNA fragments on the basis of
their sequence in addition to their size (Riesner et al., 1989). Samples of DNA
purified from a polymerase chain reaction are electrophoresed through a
polyacrylamide gel subject to a linearly increasing temperature gradient. At a certain
temperature (Tm, governed by the sequence composition of the fragment) the DNA
duplex will partially separate and the fragment will be retarded in the gel. A single
base mutation is sufficient to alter the temperature (Tm) at which this separation
occurs and fragments with different Tms will therefore migrate different distances in
the same gel. Thus, samples which are mutated relative to control DNA can be easily
identified by their final position in the gel. Only these identified samples need to be
sequenced to determine the nature of the mutation. This technique of denaturing
gradient gel electrophoresis is able to detect up to 95% of mutations within a DNA
fragment (Myers et al., 1987). The method can be rendered more sensitive by PCR
amplification of the fragment with a GC clamp attached to one end (Sheffield et al.,
1989).
Androgen insensitivity (AIS) is a rare X-linked inherited disorder characterised by a
failure of androgen action. Affected patients are either phenotypically female, with
absent internal genitalia and male gonads (complete insensitivity or complete AIS) or
partially virilised, with ambiguous genitalia, hypospadias and gynaecomastia (Wilson,
1992). Causative defects in the androgen receptor (AR) gene have been found in
these patients ranging from deletions of whole or part of the gene (Brown et al., 1988)
to single mutations scattered throughout the eight exons of the gene (Marcelli et al.,
1990b).
Detection of AR gene mutations in these patients can be laborious by standard
techniques of gene sequencing and so we have established a TGGE system in our
laboratory. Samples from patients previously identified as having mutations were
used as positive controls (Saunders et al:, 1992). Subsequently, we have identified
novel point mutations in two patients: a C to T mutation creating a premature
termination codon in exon 5, in a patient with complete AIS; an A to G mutation
causing the substitution of glycine for the normal glutamic acid at amino acid 772, in
a patient with partial AIS.
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12th Joint Meeting of British Endocrine Societies, Liverpool, 29th
March - 1st April 1993
Clinical, biochemical & molecular aspects of and response to high dose
testosterone in male pseudohermaphroditism (Reifenstein syndrome)
(Tincello etal., 1993)
D.G. Tincello, T.B. Hargreave, P T. Saunders* and F.C. Wu. University Department
of Surgery, Western General Hospital, Edinburgh EH4 2XU; *MRC Reproductive
Biology Unit, Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3
9EW, & Dept. Medicine, Hope Hospital, Salford, Manchester.
Androgen insensitivity (AIS) is an X-linked inherited disorder characterised by a
failure of androgen action. Reifenstein's syndrome is one of the clinical
manifestations of the partial form of the syndrome, where the individual presents
with an obviously male phenotype, but is poorly virilised (Wilson, 1992). There is
usually marked hypospadias, gynaecomastia and the testes are small and often
undescended. Secondary sexual development is impaired. Defects in the androgen
receptor (AR) gene have been found in patients with AIS ranging from deletions of
whole or part of the gene to point mutations scattered throughout the gene, mainly in
the exons encoding the hormone binding or DNA binding domains.
We present two men with Reifenstein's syndrome. Patient 1 had hypospadias,
gynaecomastia, testicular maldescent, and a small penis. Patient 2 had ambiguous
genitalia at birth, was reared as a boy and given androgen therapy with little response.
His genealogy shows an X linked recessive trait of impaired virilisation. Genital skin
fibroblasts (GSF) from patient 1 had a normal Bmax & elevated Kd for androgen;
dissociation was shown to be biphasic. GSF from patient 2 showed normal Bmax &
Kd. Nuclear localisation of liganded receptor was impaired. Both men were
subjected to high dose testosterone therapy and serum testosterone and
gonadotrophins measured. Patient 1 showed some suppression of gonadotropins
during administration of 5 mg/kg/day testosterone propionate; patient 2 had little
change during the entire period. Patient 1 developed positive nitrogen balance, but
no change in sebum secretion. Patient 2 also developed positive nitrogen balance,
but showed a normal response in sebum secretion.
The AR gene of both men has been sequenced. Patient 1 has a mutation of arginine
608 to lysine in exon 3 (Saunders et al.; 1992) and patient 2 a mutation in exon 5
from glutamic acid 772 to glycine (Tincello et al., 1992b). The site of these
mutations correlates with the in vivo and in vitro data above. A mutation in exon 5
(hormone binding domain) results in a mild reduction in binding affinity for
androgen, which can be overcome by high dose therapy; a mutation in exon 3 (DNA
binding domain) impairs the ability of the receptor to bind to DNA and activate target
gene, and this effect is not altered by high dose androgens.
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Point mutations detected in the androgen receptor gene
of three men with partial androgen insensitivity syndrome
P. T. K. Saunders, T. Padayachi, D. G. Tincello,
S. M. Shalet* and F. C. W. Wu
MRC Reproductive Biology Unit, Edinburgh, and
'Department of Medicine and Endocrinology, Christie
Hospital & Holt Radium Institute, Wilmslow Road,
Manchester M20 9BX, UK
(Received 14 January 1992; returned for revision 6 February
1992; finally revised 6 March 1992; accepted 8 April 1992)
Summary
OBJECTIVE Determine the sequence of the androgen
receptor gene in men with impaired responsiveness to
androgens in order to identify the molecular basis of their
under-virilization.
DESIGN Blood samples were used as the source of
genomic DNA. Portions of the androgen receptor gene
were amplified by polymerase chain reaction and
sequenced.
PATIENTS Samples were obtained from three patients
and five normal fertile controls. Patients were all 46 XY and
were undervirilized with ambiguous external genitalia,
gynaecomastia and infertility.
MEASUREMENTS Total cellular DNA was purified from
peripheral blood leucocytes. Pairs of oligonucleotide
primers designed to flank the individual exons of the
androgen receptor gene were synthesized. The specific
regions of the androgen receptor were amplified from the
samples of cellular DNA by polymerase chain reaction.
Amplified DNA was purified, sequenced and compared to
the published sequence.
RESULTS In all three patients point mutations in the
androgen receptor gene were detected but no defects
were detected in samples from normal controls. In two of
the patients, an identical single nucleotide change from G
to T was detected. This nucleotide was within the codon for
amino acid 866 and would change it from valine to leucine.
Amino acid 866 is found within an area of the steroid
binding domain thought to be involved in receptor dimeri-
zation. Within the repetitive sequence of exon I patient 1
had 21 glutamine residues and patient 2 had 25. In the third
patient a single change of G to A would result in
incorporation of lysine in place of a conserved arginine
Correspondence: Dr Philippa T. K. Saunders. MRC
Reproductive Biology Unit, 37 Chalmers Street. Edinburgh EH3
9EW, UK.
residue at position 607 within the second zinc finger of the
DNA binding domain. The sequence of the androgen
receptor gene of the mother of the third patient revealed
her to be heterozygous for the same defect.
CONCLUSION Patients 1 and 2 are unrelated although
they have an identical point mutation in their androgen
receptor gene. A patient with complete androgen insensit¬
ivity syndrome has been reported to have a defect at the
same position causing the amino acid substitution of
methionine for valine. Therefore we confirm that the
nature of the amino acid change in the peptide sequence of
the androgen receptor as well as its location within the
protein, can have a profound effect on the phenotypic
severity of androgen resistance. Studies on mutated
receptors from individuals with a wide range of degrees of
androgen resistance may enable us to construct a map of
the key amino acids in the different domains of the protein.
Androgens are essential for the determination, maintenance
and expression of the male phenotype. They are responsible
for masculinization of the brain, the reproductive tract and
the external genitalia during development in utero (Bardin,
1986). Subsequently, androgens are responsible for the
development and maintenance of secondary sexual charac¬
teristics, libido and fertility. A spectrum of androgen resis¬
tance syndromes has been described ranging in severity from
complete feminization to slight under-virilization with nor¬
mal fertility (Griffin & Wilson, 1989; Grino et al., 1988).
Normal androgen action is initiated by the interaction of
the steroid with a specific receptor expressed in target tissues.
The cDNA for the human androgen receptor (AR) has been
cloned, sequenced and its amino acid structure determined
(Chang et al., 1988; Lubahn et al., 1988). The AR is a
member of the steroid receptor family in which the basic
structural organization of the receptor cDNA and protein is
highly conserved (Carson-Jurnica et al., 1990) and can be
considered as a series of amino acid domains which act
separately, and cooperatively, to confer the full function of
the receptor. The AR is encoded on eight exons (Lubahn et
al., 1989; Marcelli et al., 1990). The hormone-binding
domain which confers steroid specificity on the AR is found
towards the C-terminus of the protein encoded on exons 4 to
8 (Carson-Jurnica et al.. 1990; Ris-Stalpers et al., 1990). The
DNA binding domain is characterized by the presence of two
zinc fingers, which are encoded on exons two and three and
are in the mid region of the receptor. The zinc fingers interact
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with specific recognition sequences of androgen regulated
genes, the hormone-response elements (HRE), to cause
alterations in the rate of gene transcription (Carson-Jurnica
et al., 1990). The N-terminal domain has recently been
shown to interact with other domains to promote full
transcriptional activity (Simental et al., 1991).
Patients with female phenotype diagnosed as suffering
from complete androgen insensitivity (testicular feminiza¬
tion or CAIS) have been investigated for genetic defects.
There is a clear pattern of familial inheritance of the
syndrome via heterozygous carrier females consistent with
the location of a single AR gene on the X chromosome
(Lubahn et al., 1988). Defects in the AR gene of individuals
with CAIS have been detected which appear to be respon¬
sible for their inability to respond to endogenous androgens.
The alterations documented range from deletions and
premature stop codons (Brown et al., 1988; Marcelli et al.,
1990; Ris-Stalpers et al., 1990; Quigley et al., 1991) to point
mutations in the AR coding sequence leading to changes in
key amino acids in the steroid-binding or DNA-binding
domains (Lubahn et al., 1989; Zoppi et al., 1991). Limited
information has been available for patients with the milder
forms of androgen resistance. However, recently McPhaul
and co-workers (1991) have described a family with under-
virilization where two defects in the receptor protein
appeared to act cooperatively to impair the ability of the
receptor protein to activate genes. In addition, at a recent
meeting, single point mutations have been recorded for
patients described as suffering from partial AIS (De Bellis et
al., 1991; Chang et al., 1991).
In this paper we present data from three patients with
clinical features of partial AIS, in whom we have detected
point mutations in their AR gene. Each of the changes found
would cause an alteration in an amino acid incorporated into
a key domain of the AR protein consistent with impaired
functioning of the receptor in vivo.
Materials and methods
Patients
Peripheral blood was obtained from three patients with
incomplete androgen insensitivity and from five normal men
ofproven fertility. Informed consent was obtained from each
individual. Patient 1 is a 36-year-old man (46 XY) who had
several operations for hypospadias as a child (the severity
was unrecorded). At age 13 he developed bilateral gynaeco-
mastia requiring simple mastectomy. He has never needed to
shave. His pubic hair has a female distribution, the penis is 3
cm in length and the testes measure 6 ml and 8 ml. He is
married and is able to have intercourse, but has never
produced an ejaculate (i.e. he is azoospcrmic). Serum
testosterone is elevated at 90 nmol/1, FSH > 32 U/l,
LH>32U/1, with no response to a gonadotrophin releasing
hormone test. Genital skin fibroblasts failed to grow in
culture and so 5oc-reductase activity was not measured.
Patient 2 is 35 years old and the youngest of three brothers.
The whole family have under-virilization and have been
reported by Jukier et al. (1984). Patient 2 had perineo-scrotal
hypospadias requiring a two stage repair, gynaecomastia and
a high pitched voice. Pubic hair distribution was reasonable
but he had scanty facial hair. He is azoospermic with a serum
testosterone of 62-3 nmol/1, FSH of 16-1 U/l and LH of 24-1
U/l. His two brothers also had third degree penile hypospa¬
dias, a bifid scrotum and developed gynaecomastia. They
both have sparse pubic hair and a female distribution of body
fat. Specific dihydrotestosterone binding activity of genital
skin fibroblasts of the patient's brothers showed a normal
#max, but the equilibrium dissociation constant was 116
nmol/1, compared to 0-22 nmol/1 in normal men. Unfortuna¬
tely, the cell line derived from patient 2 was lost before any
studied could be performed (Jukier et al., 1984). The patient
showed normal 5a-reductase activity, although his brother
had virtually undetectable levels. Thus, the clinical picture in
the brothers appears to be a combination of 5a-reductase
deficiency and impaired androgen receptor function. By
inference, patient 2 would appear to have the qualitative
abnormality of androgen receptor action in isolation.
Patient 3 is 48 years old (46 XY) and was diagnosed as
suffering from Reifensteins's syndrome; he was born with
ambiguous external genitalia (minute phallus, bilateral
inguinal testes) and received weekly androgen injections to
age 5. At 18 years old bilateral mastectomy was performed
because of marked gynaecomastia. The right testis has been
biopsied and the left testis removed following repeated
epididymitis; both contained Sertoli cell-only seminiferous
tubules and abundant Leydig cells. In cells from a genital
skin biopsy specific high affinity binding sites for 5a-
dihydrotestosterone was 50 fmol/mg protein (normal range
16-5—55-0) with a Kd of 0-2 nmol/1 (normal 0-05-0-53) at
37°C; 5a-reductase activity was normal (M. B. Hodgkins,
University of Glasgow, unpublished results). This patient
has not virilized despite repeated courses of androgen
therapy. In his family, abnormalities of male sexual develop¬
ment have been evident in three generations consistent with
transmission of an X-linked recessive trait via carrier females
(Fig. 1). Blood samples were obtained from his mother, his
sister and her two daughters.
Isolation of genomic DNA and amplification of AR
Blood (10ml) was mixed with acid-citrate-dextrose buffer (1
ml/10 ml whole blood) and DNA extracted as detailed by
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Fig. 1 Family history of patient 3 showing the incidence of partial
androgen insensitivity in males from three generations. The
affected individuals (closed boxes; patient 3 arrowed) had high
pitched voices, gynaecomastia, hypospadias, and were
hypogonadal. * Individuals from whom blood was obtained; O,
carrier females. The carrier status of individuals not directly
examined was inferred from the appearance of the defect in their
offspring. The patient was examined by one of us (FCWW) and
the family tree prepared from information supplied by him.
Sambrook et al. (1989). Polymerase chain reaction (PCR;
Saiki et al., 1988) was performed either using pairs of
oligonucleotide primers (18-20 mers) detailed below or those
published by Lubhan et al. (1989). Oligonucleotide primers
(written 5-3'): exon 6-7 = 5' (2845-) TATCGCATGCA-
CAAGTCCCG, 3' (3097-rev) AAGCGTCTTGAGCAG-
GATGT; exon 7-8 = 5' (3005-) TCTTTGATGAACTTCG-
AATGA, 3' (3288-rev) TCACAGGGTGTGGAAATAGA.
The standard PCR reaction mixture was as follows; 100 p\/
tube containing 50 mM KC1, 10 mM Tris-HCl, pH9 at 25°C,
1-5 mM MgCl2, 0-01% gelatin, 0-1% Triton X100, 100 fiM
dNTPs (Pharmacia Ltd, Milton Keynes, UK), 0-5 nm each
primer, 2-5U Thermus aquaticus DNA polymerase (Taq
polymerase, Promega Ltd, Southampton, UK) and 0-5-1 ftg
genomic DNA. Amplification conditions typically consisted
of an initial melt at 94°C for 2 min followed by 30 cycles of
melting for 0-5 min at 94°C, annealing for 1 min at 55°C and
extension for 0-5-1 min at 72°C. Amplified double stranded
AR DNA was purified by gel electrophoresis in NuSieve
agarose (FMC, Flowgen), recovered using a Geneclean kit
(USB, Cambridge Biosciences, UK) and quantified. DNA
was denatured by boiling and sequenced using Sequenase
(Cambridge Biosciences) according to the standard protocol
and GTP or ITP nucleotide mixes but with the following
minor modifications. Dimethyl sulphoxide (DMSO) was
added to DNA during the annealing reaction (6:1,
DNA:DMSO) and to termination mixes at a ratio of 9:1
(mix: DMSO).
Results
Amplified exons were of the expected size in all controls and
patients. Direct sequencing of PCR amplified DNA from
normal fertile controls revealed no differences from the
published sequence (Chang et al., 1988) consistent with the
PCR amplification producing a faithful copy of the original
DNA. In contrast, in the patients with partial AIS, the
following point mutations were detected. In exon 7 of
patients 1 and 2 there was a single base pair change (G to T)
in the codon for amino acid 866 (Fig. 2). The codon TTG
replacing the normal GTG at this position results in the
inclusion of leucine in place of valine in this part of the AR
which has been identified as part of the steroid-binding
domain. DNA amplified from exon 1 to include the hyper-
variable domain (which begins at amino acid 62; Chang et
al., 1988) of patients 1 and 2 was found to be of different
lengths on agarose gels. Direct sequencing confirmed that
patient 1 had 21 glutamine residues within this region whilst
patient 2 had 25.
Patient 3 had a single nucleotide substitution in exon 3
where a change from G to A (Fig. 3) results in a change in the
amino acid in position 607 from arginine to lysine; he had a
normal complement of 23 glutamine residues in exon 1. This
arginine is within the 'tip' of the second zinc finger of the
DNA binding domain (Fig. 4) and is conserved in other
members of the steroid receptor family. His mother was
found to be heterozygous for the defective AR whilst his
sister and her daughters had normal DNA sequence for the
AR on both of their X-chromosomes (data not shown).
Amplification and sequencing of exons in which base pair
changes were detected was repeated three times. Except for
the changes detailed above no other changes have been
detected in these patients.
Discussion
Three male patients with partial AIS, characterized by
under-virilization with ambiguous external genitalia, gynae¬
comastia and infertility, were investigated to determine
whether they had mutations in the gene encoding theii
androgen receptor (AR). In all cases point mutations in the
nucleotide sequence were detected which would give rise to a
change in one amino acid in the AR protein. In patients 1 and
2 an identical mutation was detected in the codon for amine
acid at position 866. This would result in a change from
valine to leucine in the AR protein. Sequence of the
polymorphic homopolymeric (CAG) repeats in exon 1
revealed 21 codons in patient 1 and 25 codons in patient 2 in
this position. This therefore confirms family investigations
which indicated that they are not related.
It is notable that Lubahn and co-workers (1989) have
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Fig. 2 Sequence data from exon 7 of patient 1 compared to that of a control. A single base pair change (G to T) in the codon for amino
acid 866 was observed (arrowed).
described a patient with complete AIS in which a point
mutation at the same nucleotide resulted in incorporation of
methionine in place of valine. Examination of the amino acid
structure of valine and leucine reveals the slight nature of the
change in patients 1 and 2, with both being non-polar and
only differing by a single methyl group (Fig. 3). In the patient
with complete AIS (Lubahn et al., 1989; Fig. 3) the amino
acid substitution (methionine in place of valine) results in a
more substantial change in the size and structure of the
amino acid than that seen in our patients with partial AIS.
Brown et al. (1990) used transfection of COS cells with
mutant AR to recreate this defect in vitro and found that an
AR with methionine in this position was able to activate a
reporter gene but only at concentrations of steroid unlikely
to occur naturally.
Work on steroid receptors has indicated that amino acid
366 falls within a portion of the receptor protein involved in
iimerization after ligand binding (Fawell et al., 1990). One of
he key hydrophobic amino acids in the dimerization domain
tf the AR is believed to be valine 866, a finding consistent
vith the amino acid at this position having a profound effect
on function of the receptor in vivo. The finding ofan identical
base change in these two patients would support the idea
advanced in a previous paper (Lubahn et al., 1989), that this
site is a 'hot-spot' for mutation.
In favour of this hot-spot theory, Ris-Stalpers and co¬
workers (1991) have similarly identified two different point
mutations in three unrelated families at codon 686, a
conserved aspartic acid in exon 4. In these families changes of
this amino acid to histidine or asparagine resulted in
impaired receptor function and a CAIS phenotype.
In patient 3 a nucleotide substitution in exon 3 results in a
codon for lysine in place of arginine. His mother was
heterozygous for the same defect. The amino acid so changed
(607) is found within the second zinc finger and is conserved
as arginine in all members of the steroid receptor family
(Carson-Jurnica et al., 1990). Previous clinical investigation
of this man had indicated that the binding of androgen to
receptor protein from this individual was in the normal
range, consistent with the finding of normal nucleotide
sequence in the steroid binding domain. Deletion of the
entire second zinc finger of the AR has been detected in a
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Fig. 3 Sequence data from exon 3 of patient 3 compared to a normal control. A single base pair change (G to A) was detected.
patient with complete AIS (Quigley et al., 1990). In addition,
De Bellis et al. (1991) report a point mutation at amino acid
616 (leucine to arginine) in a partial AIS subject and Marcelli
et al. (1991) a change from arginine to proline at position 615
in a patient with complete AIS.
The role(s) of the two zinc fingers in determination of the
specificity of interaction with hormone response elements
and subsequent modification of gene transcription has been
the subject of several studies. Work on oestrogen receptors
has demonstrated that the identity of the three amino acids at
the base of the first zinc finger plays a key part in the
recognition specificity of the receptor for the androgen
receptor hormone response element (Mader et al., 1989).
Studies in which mutations were introduced into the second
zinc finger of the glucocorticoid receptor have suggested that
this region extends away from the DNA and interacts with
proteins of the transcription machinery (Hard et al., 1990).
In patient 3, binding of the occupied AR to the hormone
response element may occur but the rate of activation of
transcription of androgen-regulated genes may be reduced
compared to normal. All patients had a complement ofCAG
repeats in exon 1 within the normal range of 17 to 26.
McPhaul and co-workers (1991) found this region to be
truncated in a partial AIS subject and La Spada et al. (1991)
found it to be much increased in size in individuals with X-
linked spinal and bulbar muscular atrophy. Confirmation ol
the effect of the mutations described in this paper on the
biological function of the AR will be explored further b)
transfection and dimerization studies.
In patients with complete AIS substitutions tend to involve
a change in both the size and charge of the amino acid, e.g
arginine to cysteine; arginine to glutamine (Brown et al.
1990), an exception being the substitution ofmethionine foi
valine at position 866 where only the size of the amino acid i:
changed (Lubahn et al., 1989). Data for two unrelatec
individuals in which the codon for amino acid 855 (arginine
was changed support this hypothesis. An arginine to cysteini
(basic to neutral) change was detected in a complete Alf
patient (De Bellis et al., 1991) whilst substitution of histidini
(basic to basic) resulted in partial AIS (Chang et al., 1991)
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'Fig. 4 Amino acid sequence of the second zinc finger of the AR
drawn to be homologous with the structure of that of the
glucocorticoid receptor (Severne et at., 1988), showing the
location of the amino acid substitution in patient 3 (arginine to
lysine, *). Amino acids conserved between the different members
of the steroid receptor family are shown in bold type. Other
mutations reported for patients with AIS are boxed: A, Arg 615
to Pro (Zoppi et at., 1991); B, Leu 616 to Arg (De Bellis et at.,
1991).
Our data, in which partial AIS resulted from 'conservative'
amino acid substitutions; arginine to lysine (basic to basic)
and valine to leucine (neutral to neutral) are consistent with
these findings.
In conclusion, examination of previous reports suggest to
us that the nature of the amino acid substitution as well as its
location can have a profound influence on the function of the
receptor protein and consequent phenotype of the indi¬
vidual. Studies on mutated AR from individuals with a wide
range of degrees of androgen resistance has contributed to
identification of some of the key amino acids within the
different domains of the AR.
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